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ABSTRACT 
Kari Debbink: Mechanisms of GII.4 Norovirus Antigenic Variation and Evolution 
(Under the direction of Ralph S. Baric) 
Noroviruses infect an estimated 21 million people annually in the United 
States, resulting in ~70,000 hospitalizations and ~800 deaths. These viruses are 
easily transmitted among people in close proximity, including healthcare and 
educational settings, cruise ships, military environments, and restaurants. Norovirus 
symptoms include vomiting and diarrhea over a period of 24-72 hours, but life-
threatening or chronic infections can develop in infants and very young children, the 
elderly and immunocompromised individuals. Unfortunately, there are no licensed 
norovirus therapeutics or vaccines currently available.   
One factor complicating vaccine and therapeutic design for noroviruses is 
antigenic variation in GII.4 norovirus, which account for over 70% of all outbreaks.  
Every 2-4 years the predominant circulating GII.4 strain is replaced by a new 
emergent strain. In predominant GII.4 strains, genetic changes are most prevalent in 
continuously evolving areas of the capsid P2 domain and correlate with antigenic 
changes. This suggests that GII.4 norovirus strain emergence is driven by changes 
in neutralization epitopes as a result of escaping herd immunity to the previous 
strain. Therefore, effectively designed therapeutics and vaccines must be broadly 
active or easily reformulated to account for the antigenic properties of emergent 
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viruses.  Our work aims to define the mechanisms that drive genetic changes 
leading to antigenic changes in GII.4 noroviruses.  
In Chapter 2, we use structure-guided approaches to map epitope A, the 
immunodominant GII.4 blockade (potential neutralizaton) epitope.  Chapter 3 
characterizes antigenic changes between two successive GII.4 strains, GII.4-2009 
New Orleans and GII.4-2012 Sydney.  In Chapter 4, we investigate the antigenic 
change that occurs within an individual chronically infected with norovirus over time, 
map the varying epitopes and compare the degree of change with population-wide 
changes.  We also propose that broadly-blocking GII.4 human monoclonal antibody 
71.4 is a potential treatment for chronic norovirus infection. Chapter 5 proposes a 
VLP-based vaccine platform that utilizes chimeric particles to induce a broadly-
blocking immune response against multiple GII.4 strains.  These GII.4 norovirus 
studies have allowed us to identify major determinants of antigenic change in GII.4 
noroviruses that will allow for rapid diagnostic identification of new epidemic strains 
and direct the rational development of norovirus therapeutics and vaccines. 
	   v	  
 
To my son, Jaxon, and my husband, Jesse, who have been constant sources of 
support and joy. 
	   vi	  
 
ACKNOWLEDGEMENTS 
 I would like to express my deepest appreciation to my advisor, Dr. Ralph S. 
Baric for his guidance and mentorship over the past five years.  Truly, my successes 
as a graduate student and in my future career can be directly attributed to Ralph’s 
genius as a scientist and support as a mentor.  Thank you for always encouraging 
me in a positive and constructive way and allowing me to pursue opportunities to 
better myself as a scientist and educator.  You are an exceptional role model as both 
a scientist and as a human being, and I hope to emulate your mentorship qualities in 
the future with my own students.  Working in your lab was a joy every day, and I will 
miss it wholeheartedly. 
 Baric lab members Lisa Lindesmith and Dr. Eric Donaldson were also 
instrumental in my training and successes, and I genuinely appreciate the time that 
each of them took to teach me lab and bioinformatics skills (respectively).  I am also 
grateful to Lisa Lindesmith and Dr. Vineet Menachery who were always willing to 
engage in scientific discussions that improved my research and expanded my ideas. 
 I would also like to thank my committee members, Dr. Aravinda de Silva, Dr. 
Mark Heise, Dr. Stanley Lemon, and Dr. Roland Tisch for helping guide aspects of 
my research, giving me constructive career advice, writing recommendation letters, 
and acting as instructors for classes I’ve taken. I appreciate the time and effort 
you’ve devoted to my education and scientific development. 
	   vii	  
 My family has provided much support and encouragement throughout my 
educational career.  Thank you to my grandparents, John and Jean Debbink, my 
parents, Lynn Davis and David Debbink, and my stepmother, Marcia Debbink, for 
financial and moral support over the years.  Thank you to my husband, Jesse 
Hardin, and my son, Jaxon Hardin, for allowing me the flexibility to fully engage in 
graduate school by giving me the time and space I needed to complete my work and 
participate in conferences and activities away from home without ever making me 
feel guilty or burdensome.  In addition, my friends Vijay and Heather Sivaraman and 
Maggie Davis (who are like family) have been a wonderful source of support. 
 I would also like to acknowledge those who made possible my return to 
graduate school after many years as a middle school teacher away from academia.  
I would like to thank my undergraduate mentor Dr. Sandra Gilchrist, who wrote me 
letters of recommendation and has since supported my continued development as a 
researcher and educator.  I thank Dr. Walt Klimecki and Dr. David Gang who both 
gave me the opportunity to work in their labs at University of Arizona during 
consecutive summers and wrote me recommendation letters for graduate school, 
and particularly Dr. Klimecki who made me believe I had the aptitude for a more 
academic career.  Finally, I thank the UNC BBSP admissions committee for taking 
the chance on an applicant with a very non-traditional background. 
	   viii	  
 
TABLE OF CONTENTS 
LIST OF TABLES....................................................................................................... xi 
LIST OF FIGURES.................................................................................................... xii 
LIST OF ABBREVIATIONS...................................................................................... xiv 
CHAPTER 1:  NOROVIRUS IMMUNITY AND VACCINE DESIGN..........................15 
 Noroviruses represent a significant worldwide disease burden .....................15 
 Specific host and virus genetic factors influence NoV  
 Susceptibility, evolution, and immunity ..........................................................16 
 Norovirus immunity: Humoral Immune Response..........................................18 
 Norovirus immunity: Cellular Immune Response ...........................................21 
 Factors Complicating Vaccine Design ...........................................................21 
 Vaccine Strategies for Noroviruses................................................................25 
 Vaccine Protection of At-Risk Populations.....................................................27 
 Current Control Measures..............................................................................29 
 Conclusions....................................................................................................31 
CHAPTER 2:  GENETIC MAPPING OF A HIGHLY VARIABLE  
NOROVIRUS GII.4 BLOCKADE EPITOPE: POTENTIAL ROLE 
IN CONTRIBUTION IN ESCAPE FROM HUMAN HERD IMMUNITY ......................34 
 Introduction ....................................................................................................34 
 Methods..........................................................................................................38 
 Results ...........................................................................................................42 
 Discussion......................................................................................................54 
	   ix	  
 
CHAPTER 3:  EMERGENCE OF NEW PANDEMIC GII.4 SYDNEY  
STRAIN CORRELATES WITH ESCAPE FROM HERD IMMUNITY ........................64 
 Introduction ....................................................................................................64 
 Materials and Methods...................................................................................66 
 Results ...........................................................................................................68 
 Discussion......................................................................................................74 
CHAPTER 4:  WITHIN HOST EVOLUTION RESULTS IN ANTIGENICALLY 
DISTINCT GII.4 NOROVIRUSES .............................................................................79 
 
 Introduction ....................................................................................................79 
 Methods..........................................................................................................83 
 Results ...........................................................................................................87 
 Discussion......................................................................................................94 
CHAPTER 5:  A VLP-BASED GII.4 NOROVIRUS VACCINE PLATFORM  
ELICITS A BROADLY BLOCKING IMMUNE RESPONSE AGAINST  
ANCESTRAL AND CONTEMPORARY GII.4 STRAINS.........................................104 
 
 Introduction ..................................................................................................104 
 Methods........................................................................................................108 
 Results .........................................................................................................110 
 Discussion....................................................................................................116 
CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS ................................122 
 Summary......................................................................................................122 
 Norovirus Epitope Mapping..........................................................................124 
 Norovirus Vaccine Design............................................................................128 
 Norovirus Therapeutics ................................................................................133 
 Conclusions..................................................................................................134 
	   x	  
APPENDIX 1: CHAPTER 1 GRAPHS AND TABLES .............................................136 
APPENDIX 2: CHAPTER 2 GRAPHS AND TABLES .............................................143 
APPENDIX 3: CHAPTER 3 GRAPHS AND TABLES .............................................160 
APPENDIX 4: CHAPTER 4 GRAPHS AND TABLES .............................................171 
APPENDIX 5: CHAPTER 5 GRAPHS AND TABLES .............................................182 
APPENDIX 6: CHAPTER 6 GRAPHS AND TABLES .............................................193 
REFERENCES........................................................................................................194 
	   xi	  
LIST OF TABLES 
Table 2.1: Relative reactivity of chimeric versus parental homotypic VLPs............152 
Table 4.1: Chronic Infection Strain HBGA Binding Preferences .............................173 
Table 4.2: GII.4 Mouse and Human mAb EIA Reactivity with Chronic  
 Infection Strains ...........................................................................................174 
	   xii	  
LIST OF FIGURES 
Figure 1.1: Norovirus Structure, Phylogeny, and HBGA Phenotype Pathways ......136 
Figure 1.2: GII.4 Variation in Blockade Epitopes ....................................................138 
Figure 1.3: Factors Complicating Norovirus Vaccine Design..................................140 
Figure 1.4: Design of a Multivalent Norovirus VLP Vaccine ...................................141 
Figure 2.1: Putative Epitopes A and D....................................................................143 
Figure 2.2: Epitope D chimeric VLP reactivity with synthetic HBGAs  
 and anti-GII mAbs ........................................................................................145 
Figure 2.3: GII.4-2006(+87A.1) reactivity with anti-GII.4 mAbs ..............................147 
Figure 2.4: Epitope A chimeric VLP reactivity with synthetic HBGAs .....................148 
Figure 2.5: GII.4-2006(+87A.2) reactivity with anti-GII.4 mAbs ..............................149 
Figure 2.6: GII.4-2006(+87A.3) reactivity with anti-GII.4 mAbs ..............................150 
Figure 2.7: GII.4-2006(+87A.4) reactivity with anti-GII.4 mAbs ..............................151 
Figure 2.8: Anti-GII.4 mAb blockade of VLP/synthetic HBGA interactions .............153 
Figure 2.9: GII.4-1987 mouse polyclonal sera blockade.........................................154 
Figure 2.10: 1988 human outbreak sera blockade .................................................156 
Figure 2.11: Homology models comparing GII.4-1987, GII.4-2006,  
 and GII.4-1987(+06D) ..................................................................................158 
Figure 3.1: GII.4 norovirus Structure and Genetic Variability  
 in Blockade Epitopes....................................................................................160 
Figure 3.2: GII.4-2012 HBGA Binding.....................................................................161 
Figure 3.3: GII.4-2006 Mouse mAb EIA Reactivity and Blockade  
 Response Against GII.4-2012 ......................................................................162 
Figure 3.4: GII.4-2009 Mouse mAb EIA Reactivity and Blockade  
 Response Against GII.4-2012 ......................................................................164 
Figure 3.5: GII.4 Human mAb EIA Reactivity and Blockade Response  
	   xiii	  
 Against GII.4-2012 .......................................................................................166 
Figure 3.6: Monoclonal Antibody Blockade of Chimeric GII.4-2012 VLPs..............168 
Figure 3.7: GII.4-2012 and GII.4-2012.09A Blockade by GII.4-2009  
 Outbreak Human Sera .................................................................................169 
Figure 3.8: GII.4-2009 Outbreak Human Sera Blockade by Individual ...................170 
Figure 4.1: Sequence Changes in Chronically Infected Patient Strains  
 Compared to GII.4-2006b ............................................................................171 
Figure 4.2: GII.4 Mouse and Human mAb Blockade Response  
 Against Chronic Infection Strains .................................................................175 
Figure 4.3: Blockade Activity of Mouse Polyclonal Sera Against  
 Homotypic and Heterotypic VLPs ................................................................177 
Figure 4.4: Antigenic Cartography for GII.4 Noroviruses ........................................179 
Figure 4.5: Expansion of Epitope A ........................................................................180 
Figure 4.6: Comparison of Epitope D Polar Interactions Among  
 GII.4-2006 and Chronic Infection Strains .....................................................181 
Figure 5.1: Design of Chimeric Vaccine VLPs ........................................................182 
Figure 5.2: Single Strain VRPs Do Not Induce a Broad Blockade Response.........183 
Figure 5.3: Single Strain VRP Sera Blockade Response Against Chimeric VLPs..184 
Figure 5.4: Chimeric VRPs Induce Broad Blockade Responses ............................185 
Figure 5.5: Comparison of Chimeric VRP Sera Blockade Response  
 Against Parental GII.4 VLPs ........................................................................186 
Figure 5.6: Comparison of Chimeric versus Multivalent VRP Sera  
 Blockade Response Against Parental GII.4 VLPs .......................................188 
Figure 5.7: Parental Strain Blockade Comparisons Among Homotypic,  
 Heterotypic, Chimeric, and Multivalent Sera ................................................190 
Figure 5.8: Model of Chimeric GII.4 VLP-based Vaccine Reformulation Strategy..192 
Figure 6.1: Putative Updated Blockade Epitopes ...................................................193 
	   xiv	  
LIST OF ABBREVIATIONS 
CHO  Carbohydrate 
EIA  Enzyme-linked immunosorbent assay 
ELISA  Enzyme-linked immunosorbent assay 
HBGA  Histoblood group antigens 
mAb  Monoclonal antibody 
NoV  Norovirus 
VLP  Virus like particle 
VRP  Virus replicon particle
	   15	  
 
CHAPTER 1:  NOROVIRUS IMMUNITY AND VACCINE DESIGN1 
Noroviruses represent a significant worldwide disease burden.  
Noroviruses (NoV), members of the calicivirus family, are small, positive 
polarity RNA viruses and the most important cause of human food-borne viral 
gastroenteritis, worldwide. These viruses cause gastrointestinal disease, resulting in 
recurrent bouts of vomiting and diarrhea, which typically last 24-48 hours. Each year 
in the United States, noroviruses infect an estimated 21 million people and result in 
70,000 hospitalizations, 800 deaths [1]. Furthermore, following the recent 
introduction of the rotavirus vaccine, noroviruses represent the primary cause of 
acute gastroenteritis requiring medical care in children [2]. Norovirus infections are 
most prevalent in the fall and winter months and can spread easily in areas where 
people are in close proximity, including daycares, schools, cruise ships, and in 
health care settings.  In health care settings, noroviruses can cause death, severe 
disease outcomes or chronic infection in immunocompromised individuals like the 
elderly, transplant patients, and those with immune disorders [3].   
Upon infection, noroviruses replicate in mostly undefined cells in the small 
intestines and virus is shed in feces.  Noroviruses infect via the oral route, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This	  chapter	  is	  a	  combination	  of	  work	  that	  previously	  appeared	  in	  PLoS	  Pathogens	  and	  in	  Clinical	  Infectious	  Diseases.	  	  The	  original	  citations	  are	  as	  follows:	  Debbink	  K,	  Lindesmith	  LC,	  Donaldson	  EF,	  and	  Baric	  RS.	  “Norovirus	  Immunity	  and	  the	  Great	  Escape.”	  PLoS	  Pathogens	  October	  2012	  8(10):e1002921.	  Debbink	  K,	  Lindesmith	  LC,	  and	  Baric	  RS.	  “The	  State	  of	  Norovirus	  Vaccines.”	  Clinical	  
Infectious	  Diseases	  February	  27,	  2014.	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transmitted through contact with fecal matter or aerosolized vomitus from infected 
people and contaminated surfaces, food, or water.  Noroviruses are environmentally 
stable and have an infectious dose between 18 and 2800 particles [4, 5], making it 
difficult to prevent their spread as even small amounts of viral contamination can 
seed new infections.   
There are currently no licensed vaccines or therapeutics for noroviruses, 
although several candidates are under development.  Development of vaccines and 
therapeutics face considerable challenges as there is no cell culture system or small 
animal model for human disease, and these viruses are highly heterogeneous and 
undergo antigenic variation in response to human herd immunity, further 
complicating our understanding of the complex immune interactions that regulate 
susceptibility and disease.   
 
Specific host and virus genetic factors influence NoV susceptibility, evolution, 
and immunity.  
Noroviruses are divided into 5 genogroups (GI-GV), which differ by >60% 
based on capsid sequence [6], and GI and GII NoVs cause human disease (Figure 
1.1A-C). Genogroups are further divided into 9 and 22 distinct genotypes, 
respectively, which differ by >15% in the capsid sequence [7]. GI.1 is the prototypic 
“Norwalk” genotype, and the GII.4 genotype is the genotype responsible for the 
majority of outbreaks.  While fluctuations in norovirus epidemiology occur by year 
and geographic locations, genogroup I strains generally cause ~10% of human 
disease, while the GII strains are responsible for the remaining ~90% [8].  A single 
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genotype, GII.4 is responsible for over 70% of all human outbreaks since the mid 
1990s [8], so in terms of medical relevance, GII.4 noroviruses are key strains 
targeted by vaccines and therapeutics.  
GII.4 noroviruses, in particular, appear to accommodate a high level of 
sequence diversity and undergo positive selection in key surface-exposed residues, 
likely allowing for escape from herd immunity [9, 10]. Differences in evolution rates 
among different GI and GII norovirus have been attributed to receptor switching and 
effective population size, VP1 sequence space and structural plasticity, duration of 
herd immunity, and replication fidelity [9, 11-14].   
Histoblood group antigens (HBGAs) are a diverse family of carbohydrates 
expressed on mucosal surfaces where they serve as binding ligands and putative 
receptors for norovirus docking and entry.  HBGAs are differentially expressed in 
individuals, and binding to specific HBGAs varies by norovirus strain.  Expression of 
most HBGAs on mucosal tissues is dependent on the presence of a functional FUT2 
gene, which codes for a fucosyltransferase that adds side chains to a precursor 
molecule.  About 20% of people do not encode a functional FUT2 gene and are 
considered “non-secretors” (Figure 1.1D). Non-secretors are resistant to GI.1 
(Norwalk virus) infection [15]; however, some other NoV strains are known to infect 
non-secretors, probably by attachment to Lewis carbohydrates [16-19]. GII.4 strains 
may predominate because the epidemic strains bind A, B, and O secretors, 
representative of 80% of the population. Antibodies that block virus binding to HBGA 
are considered “blockade antibodies” and are predicted to be neutralizing.  
Importantly, high pre-challenge blockade antibody titers correlate with protection 
	   18	  
from infection following primary challenge and vaccination [20]. The development of 
more human challenge strains and therapeutic antibodies will be key for illuminating 
the complex relationships among HBGA affinity, host susceptibility, short and long-
term immunity outcomes, and the mechanism of action by which blockade 
antibodies prevent infection. 
 
Norovirus immunity: Humoral Immune Response.   
A handful of human challenge studies provide insight into the potential for 
protective immunity to noroviruses.  Short-term immunity has previously been 
established for GI.1 viruses [21], and a recent vaccine study found that intranasal 
vaccination with GI.1 VLPs protected against disease three weeks post vaccination 
[22]. The existence of long-term immunity is more controversial; however, multiple 
studies found protective responses against GI.1 were present six months after 
challenge in some but not all individuals [20, 22, 23]. Mucosal IgA responses to 
Norwalk virus indicate that an early salivary IgA response (days 1-5), rather than a 
late response, correlated with protection from infection in secretor positive 
individuals; this suggests that previous strain exposure elicited a protective memory 
response against the challenge strain [15].  The rapid epidemic GII.4 strain 
replacement by new isolates every 3-7 years is consistent with protective, long-term 
herd immunity in a substantial portion of the population [24]. 
GI and GII antibodies are high in acute sera, while cross-blockade patterns 
are genogroup-specific [20, 25]. Sera against GI outbreaks are cross-blocking within 
the genogroup and are sometimes higher for a heterologous strain immediately after 
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infection [12, 25]; however, the blocking response does not extend to GII 
noroviruses [26]. In contrast, sera against GII outbreaks have much higher strain-
specific homologous responses and not broad GII blocking responses [27, 28]. 
These studies are complicated by complex pre-exposure histories in human 
populations, coupled with a very poor understanding of the serologic relationships 
among strains. Using mouse sera targeting single strains, reactivity across GI 
genotypes is about 5-10% of the homotypic response and is less than 5% between 
genogroups [29]. Simultaneous exposure of rodents/rabbits to multiple strains 
significantly boosts cross reactive antibody responses, suggesting that complex 
patterns of cross reactivity may exist within multiple GI or multiple GII genotypes or 
that repeat/multivalent exposure selects for high affinity antibodies that tolerate 
variation within target epitopes [14, 29].   
Classic approaches for mapping epitopes cannot be applied to NoV because 
of the lack of a cell culture system for isolating antibody escape mutants. For G1 
NoVs, point and deletion mutations have identified regions of VP1 targeted by 
antibodies [30, 31]. For GII.4 strains, epitope mapping has been done primarily by 
using bioinformatics approaches to identify rapidly evolving amino acid residues and 
exchanging these regions between strains [10, 11, 13, 32] (Figure 1.2A).  This has 
allowed for precise mapping of key residues that drive antigenic change in response 
to human and rodent antibody binding and blockade responses. These mapping 
studies define key sites of antigenic change; however, the actual antibody binding 
epitope is usually conformational and likely includes proximal conserved and varying 
residues that contribute to escape from human herd immunity. A recent 
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crystallography study mapped the binding of a cross-reactive GII monoclonal 
antibody in complex with a GII.10 P particle to a highly-conserved, occluded site 
within the P1 subdomain, suggesting that the norovirus P domain may 
accommodate high conformational flexibility [33]. 
Monoclonal antibodies that target distinct GII.4 strains demonstrate that 
antigenic variation is high and these strains are evolving in response to human herd 
immunity.  These data also support the hypothesis that many human and mouse 
blockade monoclonal antibodies appear to target similar varying epitopes in GII.4 
VLPs. Three blockade epitopes have been confirmed, designated A, D, and E [10, 
11, 13, 14] (Figure 1.2B-D). A forth blockade site, designated epitope F, is 
conserved across all GII.4 tested, yet its location on the particle remains elusive 
(Lindesmith et al., in review). Epitope A is substantially recognized by human 
polyclonal sera, Epitope D (residues 393-395) is especially interesting because this 
region also alters HBGA binding affinity [11, 12, 19]. Importantly, New Orleans 2009 
and its recent derivatives demonstrate continued evolution in the major blockade 
epitopes, suggesting escape from GII.4-2006 herd immunity. These data support the 
hypothesis that antigenic changes that result in escape from herd immunity may also 
drive changes in HBGA affinities, altering population susceptibility patterns.  While 
multiple blockade epitopes change over time, conserved, unmapped GII.4 blockade 
epitopes also exist [10]. While evidence for cross-blockade GII epitopes is limited 
[26], cross blockade epitopes may be more common for GI strains, explaining the 
reduced frequency of disease patterns seen in human populations [25].  No GI or 
cross-GI and GII antibody blockade epitopes have been mapped, signaling an 
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important priority for future studies. To further characterize the complexity of the 
molecular mechanisms driving antigenic variation, additional crystal structures in 
complex with strain, genotype, and genogroup specific antibody are needed to 
define complete epitopes, tease apart overlapping epitopes, and map the exact 
residues comprising important cross reactive and cross blockade epitopes.  
 
Norovirus immunity: Cellular Immune Response.   
The role that T cells play in controlling norovirus infection is complex and not 
well characterized.  Human norovirus infection or vaccination elicits a primarily CD4+ 
Th1 response, leading to increased secretion of IFN-gamma and IL-2 [16, 25].  One 
study using human-derived PBMCs found that T cell responses were more cross-
reactive between GII strains with higher antigenic relatedness [16], while another 
study found that T cell responses toward alternate GI strains were more robust than 
the immunizing GI strain in some individuals [25].  Additional studies using a wider 
array of genotypes are needed to further characterize T cell responses and their 
relationships in controlling human infection. 
 
Factors Complicating Vaccine Design 
Vaccine development for noroviruses is complex (Figure 1.3).  Noroviruses do 
not replicate in tissue culture and, until recently, there was no small animal model for 
human norovirus infection [34]. Because of the lack of a validated tissue culture 
model, virus neutralization cannot be directly measured after infection or vaccination.  
Instead, the virus-like particle (VLP)-HBGA blockade assay has been used as a 
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surrogate to evaluate the potential neutralization response of both monoclonal 
antibodies and sera [35], and blockade titers in this assay correlate with human 
protection [20]. Both chimpanzee and gnotobiotic pig models have been developed 
to evaluate vaccine efficacy [36, 37]. However, studies have been halted in the 
chimpanzee model due to ethical restrictions on the use of these non-human 
primates. To date, only one vaccine efficacy study in gnotobiotic pigs has been 
published [36].  Because of limitations in growing virus and testing different vaccines 
and therapeutics outside of humans, the factors that modulate vaccine efficacy 
remain poorly understood. 
Noroviruses are highly heterogeneous viruses, and major antigenic 
differences exist between GI and GII noroviruses. Within the GI genogroup, 
antibodies from different genotypes share 5-10% cross-reactivity, while cross-
reactivity between GI and GII genotypes is less than 5% [29].  Furthermore, no 
shared neutralization epitopes have been identified between the two genogroups, 
suggesting that a multivalent GI + GII vaccine platform is needed to protect against 
infection with both GI and GII viruses.  Although poorly characterized, there appear 
to be some complex cross-blockade relationships that exist within and between GI 
and GII genogroups, respectively, meaning that including strategically chosen single 
representative GI and GII strains may yield a broadly protective vaccine [29]. While 
most noroviruses do not undergo substantial intra-genotype antigenic variation, GII.4 
noroviruses are the notable exception.  The GII.4 genotype, which accounts for the 
majority of human disease, varies considerably over time by both mutation and RNA 
recombination processes, suggesting that a successful vaccine will likely need to be 
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reformulated periodically with contemporary isolates, as antigenically distinct strains 
emerge that circumvent human herd immunity to ancestral isolates.  Antigenic 
variation within the GII.4 noroviruses is linked to genetic changes in potential 
neutralization sites on the major capsid protein P2 domain [11-13, 32], providing 
discrete areas to target with vaccines.  Every 2-4 years the predominant circulating 
GII.4 strain is replaced by a new, antigenically distinct emergent strain that is able to 
overcome human herd immunity [28, 38, 39].  GII.3 noroviruses also demonstrate 
antigenic changes over time; however, the evolutionary mechanisms differ from 
GII.4 noroviruses and are not as well studied [40].  In contrast, GI.1 and GII.2 
isolates demonstrate little if any antigenic variation over the past 30 years [41].  It is 
unclear whether these genogroup specific patterns of evolution are stable or whether 
all strains have the potential to evolve by epochal evolution like the GII.4 genotype 
under the appropriate environmental conditions, leading to epidemic strain 
replacement over time as seen with influenza A viruses. 
The duration of protective immunity after human norovirus infection is 
complex.  Early human challenge studies suggested that protection lasted only  ~6 
months to two years [42], leading to concerns regarding the feasibility of developing 
a successful norovirus vaccine.  Others have postulated that some individuals 
develop long-lived immunity [12].  Although still under study, more recent work 
based on modeling of epidemiological data suggests that protective immunity to 
norovirus may persist for between 4-8 years [42], suggesting that norovirus vaccines 
will effectively limit the overall severity and global disease burden.  Studies with 
monoclonal antibodies targeting time-ordered GII.4 VLPs demonstrate robust 
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blockade titers against ancestral, but not future strains; providing a mechanism to 
mediate long-term immunity [28]. Another complicating factor is the potential for 
previous exposure to norovirus strains to impact the immune response to newly-
encountered strains.  Pre-exposure history may complicate vaccine performance as 
most individuals are exposed to multiple GI and GII norovirus infections over their 
lifetime, resulting in complex patterns of cross immunity and potentially short or long-
term cross-protection.  Although controversial, repeated exposures may lead to 
deceptive imprinting, where the immune response is increasingly directed at non-
neutralizing epitopes, as has been described for other viruses like HIV and influenza 
[43].  However, this has not yet been thoroughly investigated after norovirus 
infections or after vaccination.  
Results from the single human vaccine efficacy study published to date are 
encouraging, but our ability to compare and contrast vaccine platform performance 
across studies is limited.  The high heterogeneity of antigenic profiles between 
genogroups, between some genotypes, and within the GII.4 genogroup suggests 
that broad vaccine-induced protection against multiple norovirus groups may be 
difficult but possible; especially if multivalent vaccines are used to broaden reactivity 
and blockade responses.  One study found that immunizing mice against multiple 
strains broadens the serum blockade response against both homotypic VLPs and 
VLPs representing strains not included in the vaccine formulation [29]. Likewise, a 
study examining the strain cross-reactivity induced by a bivalent GI.1/GII.4 
consensus VLP vaccine in rabbits found that heterotypic strain cross reactivity was 
induced [14]. Together, these studies suggest that a multivalent vaccine approach 
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may induce broad protection in humans; however this remains to be evaluated in 
human trials.   
 
Vaccine Strategies for Noroviruses 
There are several potential vaccine strategies for norovirus; the first human 
clinical efficacy trials evaluated a norovirus virus-like particle (VLP) vaccine.  The 
multivalent HPV vaccines Gardasil and Cervarix are VLP-based vaccines that have 
been shown to be highly effective at preventing HPV infections and precancerous 
lesions for strains included in the vaccine [44].  Success of the HPV multivalent VLP 
vaccines provides a template strategy for use with other viruses, including 
noroviruses.  Takeda Pharmaceutical Company conducted human trials on a 
monovalent GI.1 VLP-based vaccine delivered intranasally [22, 45, 46].  Participants 
in the phase one studies were all found to have significant increases in IgA and/or 
IgG memory B cell responses at the highest vaccine dose of 100 µg VLP [46]. In a 
follow-up human challenge study, participants were given two vaccine doses, three 
weeks apart, and then challenged with 10X ID50 Norwalk virus three weeks after the 
second vaccine dose [22].  Results from this study found that both gastrointestinal 
disease and Norwalk infection was reduced in the vaccinated group compared to the 
control group, by 47% and 26%, respectively [22].  Long-term efficacy trials are 
currently underway to evaluate duration of protection for this vaccine. 
 Takeda Pharmaceutical Company is also developing a bivalent VLP-based 
norovirus vaccine that contains both GI.1 Norwalk and GII.4 components.  The GI.1 
component is identical to that used in the monovalent vaccine trials, and the GII.4 
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component is based on a consensus sequence from three GII.4 outbreak strains that 
first circulated widely in 2002 and 2006 [14].  Human clinical trials with the bivalent 
vaccine formulation are currently being conducted, as are long-term vaccine efficacy 
trials, but efficacy results have not yet been published. 
Other norovirus vaccine approaches that are being explored include 
multivalent VLP-based vaccines [47], delivery of VLPs by edible vaccine [48], P 
particle-based vaccines [49], polyvalent norovirus P domain-GST complexes [50], 
and alphavirus replicon particles (VRPs) that allow formation of norovirus VLPs [51].  
While live-attenuated vaccines have been successful for rotavirus, another 
gastrointestinal virus, and influenza, the lack of a culture system for human norovirus 
makes development of a live-attenuated norovirus vaccine untenable and dependent 
upon future basic scientific discoveries. 
Because GII.4 noroviruses cause the majority of norovirus outbreaks, but also 
demonstrate antigenic variation over time in response to escape from herd immunity, 
a successful vaccine will need to address antigenic changes in new contemporary 
isolates/year.  Differing approaches to addressing GII.4 antigenic variation are being 
taken including incorporation of a VLP that represents the predominant circulating 
strain [47] and design of a GII.4 consensus meant to broaden the GII.4 neutralization 
response [14].  The recent identification of three evolving GII.4 blockade epitopes 
(designated A, D, and E) that are linked to antigenic changes in GII.4 strains provide 
more focused vaccine targets [10, 11, 13] (Figure 1.2B).  In addition to modulating 
antigenicity, epitope D is located in the HBGA interaction site, and evolution in this 
epitope impacts specificity of HBGA binding, potentially altering the population 
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susceptible to infection over time [10]. Importantly, these discrete epitopes retain 
their unique antigenic characteristics when moved between GII.4 strains.  Although 
speculative, a reformulation strategy where the GII.4 vaccine component is changed 
based on population-wide monitoring of these epitopes could be developed.  
Chimeric VLPs that incorporate epitopes from both the emergent strain and 
circulating strain could be built to broaden the neutralization response against 
multiple GII.4 strains including novel variants.  Importantly, no putative neutralization 
epitopes have been mapped in other GI or GII genotypes, making this a basic 
objective for improving vaccine design in the future.  
 
Vaccine Protection of At-Risk Populations 
Though a licensed norovirus vaccine is not yet available, several populations 
would benefit.  A norovirus vaccine should save lives, reduce disease severity, 
reduce the global disease burden, and decrease norovirus-associated economic 
losses.  Populations who are at the highest risk for death, dehydration, and nutrient 
deficiencies include infants and very young children, the elderly, and the 
immunocompromised [52].  Over 60% of norovirus outbreaks occur in long-term care 
facilities that serve elderly populations [8], making protection of this group a top 
priority.  In addition, clinicians who work with immunocompromised populations like 
transplant patients, HIV-infected individuals, cancer patients undergoing 
chemotherapy, and those with primary immunodeficiencies, should be aware that 
chronic norovirus infections can develop and persist in these patient populations for 
months to years [53].  Because the elderly and immunocompromised respond poorly 
	   28	  
to vaccines [54, 55], vaccination of people who interact with these populations may 
be critical to reduce the risk of exposure and spread.  Health care workers and 
family members should all be vaccinated to protect against secondary spread.   
Recent work shows that a ~7.2% of norovirus outbreaks occur in child care 
center and school environments [8]. In addition, children are reported to be most 
efficient at transmitting virus compared to other age groups [42].  Together, these 
data suggest that children and students in daycare or educational environments may 
be important populations to target with a vaccine [8]; however, vaccine outcomes in 
young infants and toddlers may be dramatically different from adults due to limited 
exposure histories, presence of maternal antibodies and a maturing immune system 
in infants. Vaccine safety and efficacy trials in young children will be critical for 
illuminating these differences.  
Other at-risk populations include military personnel, food handlers, and 
travelers.  Outbreaks can spread rapidly in military barracks and vessels [56], thus 
vaccination of military personnel could reduce disease burden and preserve 
scheduled operations and security in this environment.  Noroviruses are the leading 
cause of foodborne illness [57], thus vaccinating food handlers could prevent 
recurrent outbreaks, which has tarnished the reputations of several internationally-
renown restaurants.  Some of these outbreaks result from contamination of food 
during production, but most are due to contamination by food handlers during 
preparation or processing [57].  Despite the transient nature of employment, those 
who work on farms, work in food processing facilities, or prepare food should also be 
vaccinated against norovirus to prevent outbreaks in restaurants, cruise ships, 
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cafeterias, at catered events, and from grocery items.  Travelers and travel industry 
workers are another group that may benefit from a vaccine as 2.6% of outbreaks 
occur in vacation settings such as on cruise ships [8]. 
 
Current Control Measures 
In the absence of an available norovirus vaccine, the best options for 
controlling norovirus infection focus on preventing spread to high-risk populations 
and potentially treating chronically infected patients in a hospital setting.  Basic 
norovirus control measures in health care settings should combine barrier nursing 
techniques, increased personal hygiene measures, robust decontamination 
strategies, and isolation of infected individuals. The incubation period between 
infection and beginning of symptoms ranges from between 12 and 48 hours, and 
infected people are contagious for up to 14 hours before the onset of clinical 
symptoms and for the duration of symptomatic infection [58].  In addition, viral 
shedding often peaks, and then persists for weeks, following symptomatic infection 
[58].  It is possible to transmit virus after recovery from clinical symptoms during this 
shedding period [59], although it is presently unclear whether virus shed at later time 
points is infectious. 
In clinical and long-term care environments, it is important for staff who 
experience gastroenteritis symptoms to remain at home to avoid seeding an 
outbreak in at-risk populations.  Upon return to work, staff should practice frequent 
hand washing with soap and running water, which minimizes norovirus spread.  
Notably, alcohol-based hand sanitizers do not effectively control norovirus [60], and 
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should not be used as a substitute for handwashing with running water. Some 
individuals infected with norovirus are asymptomatic, and there appears to be a role 
for this population in norovirus transmission [61], so staff who experience a potential 
norovirus exposure should follow rigorous hand hygiene protocols to protect high-
risk populations. Futhermore, decontamination efforts should consider that norovirus 
is stable, able to persist for up to 6 weeks on environmental surfaces and in food for 
up to 2 weeks [62].  Noroviruses are resistant to common disinfectants including 
alcohol-based disinfectants and ammonia-based compounds [63].  Effective 
cleansers against norovirus include hypochlorite solutions above 10% [63] and 
hydrogen peroxide vapor solutions of 30% [64]. 
 Despite the implementation of decontamination and isolation protocols, there 
is always the possibility that individuals in high-risk populations may be infected and 
require hospital care.  While there are no standard treatments for norovirus, patients 
can be given IV fluids and nutrition to counter dehydration and nutrient deficiencies 
or, for select patients on immunosuppressive therapies, drug dose can be decreased 
[53].  A handful of studies have investigated other potential norovirus treatments 
including antivirals and IgG therapy.  While the short duration of most norovirus 
infections make these therapies ineffective for the general population, their value in 
reducing disease and transmission of virus in high-risk settings may make 
development important. Antivirals have shown a limited ability to improve norovirus 
symptoms, but they fail to clear norovirus infection [53].  Administration of IgG has 
also been evaluated with mixed results; in some patients IgG did not improve 
disease outcomes, but this therapy was successful in reducing symptoms and 
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clearing virus in a few studies [65, 66]. Differences in efficacy are possibly due to the 
lack of strain-specific neutralizing (blockade) antibodies against the patient’s 
norovirus strain in the IgG used for some of these treatments, and future studies 
using IgG should control for this possibility.  Successes with IgG suggest that the 
potential for treating chronically infected patients with neutralizing monoclonal 
antibodies should also be evaluated [10].  Although in its infancy of development, 
norovirus protease inhibitors are another potential future treatment option.  Norovirus 
protease crystal structures provide a tool for structure-guided discovery of protease 
inhibitor molecules.  This approach has allowed identification of several inhibitor 
molecules that may have therapeutic value, though they have not yet been tested in 
humans [67].  
  
Conclusions 
The availability of a licensed norovirus vaccine will reduce disease severity 
and burdens in high-risk populations.  As licensed norovirus vaccines become 
available, it will be necessary to continue to improve vaccine efficacy.  There are 
several important considerations that will guide vaccine design. 1) Mapping and 
determining the relative contribution of each blockade epitope as a correlate of short 
or long-term protective immunity is key to successful vaccine design, especially 
against strains that evolve over time. Mapping conserved intra- or inter-genotype 
epitopes may uncover more broadly-acting therapeutic targets. 2) Additional human 
challenge studies with both GI and GII noroviruses need to be conducted to more 
fully understand how long protective immunity lasts among different genogroups and 
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genotypes. 3) The impact of pre-exposure history and temporal and phylogenetic 
space on contemporary strain vaccine immune responses will need to be clarified.  
4) The contribution of T cell responses (CD4+, CD8+, Th17) in protective immunity 
will need to be further elucidated. 5) The role of innate immunity in viral 
pathogenesis and in short and long-term herd immunity.  In order to keep abreast of 
novel surface variation that may lead to escape from herd immunity and emergence 
of new pandemic strains, areas of the capsid undergoing positive selection over time 
in rapidly-evolving norovirus genotypes will need to be continuously monitored. 6) 
The potential effects a vaccine would have on the evolutionary dynamics of 
emerging NoV strains will need to be clarified.  Addressing these questions will not 
only allow better design of norovirus vaccine and immunotherapeutics, but will 
inform strategies for minimizing the global disease burden of other highly variable 
and highly pathogenic human viruses. 
These factors represent considerable challenges for the vaccine industry 
(Figure 1.3).  Despite this, epidemiological and immunologic data generated by the 
norovirus field provide a basis on which to design and to reformulate vaccines 
(Figure 1.4) including several recent advances that will likely contribute to the 
improvement of vaccines.  Important antigenic sites have been identified for GII.4 
noroviruses, allowing for more targeted vaccine approaches.  In addition, recent 
comparative studies on multiple vaccine platforms are beginning to elucidate which 
approaches generate the most robust immune responses.  In addition, on-going and 
potential future vaccine efficacy studies using the new mouse model and gnotobiotic 
pigs will inform development and improvements to human vaccines.  Furthermore, 
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continued work using available human challenge models for GI.1, GII.2 and GII.4 
strains provides numerous opportunities to test vaccine and immune outcomes in 
immunocompetent and at-risk populations, a strength for improving vaccine design 
over the next decade. 
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CHAPTER 2: GENETIC MAPPING OF A HIGHLY VARIABLE NOROVIRUS GII.4 
BLOCKADE EPITOPE: POTENTIAL ROLE IN CONTRIBUTION IN ESCAPE 
FROM HUMAN HERD IMMUNITY2 
 
Introduction 
Noroviruses (NoVs) are members of the Calicivirus family and represent the 
most significant cause of human acute viral gastroenteritis worldwide [68].  
Approximately 23 million norovirus infections occur each year in the United States 
alone [69], burdening retirement homes, day cares, the military, cruise ships, 
hospitals, educational institutions, and other community settings where close contact 
between humans is unavoidable.  The elderly, very young, and 
immunocompromised are at the highest risk for severe complications and death [3, 
70, 71], and economic costs of norovirus outbreaks are significant [72, 73].  Although 
an estimated 200,000 deaths occur each year from NoV-induced gastroenterisits 
[74], there are no approved vaccines or antiviral therapies for the prevention or 
treatment of norovirus infections.  However, current clinical trials are encouraging 
and support the use of norovirus virus like particles (VLPs) as a vaccine platform to 
ameliorate the human disease burden [45]. 
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  appeared	  as	  an	  article	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  of	  Virology.	  	  The	  original	  citation	  is	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  Debbink	  K,	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  EF,	  Lindesmith	  LC,	  Baric	  RS.	  “Genetic	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  a	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  (January	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Noroviruses encode a 7.5 Kb single-stranded, positive sense RNA genome 
packaged within a 38 nm non-enveloped icosahedral capsid.  The genome encodes 
three open reading frames: ORF1 encodes the replicase polyprotein while ORF2 
and ORF3 encode the major (VP1) and minor (VP2) structural proteins, respectively 
[75]. Expression of VP1 from Baculoviruses [76] or Venezuelean equine encephalitis 
[77] replicon particles (VRPs) results in the production of NoV virus like particles 
(VLPs). The capsid protein is divided into two distinct domains in the virion, the shell 
(S) and the surface protruding domain (P). The P domain is further subdivided into 
the P1 and P2 subdomains, with the P2 subdomain flanked by portions of P1 in the 
primary coding sequence [75].  The shell forms the base of the capsid, while the P1 
region forms a stalk protruding from the shell. The P2 subdomain is positioned atop 
the P1 stalk, where it is the most surface-exposed region, able to interact with both 
carbohydrates (CHOs) and antibodies [78, 79].  Histoblood group antigens (HBGAs) 
are a diverse family of CHOs expressed on mucosal surfaces.  These CHOs are 
differentially expressed in humans and have been hypothesized to be receptors or 
co-receptors that allow NoVs to attach to and enter permissive cells. Conserved 
amino acids 343-345, 374, and 441-443 are important for HBGA binding [79], 
although it is unclear how nearby amino acid variation affects capsid surface 
topology and contributes to HBGA binding affinity differences noted in time-ordered 
GII.4 VLPs. Partly because there is no cell culture or small animal model for human 
NoVs, the development and testing of vaccines and drug treatments for NoVs have 
only recently been evaluated in larger animal models of human disease 
(swine/primate models) [36, 37] and in humans [45]. Importantly, VLPs, created by 
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the expression of VP1 in a Venezuelan Equine Encephalitis (VEE) Virus [77] or in 
baculovirus [76] expression vector, are both physically and antigenically similar to 
norovirus virions.  These systems offer a promising strategy to study norovirus 
structure and function, which may lead to the development of effective vaccines and 
treatments [80]. 
Noroviruses are a genetically diverse group of viruses, divided into five 
genogroups (I-V) based on ORF2 sequence homology, where protein sequence can 
differ by up to 60%. Each genogroup is further divided into several genoclusters, 
differing by 20%-30% in VP1 sequence [81].  Genogroups I and II predominantly 
encode strains that cause significant human disease [81]. Among these, genocluster 
GII.4 noroviruses account for >80% of norovirus outbreaks [82]. The emergence of 
new GII.4 NoV epidemic strains has been linked to changes in HBGA binding profile 
using synthetic CHOs [12].  The 1974 strain, currently the prototypic ancestral strain, 
binds O type CHOs (H3 and Le-y) [83], 1987 Camberwell binds O type CHOs (H3 
and Le-y), while 1997 Grimsby, a pandemic strain, binds A tri, B tri, and O (H3 and 
Le-y) CHOs. Farmington Hills 2004 binds B tri and O (H3 and Le-y) CHOs [12]. The 
most recent pandemic strain, 2006 Minerva, binds A tri, B tri, and O (H3 and Le-y) 
type CHOs [26]. It is also clear that microvariation within the P2 domain between 
closely related strains influences CHO binding patterns [12, 19, 84, 85]. 
Among the GII.4 strains, the P2 region of ORF2 is evolving more rapidly than 
other domains and subdomains of the GII.4 norovirus capsid protein, with certain 
amino acids undergoing positive selection, likely in response to herd immunity [12, 
86].  Antigenic changes are also evident over time, culminating in the emergence of 
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new GII.4 strains [12, 24, 86]. On the capsid surface, highly variable amino acids 
surround the binding pocket, altering HBGA and antibody binding affinity. Multiple 
studies have identified specific residues within the P2 subdomain that are important 
for antibody and HBGA interactions [12, 32, 87, 88]. Lindesmith et al. (2008) showed 
that residues 393-395 are important for HBGA interactions and antigenicity in GII.4 
noroviruses [12].  A D393G change occurred between GII.4-1987 and GII.4-1997. 
Importantly, introducing the mutation D393G into the 1987 strain converted GII.4-
1987 into a B binding VLP [86]. In addition, two groups identified amino acids 296-
298 as potentially important for antigenicity and HBGA binding interactions [86, 87] 
and Allen et al (2008) demonstrated these amino acids are involved in strain-specific 
antibody recognition [32]. However, it was not clear whether antibodies targeting 
these sites blocked VLP-CHO binding interactions, as a surrogate neutralization 
assay was not performed [32].  Both of these amino acid clusters (296-298 and 393-
395) comprise exposed loop regions of the P2 subdomain. In addition, Tan et al. 
identified amino acids 346 and 441 as important to A, B, and H binding and showed 
that several other amino acids in and around the binding pocket modulate HBGA 
specificity [88]. A more recent study based on comparing crystal structures from 
GII.4-1996 and GII.4-2004 strains suggests that temporal HBGA affinity differences 
exist among strains, and that residues 393-395 directly impact Lewis HBGA, but not 
ABH HBGA binding [85]. However, the effects of amino acid differences at these 
positions may remodel the conformational and electrostatic landscape around the 
binding pocket, indirectly impacting ABH binding affinity.  Together, the previous 
data demonstrate that clusters of mutations likely work independently or in concert to 
	   38	  
alter HBGA binding profiles and antibody binding.  However, the specific interactions 
that take place to modulate HBGA binding and antigenicity are still not well 
understood. 
In this manuscript, we designed and produced a panel of recombinant and 
chimeric GII.4 NoV VLPs that exchanged surface-exposed predicted epitopes 
between an ancestral GII.4 strain (GII.4-1987, Camberwell) and the most recent 
pandemic GII.4 strain (GII.4-2006, Minerva).  Our HBGA binding results provide 
further evidence for the hypothesis that amino acids 393-395 are important for 
HBGA A and B binding. Using a panel of mouse monoclonal antibodies derived 
against GII.4-1987 or GII.4-2006 [28] and human and mouse polyclonal sera, we 
employed gain and loss of function assays to map varying antibody blockade 
epitopes, which are potentially critical sites of virus neutralization and protection from 
clinical disease [12, 20, 35]. These data implicate amino acids 296-298 as well as 
other nearby amino acids that potentially contribute to antigenic differences among 
time-ordered GII.4 strains that are likely associated with escape from herd immunity.  
These data provide further support for the hypothesis that the GII.4 viruses are 
evolving by epochal evolution and antigenic variation in VP1 [9, 12, 86]. 
 
Methods 
Prediction of putative epitopes 
 Multiple sequence alignments were generated for all full-length GII.4 norovirus 
capsid peptide sequences in GenBank using ClustalXv1.86 [89].  A phylogenetic 
tree was generated by Bayesian Inference using MrBayes [90], and 36 
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representative sequences were selected and analyzed based upon unique 
phylogenetic clustering characteristics. Representative strains of GII.4 noroviruses 
were selected from 1974, 1987, 1997, 2002, 2004, 2005, 2006, 2007, 2008 and 
2009.  These representative sequences were aligned using clustalXv1.86, and P2 
subdomain variation was exported into Excel and amino acid variation over time was 
analyzed.  Homology models were generated using Modeller (Max Planc Institute 
Bioinformatics Tool Kit) building structural models based upon the crystal structure 
of V387 (pdb accession: 2OBT) [79] for of each of the reference sequence P 
domains.  Variable sites that were potentially exposed on the surface of the capsid 
were mapped and analyzed as these changes occurred over time from 1974-2009.  
Five discrete regions were identified as putative epitopes defined as local regions 
where clusters of amino acids map to similar structural regions on the capsid 
surface. 
 
Production of VLPs 
 Parental VLPs were expressed in a VEE expression system as previously 
described [12, 26, 77]. Chimeric VLPs were created by replacing the P2 subdomain 
of ORF2 in the parental strains with the chimeric sequences (synthesized by 
BioBasic) [12]. RNA was electroporated  into 1 X 107 BHK cells using BioRad 
GenePulser Xcell pulsed 3X with voltage 850V, capacitance 25 µF, resistance ∞Ω 
and cuvette size 4 mm. Cells were then incubated 24-28 hours at 37° in MEM-alpha 
supplemented with 10% FCS, 10% TPB, 1% anti/anti, and 1% NEAAs.  VLPs were 
harvested by spinning in 40% sucrose using a Ti-55 rotor at 31,500 RPMs for 75 
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minutes. The sucrose cushion containing the VLPs was frozen at -80 degrees.  
VLPs were quantified by protein assay and confirmed by electron microscopy.  
 
ELISA assays 
 ELISAs were performed as previously described [12].  Briefly, EIA high-binding 
plates were coated with 100 µl 2 µg/mL VLPs in PBS and incubated for 4 hours at 
room temperature.  Plates were washed 3X with PBS-0.05% Tween-20, and then 
100 µl 5% blotto was added to each well and blocking was done overnight at 4°C.  
Plates were again washed 3X with PBS-.05% Tween-20, and 100 µl 2 µg/mL 
primary mouse mAb or 1:500 polyclonal sera in 5% blotto was added to each well, 
and incubated at 37° for 45 minutes.  Following another wash as described above, 
100 µl secondary anti-mouse AP antibody (Sigma, Jackson Laboratories) in 5% 
blotto was added and allowed to incubate at RT for 30 minutes.  Plates were again 
washed as described and detected using pNPP (Sigma).  Values used in this paper 
indicate binding in the linear portion of the binding curve. 
 
CHO Binding assays 
 CHO binding assays were performed as previously described [12]. Briefly, 
avidin-coated plates were washed 3X, and 100 µl 10 µg/mL biotinylated CHO 
(GlycoTech) in 5% blotto was added to each well and incubated for 4 hrs. Plates 
were then washed 4X with 15 sec soak in PBS/Tween and 100 µl 2 µg/mL VLP was 
added to each well and incubated for 1 ½ hrs at RT.  Plates were washed 4X with 15 
sec soak, and 100 µl of 2 µg/mL primary mAb antibody or 1:1000 polyclonal sera 
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was added and incubated for 45 min at RT. Plates were then washed 4X with 15 sec 
soak, and 100 µl of 1:10,000 HRP-tagged anti-mouse antibody (GE Healthcare) was 
added and incubated for 30 min at RT. CHO binding was measured by adding 100 µl 
Ultra TMB ELISA solution (Thermo Scientific). Sera and mouse mAbs were 
produced as described previously [12]. 
 
Blockade assays 
 Blockade assays were performed as has been described previously [12]. 
Briefly, NeutriAvidin-coated plates (Pierce, Rockford, IL) were washed 3X, and 100 
µl of 10 µg/mL synthetic biotinyated-H3 CHO (Glycotech, Gaithersburg, MD) in PBS 
was added to each well and incubated for 1 hr.  VLP-mouse mAb dilutions (1 µg/mL 
VLP+ 2 µg/mL mAb) were prepared in a separate, non-binding plate and incubated 
for 1 hr.  The avidin-coated plate was then washed 3X and VLP-Ab dilutions were 
added and incubated for 1 1/2 hrs. The plate was then washed 4X with 15 sec soak 
and 100 µl of 2 µg/mL anti-GII VLP rabbit polyclonal antisera in 5% blotto was added 
to each well and incubated for 30 min. The plate was then washed 4X with 30 sec 
soak and 100 µl of 1:10,000 dilution of HRP-tagged anti rabbit IgG antibody was 
added and incubated for 30 min. The plate was washed 4X for 60 secs and then 
developed by adding 100 µl TMB-Elisa solution (Thermo Scientific) and 50 µl stop 
solution.  The plate was read at OD450.  All incubations were done at room 
temperature. Sera and mouse mAbs were produced as described previously [12]. 
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Statistical Analysis 
 Statistical analysis was performed using Prism GraphPad; results with P<0.05 
were considered significant.  Two-way ANOVA was used to analyze CHO binding 
and mAb reactivity. One-way ANOVA was used to analyze BT50 values for blockade 
differences. Since GII.4-2006 was not blocked even at the highest mouse serum 
concentration, individual replicates not reaching 50% blockade were assigned a 
BT50 value of 1:5 (2X the highest serum concentration tested) for the purposes of 
statistical analysis. 
 
Results 
 Multiple sequence alignments were generated for all full-length GII.4 norovirus 
capsid genes in GenBank, and 36 representative sequences were selected and 
analyzed, based upon unique phylogenetic clustering characteristics. Representative 
GII.4 norovirus strains were selected from 1974, 1987, 1997, 2002, 2004, 2005, 
2006, 2007, 2008 and 2009.  These representative sequences were aligned, and P2 
subdomain variation was mapped upon homology models of each protruding domain 
to identify variable sites that were potentially exposed on the surface of the capsid 
and therefore to the external environment.  Five discrete regions [9, 82], two of 
which are discussed here, were identified as putative epitopes defined as local 
regions where variation appears to cluster on the surface (Figures 2.1A,B). Putative 
Epitope A is a conformational site comprised of amino acid 294, 296-298, 368 and 
372, and Epitope D is an epitope comprised of contiguous amino acids 393-395.  Of 
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interest, position 394 is the site of a single amino acid insertion that occurred in 2002 
and has been fixed in the GII.4 NoV population since this time. 
 
Design of GII.4 1987 and 2006 Chimeric VLPs.  
 The P1 and P2 regions of the GII.4 NoV VP1 protein include residues that 
undergo high levels of variability over time. Using a panel of time-ordered mouse 
mAbs to GII.4-1987 and GII.4-2006 VLPs, we demonstrated clear antigenic 
differences among GII.4 time-ordered VLPs [12].  To identify key varying residues 
that influence HBGA and antibody binding, we created a panel of chimeric VLPs by 
exchanging putative epitopes among strains that exhibit unique HBGA CHO binding 
and antigenic characteristics [12].  GII.4-1987 (Camberwell) has previously been 
shown to bind synthetic HBGA H3 [12], while GII.4-2006 (Minerva) binds synthetic 
HBGAs A, B, and H3 [26].  In this study, we focused on predicted Epitopes A and D, 
which are surface-exposed and likely play important roles in either HBGA binding, 
antigenicity or both (Figure 2.1B). We used synthetic cDNAs and created a panel of 
chimeric VLPs where amino acids were exchanged between GII.4-1987 and GII.4-
2006 within the identified putative epitopes (Figure 2.1).  Expression of the GII.4 
parental and chimeric VP1 genes resulted in the production of robust levels of VLPs 
as evidenced by SDS-Page gel and EM (Figure 2.1D).  
 
Epitope D affects HBGA binding but not mAb antigenicity. 
 Putative Epitope D includes amino acids 393-395, which are surface exposed 
and vary greatly over time either by amino acid variation or insertion (Figure 2.1A,B). 
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In GII.4 2002, an amino acid insertion at position 394 evolved which in later strains 
varied over time and is present in GII.4-2006 but not GII.4-1987. Previous work in 
our lab demonstrated that amino acid 393 influenced efficiency for HBGA B binding, 
but not for A binding, suggesting that other amino acids likely coordinate this HBGA 
interaction [12]. Farmington Hills 2002 contains one change in the P2 region at 
position 395 compared to Farmington Hills 2002a. Farmington Hills 2002a is able to 
interact with HBGA A, while Farmington Hills 2002 interactions are not robust, 
indicating that residue 395 likely influences A binding [12]. GII.4-1987 has been 
shown to efficiently bind O type CHOs, but only weakly (or not at all) to synthetic 
HBGAs A and B.  GII.4-2006, on the other hand, has been shown to efficiently bind 
O, A, and B CHOs.  We created chimeric VLP, GII.4-2006(+87D), where we 
introduced residues 393-395 from GII.4-1987 into the parental GII.4-2006 strain and 
then built the reciprocal chimera, GII.4-1987(+06D), by inserting residues 393-395 
from GII.4-2006 into the GII.4-1987 parental strain.   
 We performed a CHO binding assay to evaluate whether Epitope D chimeric 
VLPs GII.4-2006(+87D) and GII.4-1987(+06D), in which amino acids 393-395 are 
exchanged, would recapitulate HBGA binding characteristics of the parental strains 
(Figure 2.2A). As previously described, the GII.4-1987 parent did not efficiently bind 
A or B CHOs, while the GII.4-2006 parent bound both A and B in a time and dose-
dependent manner.  However, GII.4-2006(+87D) did not bind to A or B, indicating 
the 2006 residues at these positions are important for the ability of this strain to bind 
both A and B HBGAs.  In addition, GII.4-1987(+06D) gained the ability to weakly 
bind HBGA A and strongly bind HBGA B. Despite this gain of function, the binding 
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profile clearly differed from that of the GII.4-2006 parent, indicating there may be 
additional amino acids elsewhere in the capsid that contribute to subtle remodeling 
of the affinity of HBGA A and B interactions. These data are consistent with the idea 
that surface exposed residues in and around the conserved HBGA binding sites 
influence HBGA binding efficiency [12, 85]. 
  We were also interested in whether Epitope D amino acids are involved in 
antigenic differences between GII.4-1987 and GII.4-2006. Our group previously 
characterized a large panel of time-ordered mouse monoclonal antibodies that 
display varying interactions with time-ordered GII.4 VLPs [12].  In particular, mAbs 
GII.4-1987-G1, GII.4-1987-G2, GII.4-1987-G3, GII.4-1987-G4, and GII.4-1987-G5 
bound efficiently to GII.4-1987 but not to GII.4-2006 VLPs, while mAbs GII.4-2006-
G3, GII.4-2006-G4, and GII.4-2006-G7 bound efficiently to GII.4-2006 but not to 
GII.4-1987 VLPs [28].  GII.4-2006-G2 primarily bound GII.4-2006 but was somewhat 
cross-reactive with GII.4-1987 [28].  The availability of mAbs that recognize distinct 
epitopes on the surface of GII.4 1987 and 2006 VLPs provides a means of mapping 
key residues that influence antibody escape from binding over time. To determine if 
amino acids 393-395 contribute to antigenic differences between GII.4-1987 and 
GII.4-2006, we tested the reactivity of these parents and chimeras with our panel of 
GII.4-1987 mAbs and GII.4-2006 mAbs.  While subtle differences in overall binding 
were noted with anti-GII.4-1987 mAbs reacting with GII.4-1987 compared to GII.4-
1987(+06D), we did not detect significant differences in antigenic phenotypes 
between GII.4-1987 and GII.4-1987(+06D) or between GII.4-2006 and GII.4-
2006(+87D) (Figure 2.2B) with these characterized mAbs. These data indicate that 
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amino acid cluster 393-395 alone does not explain the antigenic differences 
observed between GII.4-1987 and GII.4-2006 for any of the mAbs tested in our 
panel.  
 
Putative Epitope A amino acids contribute to antigenic differences between 
GII.4-1987 and GII.4-2006. 
 Putative Epitope A consists of closely positioned surface exposed amino acids 
294, 296, 297, 298, 368, and 372 (Figure 2.1A,B). These amino acids form a 
conformational cluster on the surface ridge of the capsid and display charge 
variation over time, suggesting that these residues may play a key role in escape 
from herd immunity.  We created chimeric VLPs where combinations of amino acids 
294, 297, 298, 368, and 372 from GII.4-1987 were introduced into the GII.4-2006 
backbone (Figure 2.1C).  While we attempted to create the reciprocal exchange and 
produce VLPs comprised of GII.4-2006 Epitope A amino acids in the GII.4-1987 
backbone, after multiple tries, we were not able to yield VLPs that passed our quality 
control standards, which include robust protein production as determined by SDS-
page gel and BCA protein assay, visualization of particles by EM, and ability to bind 
synthetic CHOs and one or more conformationally dependent mAbs. The ability of 
these chimeras to bind anti-GII.4-1987 mAbs and anti-GII.4-2006 mAbs was 
measured and compared to parental strains. As expected, GII.4-1987 VLPs 
demonstrated strong homotypic reactivity, binding to anti-GII.4-1987-G1, anti-GII.4-
1987-G2, anti-GII.4-1987-G3, anti-GII.4-1987-G4, and anti-GII.4-1987-G5, while 
GII.4-2006 did not react with any of the GII.4-1987 mAbs tested (Figure 2.3) [28].  
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Chimeric VLP GII.4-2006(+87A.1), which contained all five of the Epitope A variable 
residues from GII.4-1987, exhibited significant increases in reactivity with anti-GII.4-
1987-G1, anti-GII.4-1987-G4, and anti-GII.4-1987-G5; this resulted in 6-fold, 14-fold, 
and 11-fold increases in reactivity, respectively, compared to GII.4-2006 (Figure 3) 
(p<0.0001). However, GII.4-2006(+87A.1) did not significantly alter binding (p>0.05) 
with the other two GII.4-1987 mAbs tested, anti-GII.4-1987-G2 or anti-GII.4-1987-
G3, suggesting the presence of another epitope located elsewhere on the virion 
(Figure 2.3). Anti-GII.4-1987-G1, -G4, and -G5 have previously been shown to be 
HBGA-VLP blocking antibodies [28], suggesting that Epitope A amino acids may 
comprise a neutralizing antibody epitope for GII.4-1987.  
 Binding of anti-GII.4-2006 mAbs was also compared between GII.4-
2006(+87A.1) and parental strains GII.4-1987 and GII.4-2006.  GII.4-2006 had 
strong interactions with anti-GII.4-2006-G2, anti-GII.4-2006-G3, anti-GII.4-2006-G4, 
and anti-GII.4-2006-G7, while GII.4-1987 bound anti-GII.4-2006-G2 much less 
efficiently than GII.4-2006 but did not bind anti-GII.4-2006-G3, anti-GII.4-2006-G4, or 
anti-GII.4-2006-G7 (Figure 2.3). Comparatively, GII.4-2006(+87A.1) more closely 
resembled the binding pattern seen by GII.4-1987.  GII.4-2006(+87A.1) exhibited an 
intermediate binding profile for anti-GII.4-2006-G2 that was slightly greater than that 
seen for GII.4-1987 but greatly reduced compared to GII.4-2006 (Figure 2.3).  GII.4-
2006(+87A.1) binding to anti-GII.4-2006-G3 and anti-GII.4-2006-G4 was negligible, 
and reactivity with anti-GII.4-2006-G7 was greatly reduced (Figure 2.3).  Overall, 
binding of GII.4-2006(+87A.1) was significantly reduced compared to GII.4-2006 for 
all anti-GII.4-2006 mAbs tested (p<0.0001). 
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 Next, we evaluated whether GII.4-2006(+87A.1) also had an increased 
reactivity to GII.4-1987 mouse polyclonal sera.  We performed an ELISA assay 
comparing GII.4-2006(+87A.1) reactivity with both GII.4-1987 and GII.4-2006 
polyclonal sera (Figure 2.3).  GII.4-1987 and GII.4-2006 parental strains bound most 
efficiently to homotypic polyclonal sera, while GII.4-2006(+87A.1) had a significant, 
nearly 5-fold increase in binding to GII.4-1987 polyclonal sera (p<0.0001) and a 
significant 20% decrease in binding to GII.4-2006 polyclonal sera (p<0.01) compared 
to the GII.4-2006 parental VLP.  However, GII.4-2006(+87A.1) did not bind to GII.4-
1987 sera as strongly as the GII.4-1987 parental VLP.  These results confirm that 
GII.4-2006(+87A.1) gained GII.4-1987 reactivity, but that there are additional amino 
acid residues and/or epitopes (elsewhere on the capsid) that influence GII.4-1987 
antigenic space.  
 
Epitope A amino acids do not influence HBGA A and B binding. 
 To determine whether Epitope A amino acids influence HBGA A and B binding, 
we performed CHO binding assays using GII.4-2006(+87A.1) and compared the 
binding profile to the parental GII.4-1987 and GII.4-2006 strains (Figure 2.4).  There 
were no significant differences in HBGA A and B binding between GII.4-
2006(+87A.1) and the parental GII.4-2006, indicating that these amino acids do not 
influence differences in HBGA A and B binding between GII.4-1987 and GII.4-2006 
under our treatment conditions. 
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Fine Resolution Mapping 
 Putative Epitope A consists of six surface exposed amino acid residues that 
cluster on the surface of the virion. To further investigate the contribution of 
individual and/or combinations of amino acids on antibody reactivity, we 
characterized the antigenic profiles of additional chimeric VLPs where only one or 
two of the residue changes within Epitope A were switched between strains (Figure 
1C).  Chimera GII.4-2006(+87A.2) contains two amino acid changes at positions 
R297H and N298D. By ELISA, GII.4-2006(+87A.2) did not react with any of the anti-
GII.4-1987 mAbs, except for displaying minimal reactivity with anti-GII.4-1987-G1, 
which was not significantly different from the binding of the GII.4-2006 parent (Figure 
2.5). In contrast, GII.4-2006(+87A.2) reactivity with anti-GII.4-2006 mAbs was more 
similar to the GII.4-1987 parent, in that anti-GII.4-2006-G3 and anti-GII.4-2006-G4 
binding were ablated and not significantly different from the GII.4-1987 parent.  
Under identical conditions, binding to anti-GII.4-2006-G7 was significantly reduced 
compared to the GII.4-2006 parent (Figure 2.5) (p<0.0001). This indicates that anti-
GII.4-2006-G3, -G4, and -G7 may target similar or overlapping epitopes in GII.4-
2006 comprising amino acids 297 and 298. However, GII.4-2006(+87A.2), like GII.4-
2006, exhibited strong binding with anti-GII.4-2006-G2, indicating that GII.4-2006-G2 
targets a different epitope from the other anti-GII.4-2006 mAbs in our panel; this is in 
agreement with previous data from our lab [28]. This indicates that these amino 
acids modulate specificity to some anti-GII.2006 mAbs, but do not account for the 
gain of reactivity seen with the additional amino acid substitutions in GII.4-
2006(+87A.1).   
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 Both chimera GII.4-2006(+87A.3) and GII.4-2006(+87A.4), which contain two 
amino acid changes at positions S368T and E372N and one amino acid change at 
position A294V, respectively, did not exhibit significantly different reactivity with anti-
GII.4-1987 or anti-GII.4-2006 mAbs compared with the GII.4-2006 parent. GII.4-
2006(+87A.3) and GII.4-2006(+87A.4) did not react to any of the anti-GII.4-1987 
mAbs, but showed reactivity with all anti-GII.4-2006 mAbs (Figures 2.6 and 2.7).  
Taken together, our data indicate that all Epitope A amino acids comprise a major 
antigenic site for GII.4-1987 and Epitope A residues 297 and 298 are important 
modulators of GII.4-2006 antigenicity (Table 2.1).  Our data support the idea that 
several noncontiguous amino acids work in concert to account for antigenic 
differences between these strains. 
  
Carbohydrate Blockade 
 Based on previous work by Lindesmith et al., anti-GII.4-1987-G1, anti-GII.4-
1987-G4, and anti-GII.4-1987-G5 are blocking antibodies for the same epitope in the 
GII.4-1987 parent strain but do not block GII.4-2006 interaction with synthetic CHOs 
[28]. While we determined that GII.4-2006(+87A.1) gained binding to anti-GII.4-1987 
mAbs G1, G4, and G5 (Figure 2.3), we also determined whether these antibodies 
were able to block the interaction between GII.4-2006(+87A.1) and HBGAs and thus 
whether Epitope A amino acids represented a possible neutralizing antibody epitope.  
To do this, we performed a CHO blockade assay comparing the ability of anti-GII.4-
1987-G1, anti-GII.4-1987-G4, and anti-GII.4-1987-G5 to block HBGA interactions 
with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.1). While anti-GII.4-1987-G1, -G4, 
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and -G5 were not able to block GII.4-2006 interactions with H3 [28], all three mAbs 
were able to block H3 interactions with both GII.4-1987 and GII.4-2006(+87.1), 
indicating that these are blocking antibodies for GII.4-2006(+87A.1) and target 
Epitope A. All three antibodies exhibited similar blocking patterns and anti-GII.4-
1987-G1 is shown as a representative (Figure 2.8A). Since GII.4-2006(+87A.2), 
GII.4-2006(+87A.3), and GII.4-2006(+87A.4) do not bind anti-GII.4-1987-G1, -G4, or 
-G5, it stands to reason that these mAbs cannot be blocking antibodies for these 
chimeras. From these data, we determined that in addition to amino acids 296-298, 
which have previously been shown to modulate antigenicity, amino acids 294, 368, 
and 372 are important for the blockade response to GII.4-1987. 
 We also determined whether a known GII.4-2006 blocking antibody was able to 
retain the ability to block our four Epitope A chimeras. We performed a CHO 
blockade assay to determine if anti-GII.4-2006-G7, a mouse mAb identified by 
Lindesmith et al. [28] to block GII.4-2006 interaction but not GII.4-1987 interaction 
with HBGAs, could block HBGA interaction with GII.4-2006(+87A.1), GII.4-
2006(+87A.2), GII.4-2006(+87A.3), and GII.4-2006(+87A.4).  While anti-GII.4-2006-
G7 was able to block H3 interaction with GII.4-2006, GII.4-2006(+87A.3), and GII.4-
2006(+87A.4) it was unable to block HBGA binding to GII.4-1987, GII.4-
2006(+87A.1), and GII.4-2006(+87A.2) (Figure 2.8B). Taken together, this indicates 
that Epitope A amino acids represent a blocking antibody epitope that is undergoing 
antigenic variation. The epitope encoded both in GII.4-1987 and GII.4-2006 is 
targeted by antibodies that block the homotypic VLP but not the heterotypic 
response.  
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 GII.4-2006(+87A.1) exhibited increased reactivity with GII.4-1987 polyclonal 
mouse sera (Figure 2.9A).  To determine the degree to which Epitope A amino acids 
contribute to the overall GII.4-1987 blockade response, we performed a blockade 
assay comparing the ability of GII.4-1987 polyclonal mouse sera to block H3 
interaction with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.1) VLPs (Figure 2.9B). 
The GII.4-1987 polyclonal sera BT50 concentration for interaction between H3 and 
GII.4-1987 was 1:160 (0.7% sera), while the BT50 for GII.4-2006(+87A.1) was 1:40 
(2.5% sera).  GII.4-2006 did not have a mean BT50 even at the highest 
concentration of GII.4-1987 polyclonal sera tested (1:10); however, some individual 
replicates in the assays performed did have a BT50 and those that did not were 
assigned a BT50 of 1:5 (20% sera) (Figure 2.9C).  By one-way ANOVA, BT50 
values for GII.4-1987 and GII.4-2006(+87A.1) were not significantly different. GII.4-
2006 was significantly different from both GII.4-1987 and GII.4-2006(+87A.1) 
(p<0.05).  Overall, these results indicate that Epitope A amino acids account for 
approximately 25% of the antibody blockade response encoded within GII.4-1987 
mouse polyclonal sera. 
 GII.4-2006(+87A.1) displayed increased reactivity with 1988 GII.4 NoV 
outbreak human sera compared to GII.4-2006 (Figure 2.10A).  To determine 
whether Epitope A amino acids contribute to the GII.4-1987 blockade response in 
humans, we performed a blockade assay comparing the ability of 1988 GII.4 NoV 
outbreak human serum samples to block CHO interaction with GII.4-1987, GII.4-
2006, and GII.4-2006(+87A.1). Since we were interested in the contribution of 
Epitope A amino acids to the GII.4-1987 blockade response, we chose to utilize nine 
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human serum samples that had the ability to block CHO interaction with the GII.4-
1987 VLP [12, 26]. Overall, the human serum samples were able to block GII.4-1987 
most efficiently, and, with the exception of one individual, were able to block GII.4-
2006(+87A.1) more efficiently than GII.4-2006, although differences were not 
significant.  When all nine sera samples were averaged at each time point, the same 
trend was seen (Figure 2.10B).  GII.4-1987 was blocked most efficiently at all 
dilutions. GII.4-2006(+87A.1) and GII.4-2006 were blocked to similar levels, although 
GII.4-2006(+87A.1) was blocked to a greater degree than GII.4-2006 at all sera 
dilutions. We then compared BT50 values (the dilution at which 50% of the VLP-
CHO interaction is blocked compared to control) for GII.4-1987, GII.4-2006(+87A.1), 
and GII.4-2006.  The average BT50 values for GII.4-1987, GII.4-2006(+87A.1), and 
GII.4-2006 were 1:1600, 1:800, and 1:400, respectively, indicating significant 
differences for BT50 values between GII.4-1987 and GII.4-2006 (p<0.05) but not 
between GII.4-2006(+87A.1) and GII.4-1987 or GII.4-2006 (Figure 2.10C).  
Together, these data suggest that Epitope A contributes to the global GII.4-1987 
blockade response in mice and humans.  In vaccinated mice, Epitope A accounts for 
approximately 25% of the total blockade response between GII.4-1987 and GII.4-
2006. Using GII.4-1987 human antisera, we can detect clear differences in blockade 
responses using time-ordered VLPs.  However, because of variation among human 
samples and unknown preexposure histories, additional human sera samples will be 
needed to detect significant differences in the blockade activity that targets individual 
epitopes.   
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Discussion 
 GII.4 NoVs exhibit epochal evolution, whereby major circulating strains give 
rise to emergent strains, likely due to escape from herd immunity [12, 86, 91]. 
Evidence supporting this includes greater positive selection in capsid P2 subdomain 
amino acids compared to the rest of the capsid protein, robust data exhibiting altered 
antigenicity and HBGA binding over time in VLPs of major outbreak and pandemic 
GII.4 strains, and the identification of strain-specific potentially neutralizing 
antibodies in GII.4 NoVs [12, 28, 86]. Similar to GII.4 NoVs, influenza A undergoes 
antigenic variation as mutations in the hemagglutinin 1 (HA1) domain of HA genes 
drive escape from existing herd immunity [92-94].  Additionally, amino acids in the 
GII.4 NoVs P2 region, which interact with antibodies and binding ligands, undergo 
positive selection similar to the mechanism in influenza whereby HA interacts with 
antibodies and sialic acid and also contains many amino acids undergoing positive 
selection [93, 95].  Individual epitopes in other viruses, like influenza, have been 
shown to lead to escape from herd immunity [92], providing the possibility that GII.4 
NoVs undergo a similar mechanism of evolution. To provide further support for this 
idea, this study used a novel mapping strategy to identify a blockade epitope in 
GII.4-1987 and GII.4-2006 that changed over time in major GII.4 outbreak strains, 
and we identified a specific epitope involved in modulating HBGA binding patterns in 
different GII.4 strains. This is the first study to identify an antibody blockade epitope 
in GII.4 NoVs. These findings will further contribute to elucidation of mechanisms 
driving evolution in these viruses, provide insight into the emergence of new 
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epidemic variants, and provide direction for broadening the antigenic design and 
cross blockade activity of potential vaccines for NoVs. 
 Five putative epitopes were predicted via sequence analysis using 36 
representative, time-ordered GII.4 stains from 1974 to 2009 to identify amino acid 
residues that varied consistently over time and were exposed on the capsid surface 
in the P2 subdomain [9].  These varying residues were then mapped onto homology 
models of each respective representative, and the structural models were compared 
to find residues that map together in discrete regions of the capsid surface.  We 
chose to build chimeras between GII.4-1987 and GII.4-2006 because of known 
differential HBGA binding and antigenicity profiles between these two strains [12, 26, 
28].  By examining reactivity of our chimeric VLPs with synthetic HBGAs and mouse 
monoclonal antibodies against GII.4-1987 and GII.4-2006, we determined that 
Epitopes A and D were important for antigenic and HBGA differences between these 
strains, respectively.  Our results suggest that changes in surface residues drive 
antigenic change in GII.4 NoVs, as has been shown previously in influenza.  
Additionally, our results validate the utility of using bioinformatics approaches to 
identify important antigenic determinants. 
  Our data clearly show that amino acids 393-395 modulate HBGA A and B 
interactions, confirming earlier observations by our lab and others [12, 32].  When 
we exchanged amino acids in positions 393-395 between GII.4-1987 and GII.4-
2006, we observed a significant decrease in interaction between GII.4-2006(+87D) 
and HBGAs A and B compared to GII.4-2006 and a significant increase in interaction 
between these HBGAs and GII.4-1987(+06D) compared to GII.4-1987, indicating 
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that these amino acids influence interaction with A and B CHOs.  However, we also 
noticed that the interaction profile of GII.4-1987(+06D) was very different from that of 
the GII.4-2006 parent, suggesting that other amino acids contribute to A and B 
interactions as well.  Teasing apart these interactions without a crystal structure can 
be complex.  While modeling programs can be used to provide predictions about 
VLP-CHO interactions, these methods rely upon models based on previously solved 
structures.  Studying the differences between GII.4 NoV strains has been impeded 
by the existence of only two GII.4 crystal structures, VA387, which models GII.4-
1997 complexed with CHOs A and B and Hunter 2004 bound to several CHOs. 
These structures were used to assemble homology models for GII.4-1987 and GII.4-
2006.  Recognizing limitations inherent in this approach, our models identified 
potential mechanisms that explain increased GII.4-1987(+06D) interactions with 
HBGA B, as compared with GII.4-2006.  Structural homology models for GII.4-1987, 
GII.4-2006, and GII.4-1987(+06D) predicted subtle differences in the positioning of 
residues 393-395 in a surface exposed loop (Figure 2.11A) and in polar interactions 
among binding pocket amino acids in sites 1 and 2 (residues 342-347, 374, 390-395, 
and 440-444) of GII.4-2006 and GII.4-1987(+06D) and CHO B (Figure 2.11B-F).  
Importantly, direct interactions between the CHO and residues 393-395 were not 
observed; however, rearrangement of polar interactions between residue 390, 393, 
and 395 (Figure 2.11B) occurred, which may slightly juxtapose the interactions in the 
binding pocket.  This suggests that these residues have long-range effects on polar 
interactions in the binding pocket.  Variation in the loop programmed specific 
differences in GII.4-1987(+06D) ability to: a) form a new hydrogen bond between the 
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fucose of CHO B and amino acid 343 (Figure 2.11C), b) terminate two hydrogen 
bonds from residue 345 and CHO B (Figure 2.11D), and c) form new hydrogen 
bonds between 343 and 444 (Figure 2.11E) and between residues 442 and CHO B 
(Figure 2.11F). Together, these altered polar interactions are predicted to stabilize 
binding of CHOs within the binding site, allowing GII.4-1987(+06D) to exhibit 
stronger binding to CHO B and potentially to H3.  However, we stress that crystal 
structures of more GII.4 strains bound to CHOs are needed to further address these 
predictions.  Other groups have suggested additional P2 amino acids that may 
modulate HBGA A and B binding. Tan et al. identified 346 as contributing to A and B 
interactions [88].  Because this residue varies between GII.4-1987 and GII.4-2006, it 
is possible that 346 also modulates A and B binding; however, we did not test this 
possibility in this study and this residue did not participate in direct polar interactions 
in our homology models.  Yang et al. reported I389 as a single amino acid residue 
important for A binding [96]. While this amino acid does not contribute to the 
differences in A and B binding between GII.4-1987 and GII.4-2006, as both strains 
encode I389, we cannot rule out the possibility that this residue contributes to HBGA 
binding in other GII.4 strains.  However, Shanker et al. also found no evidence that 
residue 389 would contribute to HBGA A binding in GII.4-2004 [85].   
 Epitope A amino acids (294, 296-298, 368, and 372) change over time and 
map to the same area of the capsid surface, likely forming a non-contiguous 
conformational epitope. Influenza and HIV provide examples of viruses that have 
variable, non-contiguous conformational epitopes that change over time, resulting in 
viruses that are able to escape the immune response [97-99]. Our data demonstrate 
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that Epitope A amino acids collectively comprise a blocking antibody epitope for both 
GII.4-1987 and GII.4-2006, suggesting that the surrounding landscape and 
conformational changes associated with amino acid variation greatly impact 
antigenicity. Variation likely reshapes the surface of the P2 region, altering the 
affinity with which different mAbs bind and neutralize the virus; however, additional 
GII.4 crystal structures coupled with mAb are essential for understanding the 
molecular basis of antibody binding, blockade, and likely for illuminating the 
mechanism of escape from herd immunity.  While predicted Epitope A also includes 
amino acid 296, this residue is conserved between GII.4-1987 and GII.4-2006, so 
our current work does not address the antigenic consequences of changes to 
residue 296.  However, Allen et al (2009) demonstrated that amino acids 296-298 
were important antigenic determinants between pre 2002 and post 2002 GII.4 
strains although they did not evaluate CHO blockade.  Our data corroborate the 
importance of these amino acids in GII.4 antigenic changes over time. Introducing 
smaller subsets of Epitope A amino acids as in GII.4-2006(+87A.2), GII.4-
2006(+87A.3), and GII.4-2006(+87A.4) did not yield gains in binding to anti-GII.4-
1987 mAbs for the chimeric VLPs tested, suggesting that all five Epitope A amino 
acid changes are needed in combination to gain robust binding phenotypes to the 
anti-GII.4-1987 mAbs tested. While speculative, some flu epitopes are proposed to 
evolve by epochal evolution characterized by drift modified by mutations of large 
effect; similar mechanisms may be operating during GII.4 persistence in human 
populations [93].  While it is possible that creating additional combinations of these 
five amino acids would yield a combination that accounts for the gain in binding to 
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anti-GII.4-1987 mAbs, we argue that it is more likely that these non-contiguous 
amino acids constitute a conformational epitope where they contribute, in concert, to 
the gain in binding to anti-GII.4-1987 mAbs.  We do not exclude the possibility that 
additional amino acids may contribute to interactions with anti-GII.4-1987 and anti-
GII.4-2006 mAbs. Importantly, based on sequence alignment data, Epitope A is still 
evolving in the currently-circulating Minerva variant, GII.4-2009 New Orleans. This 
suggests that this epitope may also constitute an important blocking epitope in future 
epidemic GII.4 strains, thus monoclonal antibodies against contemporary GII.4-2009 
strains may provide greater resolution in understanding the potential mechanisms 
driving antigenic variation and antibody blockade escape over time. To our 
knowledge, this is the first study utilizing a panel of time-ordered chimeric viruses 
with exchanged epitopes to study these processes; however, this approach may be 
highly relevant to studying antigenic variation in other viruses including influenza and 
HIV.   
 Because human NoVs lack a viable cell culture model, antibody neutralization 
potential is measured in a surrogate neutralization assay, the CHO blockade assay 
[28, 35].  This assay measures an antibody’s ability to block the interaction between 
immobilized HBGA and a particular VLP. Reeck et al. (2009) showed a correlation 
between the ability of antibodies to block VLP-HBGA interaction in this assay and 
protection from symptomatic Norwalk virus infection, demonstrating that the 
blockade assay is a relevant surrogate assay that measures a component of 
protective immunity [20].  We showed that Epitope A is a significant blockade 
epitope.  Using anti-GII.4-1987-G1, -G4, and –G5 mAbs, we demonstrated that 
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residues 294, 297-298, 368, and 372 work in concert to account for the GII.4-1987 
blockade response for these antibodies.  Using anti-GII.4-2006-G7, we 
demonstrated that amino acids 297-298 account for the GII.4-2006 blockade 
response for this antibody. GII.4-2006(+87A.1) and GII.4-2006(+87A.2), which both 
contain changes at these residues were not blocked by anti-GII.4-2006-G7, but this 
antibody blocked VLP/HBGA interaction for chimeras GII.4-2006(+87A.3) and 
GII.4(+87A.4) which did not contain substitutions at 297 or 298.  Approximately 25% 
of the total blockade response for GII.4-1987 polyclonal mouse sera was targeted 
against Epitope A based on comparing the CHO blockade potential of the parental 
GII.4-1987 compared to GII.4-2006.  This result suggests that there are either 
additional unidentified blockade epitopes present for GII.4-1987 or additional 
unidentified residues that contribute to the overall antigenic variation in Epitope A. 
This approach may be useful in future studies to predict the number of potentially 
neutralizing epitopes for each particular strain and the relative importance of each 
epitope in contributing to blocking antibody response over time. 
 Using GII.4 NoV human outbreak sera, we demonstrated that Epitope A is a 
potential blockade epitope not just in mice, but in humans as well.  Results gleaned 
from human data underscore the importance of individual variation and previous 
exposure history in the immune response to different GII.4 NoV strains.  Mouse 
polyclonal sera data, produced in a background with no previous exposure history or 
genetic diversity, yielded clear differences in blockade among GII.4-1987, GII.4-
2006(+87A.1), and GII.4-2006, where GII.4-1987 and GII.4-2006(+87A.1) were 
blocked but GII.4-2006 was not.  Human sera, on the other hand, was able to block 
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VLP-CHO interactions with GII.4-1987, GII.4-2006(+87A.1), and GII.4-2006, though 
with differences in overall BT50 values.  While the human outbreak sera were able 
to detect significant differences in BT50 values between GII.4-1987 and GII.2006, it 
was unable to distinguish significant differences at the level of a single varying 
epitope.  However, the overall trend showed that the human outbreak sera blocked 
GII.4-2006(+87A.1) more efficiently than GII.4-2006 at every dilution point.  This 
suggests that Epitope A likely contributes to the human blockade response in GII.4-
1987, but that additional human serum samples are needed to dissect the overall 
contribution of an individual epitope.  The differences in blockade between mouse 
and human sera may be due to varied NoV exposure histories from the human sera 
donors.  Ogata et al. found that previous influenza vaccination resulted in greater 
levels of neutralizing antibodies against the newly emergent human H5N2 avian 
influenza virus [100].  In addition, Lee et al. found that previous exposure to pre-
1957 H1N1 strains was able to provide some cross-neutralizing protection from the 
2009 H1N1 strain but not from a 2007 strain [101].  This suggests that in some 
cases, previous exposure history may provide subtle to substantial levels of 
protection from related, but distinct viral strains on an individual level.  Since GII.4 
NoVs and influenza exhibit similar evolutionary dynamics, previous exposure to NoV 
may provide protection from specific strains, but not others. Our data provide 
evidence that Epitope A accounts for up to 25% of the GII.4-1987 blockade 
response and suggests that there are additional blockade epitopes for GII.4-1987.   
 Our approach of using bioinformatics predictions to identify putative GII.4 NoV 
epitopes coupled with using our panel of chimeric and parental VLPs, time-ordered 
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mouse mAbs, and synthetic CHOs in ELISA-based assays to validate our 
predictions offers a powerful method to elucidate the mechanisms driving GII.4 NoV 
evolution in the absence of a cell culture or small animal model.  Despite evidence 
that preferential HBGA binding patterns and antigenicity in GII.4 NoVs change over 
time, results among different labs vary and are difficult to directly compare due to 
differences that may exist among VLPs, P particles, and P dimers; differences in 
protein concentrations used in ELISA-based assays; and lot number differences in 
reactivity of commercial biotinylated HBGAs.  Variation in CHO binding levels among 
assays in this manuscript is due to this differing reactivity among batches of 
commercially-available synthetic biotinylated CHOs; however, due to the low supply 
of these reagents, this is unavoidable without altering the amount of CHO used in 
each experiment.  However, it is clear that mutations outside of the conserved CHO 
binding residues contribute to the antigenic and HBGA binding differences apparent 
over time. Future work will seek to validate our other predicted epitopes by 
expanding the epitopes to include surrounding amino acids and building and 
characterizing additional chimeras in the GII.4-2002 Farmington Hills background. 
 GII.4 NoVs are significant human pathogens that cause considerable morbidity 
and mortality, worldwide.  The identification of highly significant, varying antigenic 
epitopes that influence VLP-ligand interaction provides important new insights into 
vaccine design and the development of therapeutics that target norovirus virions. For 
example, our data predict that vaccines derived from GII.4-1987(+06A) or GII.4-
2006(+87A) should greatly broaden the breadth of the cross antigenic and cross 
blockade response against time-ordered GII.4 NoV.  Our data predict that GII.4-
	   63	  
2006(+09A) vaccines would induce stronger blockade responses against 
contemporary GII.4 strains as compared to GII.4-2006 VLP vaccines.  These 
experiments are underway.  Finally, we anticipate that a full understanding of the 
varying antigenic and blockade epitopes of GII.4 NoV may not only help to predict 
the emergence of new epidemic strains but simultaneously identify key 
reformulations in vaccine design that will protect the public health against 
contemporary and emerging epidemic strains of the future.  
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CHAPTER 3:  EMERGENCE OF NEW PANDEMIC GII.4 SYDNEY STRAIN 
CORRELATES WITH ESCAPE FROM HERD IMMUNITY3 
 
Introduction 
Noroviruses are a leading cause of acute gastroenteritis, resulting in 
approximately 21 million infections in the U.S. annually[102]. The highly 
heterogeneous human noroviruses are divided into two principle genogroups 
designated GI and GII, which are further subdivided into 9 and 21 genotypes, 
respectively[6, 103]. The GII.4 noroviruses are responsible for >70% of all norovirus 
outbreaks[104]. Norovirus disease patterns in human populations include epidemic 
outbreaks of disease every 2-3 years, punctuated by the emergence of an 
antigenically distinct GII.4 strain that appears to escape human herd immunity to the 
previous circulating strain[10, 11, 13, 38]. The first major GII.4 norovirus pandemic 
was associated with the GII.4-1997 US95/96 strain[105, 106], which was replaced in 
2002 with GII.4-2002 Farmington Hills[107]. GII.4-2002 was then replaced in 2004 
by the Hunter strain[108-110]. In 2006, GII.4-2006 Minerva replaced Hunter[109, 
111, 112] and was the predominant strain until 2009 when it was gradually replaced 
with GII.4-2009 New Orleans[113]. In March 2012, a new strain, called GII.4-2012 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  This	  chapter	  previously	  appeared	  as	  an	  article	  in	  the	  Journal	  of	  Infectious	  Diseases.	  The	  original	  citation	  is	  as	  follows:	  Debbink	  K,	  Lindesmith	  LC,	  Donaldson	  EF,	  Costantini	  V,	  Beltramello	  M,	  Corti	  D,	  Swanstrom	  J,	  Lanzavecchia	  A,	  Vinje	  J,	  and	  Baric	  RS.	  “Emergence	  of	  New	  Pandemic	  GII.4	  Sydney	  Strain	  Correlates	  with	  Escape	  from	  Herd	  Immunity.”	  Journal	  of	  Infectious	  
Diseases	  208(11)	  (December	  2013):	  1877-­‐87.	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Sydney, was first described, and by November 2012, it had replaced GII.4-2009 as 
the primary norovirus strain in most countries in the northern hemisphere[114, 115]. 
Noroviruses are single-stranded, positive sense RNA viruses that belong to 
the family Caliciviridae. The norovirus genome is ~7.5 kb and contains three open 
reading frames. ORF1 encodes the non-structural proteins, ORF2 encodes the VP1 
major capsid protein, and ORF3 encodes the VP2 minor capsid protein[75]. The P2 
subdomain of VP1 contains potential neutralizing antibody epitopes and interacts 
with histoblood group antigens (HBGAs), which are a diverse family of 
carbohydrates and serve as putative receptors for norovirus entry[11-13, 19, 78, 79, 
84, 85, 116]. HBGAs are differentially expressed in humans and differentially bound 
by NoV strains[12, 19, 75, 85, 117].  
There is currently no cell culture or small animal model available to study 
human noroviruses, slowing progress toward understanding the mechanisms of 
protective immunity, virus evolution, and the development of an effective vaccine. 
However, VLPs, which are morphologically and antigenically comparable to native 
virions, serve as a virus surrogate, and in conjunction with bioinformatics and 
surrogate neutralization assays, provide a good model to study questions regarding 
viral evolution and human immunity, which will ultimately inform vaccine design[11, 
13, 28, 38]. 
Using human and mouse monoclonal antibodies and time-ordered wildtype 
and chimeric GII.4 VLPs, we and others have previously shown that the emergence 
of these new pandemic strains is often associated with alterations in GII.4 blockade 
epitopes mapped to the surface of the major capsid protein P2 subdomain[10, 11, 
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13, 38, 83, 87, 118, 119]. In this manuscript, we demonstrate that the emergence of 
GII.4-2012 Sydney is associated with changes in major blockade epitopes, 
especially epitopes A[11] and D[10], that lead to altered antigenicity as compared to 
GII.4-2009 New Orleans.  
 
Materials and Methods 
Virus like particles 
A synthetically-derived outbreak GII.4-2012 ORF2 cDNA was synthesized 
(BioBasic), and inserted into the Venezuelan equine encephalitis virus 3526 replicon 
vector (VRP-3526).  For GII.4-2006 and GII.4-2009 VLPs, virus replicon particles 
(VRPs) were produced and inoculated onto BHK cells as previously described[10]. 
For GII.4-2012, VLPs were expressed from VEE replicon vector RNA after 
electroporation of BHK cells and purified as described previously[11, 38]. Structural 
integrity of VLPs was confirmed by EM, EIA, and carbohydrate binding[10]. 
 
HBGA-VLP Binding Assay 
HBGA binding assays were performed as previously described[11, 12].  
Briefly, synthetic HBGAs or PGM was diluted to 10 µg/ml and coated onto plates. 2 
µg/ml VLPs were added and detected by polyclonal rabbit sera and then anti-rabbit 
IgG-HRP (GE Healthcare) followed by One-Step Ultra TMB EIA HRP substrate 
solution (Thermo-Fisher).  Data are the average of three replicates with similar 
results from at least two independent experiments.  Positive reactivity is defined as a 
mean optical density greater than 3X the background binding signal. 
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EIAs  
Mouse and human mAb reactivity was determined by EIA, as reported[10, 
13]. Briefly, 1µg/ml VLP in PBS was coated onto plates, followed by addition of 1 
µg/ml purified IgG and then anti-mouse or human IgG-HRP (GE Healthcare) 
followed by One-Step Ultra TMB EIA HRP substrate solution. Data are the average 
of three replicates from at least two independent experiments. Positive reactivity is 
defined as a mean OD 450 nm >0.2 after background subtraction[38]. 
 
VLP-Carbohydrate Ligand-Binding Antibody Blockade Assays   
Pig Gastric Mucin Type III (PGM) (Sigma Chemicals) contains HBGAs α-1,2-
fucose (H antigen) and α-1,4-fucose (Lewis antigen)[12, 13, 120] and has been 
validated as a substrate for norovirus VLP antibody-blockade assays[10, 13]. 
Blockade assays were performed as previously described[38]. VLPs bound to PGM 
or biotinylated B were detected by rabbit anti-GII.4 norovirus polyclonal sera. The 
percent control binding was defined as the VLP-ligand binding level in the presence 
of test antibody or sera compared to the binding level in the absence of antibody 
multiplied by 100[13, 35]. All antibodies were tested for blockade potential at two-fold 
serial dilutions ranging from 0.004 to 2 µg/ml for mouse mAbs, 0.008 to 16 µg/ml for 
human mAbs, or 0.008 to 1% for human serum. Data shown are the average of at 
least two replicates and are representative of similar data from at least two 
independent trials.  Sigmoidal dose response analysis was performed as previously 
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described[38]. EC50 values among VLPs were compared using One-way ANOVA 
with Dunnett’s post test. P<0.05 was considered significant.  
 
Hybridoma Production, IgG Purification, and GII.4 Outbreak serum samples  
Mouse and human mAbs were produced and purified as described previously 
by our group[10, 28]. De-identified human convalescent serum samples collected 
from eight subjects infected with GII.4-2009, as previously described were used in 
this study[38]. 
 
Results 
GII.4 noroviruses undergo genetic changes over time, which are associated 
with changes in antigenicity[28]. We previously identified three GII.4 blockade 
epitopes in VP1, designated A, D, and E, which are altered in GII.4-2012 and other 
contemporary strains and affect GII.4 norovirus antigenic profiles[10, 11, 13, 38] 
(Figure 3.1). In early strains, epitope A appears immunodominant, accounting for 40-
55% of the total blockade response[7, 9]; GII.4-2009 and GII.4-2012 share four 
common residues but have two amino acid changes at P294T and A368E. Epitope 
D shares two residues between GII.4-2009 and GII.4-2012, with differences at 
S393G and P396H. Epitope E has one differential residue between GII.4-2012 and 
GII.4-2009, a I413T change. To test the impact of these sequence changes on 
antigenicity, we produced GII.4-2012 Sydney and chimeric VLPs. Overall, GII.2-
2012 exhibited decreased EIA binding to all synthetic HBGAs tested compared to 
GII.4-2009 (Figure 3.2). Next, we compared EIA reactivity and blockade ability of 
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mAbs and human outbreak sera between GII.4-2012 and previous predominant 
strains GII.4-2009 and GII.4-2006. 
 
GII.4-2006 Mouse Monoclonal EIA Cross Reactivity and Blockade Response 
We previously characterized a set of GII.4-2006 mouse mAbs, all of which 
exhibit strong EIA reactivity with GII.4-2006 and GII.4-2009 and are blockade 
antibodies that target overlapping residues across epitope A[11, 13, 28, 38]. To 
determine whether GII.4-2006 mouse mAbs are able to distinguish GII.4-2012 from 
previous GII.4 strains, we compared five GII.4-2006 (G2, G3, G4, G6, G7) mouse 
mAbs for EIA reactivity with GII.4-2012, GII.4-2006 and GII.4-2009 VLPs. By EIA, 
GII.4-2012 did not bind with GII.4-2006-G3 and G4 mAbs (Figure 3.3A), while 
reactivity with GII.4-2006-G2, G6, and G7 mAbs was significantly reduced (p<0.05) 
1.8-4.5 fold compared with GII.4-2006 and GII.4-2009 (Figure 3.3A). 
Blockade is a more sensitive measure of antigenic variation and, unlike EIA, 
can measure potential functional differences in antigenicity that correlate with 
protective immunity in vivo[20, 121]. Three GII.4-2006 blockade mouse mAbs that 
map to epitope A demonstrated EIA reactivity with GII.4-2012 (GII.4-2006-G2, G6, 
and G7). To examine functionally relevant antigenic differences between GII.4-2012 
and previous strains, we performed surrogate neutralization blockade assays. GII.4-
2006-G2, while able to block both GII.4-2006 and GII.4-2009 VLPs, lost the ability to 
block GII.4-2012 VLP interaction with HBGA (Figure 3.3B). GII.4-2006-G6 and G7 
mAbs were both able to block GII.4-2012 VLP interaction with HBGA, but EC50 
values were significantly reduced (3.9-6.3 fold) compared with GII.4-2006 and GII.4-
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2009 VLPs (Figure 3.3C,D).  Out of five GII.4-2006 blockade mouse mAbs that 
target epitope A, only two (G6, G7) retained limited EIA and blockade ability against 
GII.4-2012 VLPs, and both of these were significantly reduced.  
 
GII.4-2009 Mouse Monoclonal EIA Cross Reactivity and Blockade Response 
To further compare the impact of epitope A changes on GII.4-2012 antigenic 
structure and function, we evaluated GII.4-2012 reactivity with four GII.4-2009 
blockade mouse mAbs. Previous work demonstrated that mAbs NO37 and NO52 
target epitope A, but the binding sites for mAbs NO66 and NO224 have not yet been 
mapped on the structure[38]. NO37 cross-reacts with GII.4-2006 and GII.4-2009[38], 
but does not bind GII.4-2012 (Figure 3.4A). The other NO antibodies tested react 
with GII.4-2009 but not GII.4-2006[38]. NO52 and NO224 binding to GII.4-2012 were 
significantly reduced (2.75-3.9 fold, respectively) compared to GII.4-2009. NO66 
failed to react by EIA with GII.4-2012 under these treatment conditions (Figure 
3.4A). 
In addition, we tested the GII.4-2009 mouse mAbs that bind GII.4-2012 in EIA 
(NO52 and NO224) for blockade potential against this strain. Both NO52 and NO224 
were able to block GII.4-2012 (Figure 3.4B,C).  Interestingly, NO52 blocked GII.4-
2012 significantly more efficiently than the homotypic GII.4-2009 VLP (Figure 3.4B), 
indicating that this mAb may target a unique motif within epitope A compared with 
other epitope A-targeting antibodies. EC50 blockade titers for GII.4-2012 and GII.4-
2009 by NO224 were not significantly different (Figure 3.4C).  These results support 
our data from GII.4-2006 mAbs, demonstrating that antigenicity between GII.4-2012 
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and previously circulating strains is significantly different at epitope A. These results 
also confirm previous findings that epitope A mAbs likely engage overlapping, yet 
distinct epitope residues. 
 
Human Monoclonal Antibody EIA Cross Reactivity and Blockade Response 
While mouse mAbs provide an excellent tool to examine targeted, strain-
specific norovirus antibody responses, it is possible that the immune systems of 
mice and humans engage norovirus epitopes differently. Therefore, we examined 
whether human mAb EIA reactivity and blockade responses were also able to 
differentiate between GII.4-2012 and ancestral strains. We previously characterized 
four blockade human mAbs, which recognize either GII.4-2006 or GII.4-2009, or 
both (NVB 43.9, NVB 71.4, NVB 97, NVB 111)[10]. Two of these mAbs map to 
epitope A (NVB 43.9, NVB 111), while another maps to epitope D (NVB 97)[10]. 
NVB 71.4 recognizes a conserved GII.4 blockade epitope across time-ordered 
strains that has not yet been mapped onto the structure. We first tested these GII.4 
blockade human mAbs for EIA reactivity with GII.4-2012. Consistent with a previous 
report, NVB 43.9, NVB 71.4, and NVB 97 recognize GII.4-2006 and GII.4-2009, 
while NVB 111 binds only GII.4-2006[10]. When we examined reactivity of these 
human mAbs with GII.4-2012, we found that NVB 43.9 and NVB 111 (epitope A), 
and NVB 97 (epitope D) lost EIA reactivity with GII.4-2012 (Figure 3.5A). NVB 71.4 
retained binding to GII.4-2012 similar to levels seen with GII.4-2006 and GII.4-2009 
(Figure 3.5A). These results corroborate the importance of epitope A changes in 
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antibody recognition of GII.4-2012. In addition, loss of binding to the epitope D mAb 
indicates that this epitope has also evolved in the GII.4-2012 strain.  
Next, we determined whether human blockade mAbs could further distinguish 
between emergent GII.4-2012 and contemporary GII.4-2009 strains.  GII.4-2012 was 
only recognized by one human blockade mAb, NVB 71.4. This broadly cross-
reactive and blocking antibody is capable of preventing HBGA binding with GII.4 
strain VLPs from GII.4-1987 through GII.4-2009[10]. When tested for blockade 
response against GII.4-2012, NVB 71.4 weakly blocked this strain, with an EC50 
significantly higher than for GII.4-2006 and GII.4-2009 (Figure 5B). We also 
evaluated NVB 97 blockade activity against GII.4-2012 despite its inability to bind 
GII.4-2012 by single dilution EIA. NVB 97 targets epitope D, another previously 
identified GII.4 blockade epitope[10]. Corroborating EIA data, NVB 97 was not able 
to block GII.4-2012 VLP-binding ligand interaction by blockade assay (Figure 5C). 
Overall, human mAb blockade data are consistent with mouse mAb blockade data 
demonstrating that GII.4-2012 is antigenically distinct in major blockade epitopes 
from previously-circulating contemporary strains GII.4-2006 and GII.4-2009.  
 
Mapping of GII.4-2012 Amino Acids Involved in Epitope A Antigenic 
Differences 
To more specifically map amino acids important for antigenic differences 
between GII.4-2009 and GII.4-2012, three epitope A chimeras between GII.4-2009 
and GII.4-2012 were constructed, where residues from GII.4-2009 were inserted into 
the GII.4-2012 background (2012.T294P, 2012.E368A, and 2012.09A). We 
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performed blockade assays using epitope A targeting antibodies against these 
chimeras and compared them to parental strain blockade data. Overall, data shows 
that GII.4-2012 residue 368E is important for the antigenic differences in epitope A 
between GII.4-2009 and GII.4-2012 as this residue impacted the blockade ability of 
all eight epitope A targeting mAbs tested (2006-G2, G3, G4, G6, G7, NO37, NO52, 
and NVB 43.9), and representative data are shown (Figure 3.6A).  Residue 294T 
was also important, synergistically contributing with 368E to the difference in 
blockade response for 4 of 8 mAbs (2006-G3, NO37, NO52, NVB 43.9), and 
representative data are shown (Figure 3.6B).  Importantly, blockade profiles between 
GII.4-2009 and GII.4-2012.09A were different for some antibodies (Figure 6A), 
indicating that there are other residues not included in the defined epitope A that 
contribute to antigenicity changes between GII.4-2009 and GII.4-2012. 
 
GII.4-2009 Outbreak Human Sera Against GII.4-2012. 
Blockade results with mAbs demonstrated differences between GII.4-2009 
and GII.4-2012 in epitopes A and D, but mAb data don’t represent the total antibody 
response. To determine if the polyclonal antibody response is different between 
GII.4-2009 and GII.4-2012 and to what degree epitope A accounts for any 
differences, we tested the blockade activity of GII.4-2009 outbreak convalescent 
human sera from eight individuals against GII.4-2009, GII.4-2012, and GII.4-
2012.09A VLPs. EC50 titers demonstrated that significantly more sera was 
necessary to block GII.4-2012 (0.066%) and GII.4-2012.09A (0.048%) compared to 
GII.4-2009 (0.021%) (Figure 3.7). This demonstrates that only ~30% of the blockade 
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against GII.4-2009 is retained against GII.4-2012, and at least 11% of the decreased 
response is due to changes in epitope A. Individually, it took significantly more sera 
to block GII.4-2012 compared to GII.4-2009 in 7/8 serum samples (Figure 3.8A-G) 
and significantly less sera to block in 1/8 serum samples (Figure 3.8H). In 4/8 serum 
samples (Figure 3.8), epitope A was responsible for a significant change in 
blockade, accounting for between 21-100% of the change. 
 
Discussion 
GII.4 noroviruses are the principle cause of epidemic norovirus gastroenteritis 
in human populations. The GII.4 genotype undergoes epochal evolution whereby a 
predominant circulating strain is replaced by an emergent strain containing antigenic 
changes facilitated by alterations in the P2 subdomain of the NoV capsid[10, 12, 83, 
87, 91, 118]. Increased evolution of GII.4 noroviruses over other genotypes has 
been correlated with mutation rate, antigenic space, and herd immunity[122]. These 
antigenic changes over time have also been shown to be specifically associated with 
GII.4 blockade epitopes[10, 11, 13, 38]. These data support the hypothesis that 
emergence of new strains is driven by evolutionary escape from human herd 
immunity[12, 86]. 
To determine if antigenic differences exist between GII.4-2012 and the recent 
circulating ancestral strains GII.4-2006 and GII.4-2009, we compared reactivity and 
blockade capacity using time-ordered VLPs, mouse and human monoclonal 
antibodies, and GII.4-2009 human outbreak convalescent sera. Out of nine tested 
mAbs that bind GII.4-2006 and GII.4-2009 (G2, G3, G4, G6, G7, NO37, NVB 43.9, 
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NVB 71.4, and NVB 97), only four retained the ability to react with GII.4-2012 (G2, 
G6, G7, and NVB 71.4), although at significantly lower levels compared with GII.4-
2006 and GII.4-2009. Of the three mouse mAbs that reacted with GII.4-2009 and not 
GII.4-2006 (NO52, NO66, NO224), two of them were able to react with GII.4-2012 
(NO52, NO224), albeit at significantly reduced levels. The majority of the tested 
mAbs target the A epitope, which has previously been identified as the predominant 
GII.4-blockade epitope in earlier strains. Our data also support earlier data that 
suggests the presence of several overlapping epitopes within epitope A. Epitope A 
targeting mAbs, except NO52, either lost blockade activity or required significantly 
more sera to block GII.4-2012-ligand binding interactions. Interestingly, while NO52 
binding to GII.4-2012 is reduced compared to GII.4-2009, this mAb blocks GII.4-
2012 more efficiently than GII.4-2009. Possible explanations for this include that 
NO52 binding to GII.4-2009 and GII.4-2012 may result in slightly different antibody 
positioning that more efficiently blocks VLP-HBGA binding in GII.4-2012, NO52 may 
recognize a rare overlapping epitope that is only targeted by the immune systems of 
a small fraction of the human population, or NO52 may represent a novel mouse-
specific epitope. In any event, differences among blockade potential of epitope A 
mAbs highlight the need for fine resolution mapping of these overlapping epitopes as 
well as the need for assays that measure the fraction of a polyclonal response 
against a unique monoclonal antibody epitope[123]. Our mAb data clearly support 
the hypothesis that major antigenic differences exist in epitope A between GII.4-
2012 and previously circulating strains, and that this epitope may represent the 
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major site for driving GII.4 escape from herd immunity over the past 15 years[10, 11, 
32, 38]. 
Previous studies by our group and others support the hypothesis that human 
immune responses may select for mutations in the HBGA binding pocket, selecting 
for varying HBGA recognition patterns over time in GII.4 noroviruses[10, 12, 19, 75, 
85, 116]. HBGA binding assays revealed similar, but reduced binding patterns as 
compared to contemporary GII.4-2006 and 2009 strains, indicating that more 
sophisticated measures of affinity binding may be needed to untangle the subtle 
changes in HBGA interactions in GII.4-2012 Sydney. Supporting earlier findings, 
human mAb NVB 97 completely lost reactivity and blockade against GII.4-2012 D 
epitope. Epitope D minimally consists of varying residues 393-395, but likely 
includes other adjacent residues that may alter norovirus strain binding affinity and 
specificity to HBGAs as well as antibody binding and blockade. Modulation of 
several residues in close proximately to the HBGA binding pocket influence HBGA 
binding[11, 12, 32, 88, 96], but most of these residues have not been evaluated for 
their roles in antibody binding. Overall, results from mAb binding and blockade 
assays demonstrate that recognition of epitopes A and D between GII.4-2009 and 
GII.4-2012 are very different, and most neutralizing antibodies generated against 
epitopes A and D during a GII.4-2009 New Orleans strain infection would probably 
not protect against the new GII.4-2012 Sydney strain. 
Blockade data from human outbreak sera also showed significant reductions 
in the global antibody blockade response for GII.4-2012 compared with GII.4-2009.  
Importantly, a comparison of mean outbreak human sera EC50 titers from a GII.4-
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2009 New Orleans outbreak between GII.4-2009 and GII.4-2012 indicate that GII.4-
2012 Sydney retained only ~30% of the GII.4-2009 blockade response, and two 
changes in epitope A accounted for 11% of the change in blockade response. On an 
individual level, epitope A changes significantly accounted for changes in blockade 
response in half of the serum samples.  This suggests that individual responses to 
new GII.4 strains are highly varied, and the immune response to specific epitopes 
may be shaped by previous exposure history.  As GII.4 noroviruses are mucosal 
pathogens with short incubation periods (<30 hours) and rapid clinical disease 
manifestations (~48 hours), waning immunity may rapidly permit repeat acute 
infections in some but not all individuals, depending on the specificity and affinity of 
the global blockade specific response to different epitopes, perhaps at both an 
individual and population level. The frequency at which monoclonal antibodies are 
produced against a specific epitope may be a key predictor of short versus long-term 
immunity, with antibody responses to the most frequently-targeted epitopes 
remaining the longest and selecting for the most antigenic variation. Given that the 
majority of blockade monoclonal antibodies that were isolated target epitope A, our 
data suggest that antibody responses against A would wane more slowly than 
antibody responses against more rarely-targeted epitopes like D, E, and the 
universal epitope. Interestingly, the ancestral blockade response against the 
universal neutralization site is weak against GII.4-2012, suggesting the emergence 
of mutations in this epitope as well. Overall, our data clearly demonstrate that GII.4-
2012 Sydney is antigenically different from both GII.4-2006 and GII.4-2009 and 
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support the hypothesis that emergence of GII.4 strains is the result of escape from 
herd immunity as they undergo evolution in major neutralizing epitopes.  
One of the factors complicating vaccine design is the high degree of GII.4 
antigenic variation over time. Because of this variation, the GII.4 component of a 
successful norovirus vaccine will likely need to be reformulated over time. Our work 
describes an important platform approach to identify GII.4 strains with pandemic 
potential and provides important insights into effective vaccine design. We 
demonstrate the importance of key reagents such as time-ordered VLPs and 
monoclonal antibodies that identify surface varying residues involved in escape from 
herd immunity. Tracking sequence and antigenic changes over time may reveal new 
patterns of evolution, distinguish important overlapping epitopes, and identify the 
emergence of new blockade epitopes. By identifying important blockade epitopes for 
GII.4 noroviruses and tracking those particular sites in new strains as they emerge, 
vaccines could be reformulated quickly and tailored specifically to new epidemic and 
pandemic strains. We may also identify important therapeutic antibodies targeting 
these epitopes in circulating strains which would be valuable for treating long-term 
chronic infections in immunosuppressed patients as has been demonstrated for 
RSV[124]. In particular, our data suggest that epitopes A and D are major drivers of 
escape from herd immunity in contemporary strains, and screening new strains for 
changes in these and other potential neutralization epitopes may provide a quick 
and valuable method for effective vaccine design and reformulation. 
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CHAPTER 4:  WITHIN HOST EVOLUTION RESULTS IN ANTIGENICALLY 
DISTINCT GII.4 NOROVIRUSES4 
 
Introduction 
Noroviruses are the leading cause of gastrointestinal illness worldwide. While 
typically an acute disease, norovirus infections can be serious in the young, old, and 
immunocompromised, as these groups are at risk for more severe disease and 
death [3, 70, 71]. Norovirus is spread rapidly in environments where people are 
found in close proximity including schools and daycares, nursing homes, cruise 
ships, and hospitals.  Importantly, hospital outbreaks can result in significant 
economic damage, with direct and indirect costs from a single outbreak reaching 
$650,000 [72]. 
Noroviruses are members of the Caliciviridae family and contain a ~7.5 kb 
single stranded, positive polarity RNA genome.  They are divided into 5 genogroups; 
genogroups I and II are responsible for the majority of human disease and are 
further subdivided into at least 9 and 22 genotypes, respectively [7].  The human 
norovirus genome encodes three open reading frames: the non-structural proteins, 
the ORF2 major capsid protein (VP1), and the ORF3  minor capsid protein (VP2) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  This	  chapter	  previously	  appeared	  in	  the	  Journal	  of	  Virology.	  The	  original	  citation	  is	  as	  follows:	  Debbink	  K,	  Lindesmith	  LC,	  Ferris	  MT,	  Beltramello	  M,	  Corti	  D,	  Swanstrom	  J,	  Lanzavecchia	  A,	  and	  Baric	  RS.	  “Within	  Host	  Evolution	  Results	  in	  Antigenically	  Distinct	  GII.4	  Noroviruses.”	  Journal	  of	  Virology	  March	  19,	  2014.	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[75].  VP1 is further divided into the shell (S) and protruding (P) domains, with the P 
domain comprised of the P1 and P2 subdomains [75]. Phylogenetic studies indicate 
that the P2 subdomain is the most variable region of the norovirus genome [12, 86].  
The P2 subdomain is also the most surface exposed region of the norovirus capsid, 
interacting with antibodies and histoblood group antigens, which serve as binding 
ligands and putative receptors for human norovirus docking and entry.   
GII.4 strains cause over 70% of all norovirus outbreaks [104] and epidemic 
outbreaks occur every 2-4 years involving a new antigenically distinct strain [12, 91].  
Studies of antigenic variation in GII.4 norovirus have shown that the P2 region is 
involved in strain specific antibody recognition [12, 28, 32], and contains at least 
three blockade (potential neutralization) epitopes [10, 11, 13].  In epidemic strains, 
genetic variation in P2 is linked to antigenic changes over time, indicating that 
evolution in the P2 subdomain is likely driven by escape from human herd immunity 
[10, 11, 13, 28, 38, 39]. 
Noroviruses typically cause acute infection in healthy individuals, resulting in 
symptomatic infection for 24-48 hours followed by viral shedding for two to four 
weeks [27, 125]. However, some immunocompromised individuals such as 
transplant patients on immunosuppressive drugs, those with primary 
immunodeficiencies, cancer patients undergoing chemotherapy, and those with HIV 
may develop chronic norovirus infection.  Symptomatic infection and viral shedding 
in these patients can persist from weeks to years [111, 126-130] and can result in 
medical issues such as dehydration and nutrient deficiencies [52], making 
development of treatment options for these patients an important priority.  
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Unfortunately, there are no approved therapeutics or vaccines for controlling 
norovirus infections.  Attempted methods to control chronic infection have included 
treatment with drugs effective against other diarrheal diseases [131], adjustment of 
immunosuppressive drug type or dosage [132], and oral or enteral administration of 
human IgG [65, 66, 133, 134].  Although reduction in immunosuppression coupled 
with IgG administration has shown promise for some transplant patients, IgG therapy 
has failed in other studies, and reduction of immunosuppression is not always 
possible. 
Existing studies provide a basis to investigate important questions about 
chronic norovirus infection.  Although unconfirmed, one recent hypothesis is that 
chronically infected norovirus patients may be important sources of infection both in 
healthcare settings [135] and as potential reservoirs for new emergent GII.4 
norovirus strains [111, 128, 130].  Although the fitness and the infectivity of 
chronically shed virus is currently unknown, potential accounts of chronic norovirus 
shedders involved in hospital outbreaks and transmission of virus to both 
immunocompromised and immunocompetent individuals have been documented  
[126, 135, 136]. 
Virus capsid sequence and phylogenetic data from chronically infected 
patients have found substantial genetic variation over the course of infection in 
many, but not all, patients [127, 128, 137]. Siebenga et al. found that capsid 
mutation rate was linked to immune impairment, suggesting that immune-driven 
selection drives evolution in the capsid during chronic infection [137], and explains 
differences in evolution depending on level of immunosuppression. Additional 
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studies have corroborated a role for intra-host immune driven selection by 
demonstrating that virus isolated from chronically-infected patients undergoes 
positive selection and exhibits higher genetic diversity in the capsid protein than 
virus from acutely infected individuals [128, 130]. In addition, in these chronically 
infected patients with GII.4 strain infections, many of the changes occur in blockade 
epitopes, areas of known or predicted antigenic importance but antigenic 
comparisions have not been performed [10, 11, 13, 127, 137].  
In this manuscript, we compare and contrast the antigenic differences using a 
panel of polyclonal and monoclonal antibodies and time-ordered VLPs derived from 
early (day 1—P.D1) and late (day 302—P.D302) capsid protein amino acid 
sequencesfrom a chronically infected immunocompromised patient [128]. Our data 
demonstrate significant antigenic differences between intra-host variants that mirrors 
variation seen in major successive norovirus strains, suggesting that chronic 
norovirus infections can evolve antigenically unique variants with the potential to 
seed future norovirus outbreaks.   
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Methods  
Sequences and Structural Homology Models 
GenBank (NCBI sequence database) sequences used in this study were 
JQ478409.1 (GII.4-2006b) [13], JQ417309 (P.D1) [128], JQ417327 (P.D302) [128], 
JN595867.1 (GII.4-2009) [13], and JX459908.1 (GII.4-2012) [138], and the VA387 
crystal structure is available from the RCSB Protein Data Bank: identifier 2OBT [79].  
Homology models of these sequences were constructed using Modeller (Max-Planck 
Institutue for Developmental Biology) and modeled in PyMOL. 
 
Production of VRPs 
Virus replicon particles (VRPs) encoding the norovirus major capsid gene 
were produced as previously described [77]. Briefly, expression vector pVR21 
encodes the VEE genome with the VEE structural genes replaced with a 
commercially synthesized norovirus ORF2 gene (BioBasic) behind the 26S 
promoter. The VEE-norovirus ORF2 construct and two separate plasmids 
expressing either the VEE 3526 E1 and E2 glycoproteins or VEE 3526 capsid 
protein were used to make RNA. RNA from all three constructs was electroporated 
into BHK cells, and 48 hours later VRPs were harvested and purified by high speed 
centrifugation. VRP titers were determined by counting fluorescent cells detected 
with FITC-labeled antibody. VLP production from VRPs and structural integrity was 
confirmed by EM. 
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Production of VLPs.  
 VLPs were produced as previously described [11, 13]. Briefly, commercially 
synthesized norovirus ORF2 (BioBasic) from chronically infected patient sequence 
or outbreak strain sequence was cloned into expression vector pVR21 behind the 
26S promotor, and genome length RNAs were synthesized in vitro using T7 RNA 
polymerase.  RNA from the VEE-ORF2 construct and helper RNAs was 
electroporated into BHK cells, and 24 hours later VLPs were harvested and purified 
by high speed centrifugation.  VLP concentration was determined by BCA Protein 
Assay (Pierce), and structural integrity was confirmed for all VLPs by EM. 
 
HBGA Binding Assay  
 HBGA assays were performed as previously described [12].  Briefly, Avidin 
coated plates (Pierce) were coated with 10 ug/mL synthetic biotinylated HBGAs 
(GlycoTech), followed by addition of 2 ug/mL VLPs.  HBGA binding was detected by 
strain specific mouse polyclonal sera followed by anti-mouse IgG-HRP (GE 
Healthcare) and then One-Step Ultra TMB HRP substrate.  Positive reactivity for 
each HBGA is defined as an OD 450 nm signal above or equal to 3X the 
background binding (background range 0.049-0.066) after background subtraction. 
 
EIAs  
Reactivity with mouse and human mAbs was determined by enzyme-linked 
immunoassay (EIA). Plates were coated with .5 µg/ml VLP in PBS, and then two-fold 
serial dilutions of mAb starting at 1 µg/ml mAb were added. Anti-mouse or human 
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IgG-HRP (GE Healthcare) followed by One-Step Ultra TMB EIA HRP substrate 
solution was used for detection. Positive reactivity is defined as a mean OD 450 nm 
>0.2 after background subtraction. Data represent at least two replicates and are 
indicative of similar data from at least two independent trials. Sigmoidal dose 
response analysis was performed as previously described [10] using the reactivity at 
1 ug/ml as 100% binding. EC50 values among VLPs were compared using One-way 
ANOVA with Dunnett’s post test. P<0.05 was considered significant.  VLPs with 
maximum reactivity below mean OD 450 nm 0.2 were assigned a value of zero for 
graphical representations. 
 
VLP-Carbohydrate Ligand-Binding Antibody Blockade Assays  
Blockade assays using Pig Gastric Mucin Type III (Sigma Chemicals) were 
performed as previously described [10]. PGM-bound VLPs were detected by rabbit 
anti-GII.4 norovirus polyclonal sera. The percent control binding was defined as the 
VLP-ligand binding level in the presence of test antibody or sera compared to the 
binding level in the absence of antibody multiplied by 100. All mAbs and sera were 
tested for blockade potential at two-fold serial dilutions ranging from 0.0039 to 2 
µg/ml (mouse mAbs), 0.0039 to 16 µg/ml (human mAbs), and 0.0098 to 5% (mouse 
sera). Data shown represent at least two replicates and are indicative of similar data 
from at least two independent trials. Sigmoidal dose response analysis was 
performed as previously described, and EC50 values among VLPs were compared 
using One-way ANOVA with Bonferroni post test. P<0.05 was considered significant. 
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Blockade assays utilize VLP concentrations in the low nanomolar range; therefore, 
this assay does not discriminate between antibodies with sub-nanomolar affinities. 
 
Monoclonal antibodies and mouse polyclonal sera 
Mouse [28] and human [10] monoclonal antibodies were isolated as 
previously described.  Balb/c mice (five per group) were immunized by footpad 
injection with 5 x 104 VRPs expressing norovirus capsid gene (GII.4-1987, GII.4-
2002, GII.4-2006b, GII.4-2009, P.D1, or P.D302).  Mice were boosted on day 21, 
euthanized 7 days post-boost, and sera were harvested.  This study followed all 
institutional guidelines for animal care and experimentation (IACUC guidelines).  
 
Antigenic Cartography 
Briefly, the EC50 blockade titers of various sera against a panel of VLPs were 
normalized to maximum blockade titer of each sera, as well as to the maximum 
overall blockade titer across sera (Normalization method 1) using AntigenMap 3D 
[139, 140].  Normalized values were used to calculate Euclidean distances, D, 
between each pair of VLPs.  AntigenMap 3D then determined XYZ-coordinates such 
that the difference between the actual D-values and XYZ D-values are as similar as 
possible.  
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Results 
Comparison of sequence changes among chronic infection isolates GII.4-
2006b. 
Previous work has shown that changes identified in a few key surface 
exposed epitopes correlate with shifts in GII.4 norovirus antigenicity [10, 11, 13, 32], 
including residues in Epitope A (294, 296-298, 368, and 372) [11], Epitope D (393-
395) [10], and Epitope E (407, 412-413) [13].  Changes in these residues likely alter 
the ability of preexisting immunity to neutralize the virus, selecting for the emergence 
of new epidemic strains.  
To study the within-host antigenic evolution of noroviruses during a chronic 
human infection, we aligned the sequence of the capsid P2 domains of GII.4-2006b, 
P.D1, and P.D302 to examine sequential amino acid changes from GII.4-2006b 
through P.D302 after at least 10 months of within-host evolution [128].  Between 
VP1 amino acid positions 248-434, there are 9 differences between GII.4-2006b and 
P.D1. After 10 months, there were 15 additional differences between P.D1 and 
P.D302, and 20 differences between GII.4-2006b and P.D302 located between 
these amino acid positions (Figure 4.1A).  Similarly, there are 16 differences 
spanning this domain between GII.4-2006b and subsequent epidemic strains, GII.4-
2009 and GII.4-2012.  Two of the differences between GII.4-2006b and P.D1 
(S368A and S393G) and four of the differences between GII.4-2006b and P.D302 
(A294G, S296T, S368A, and N412D) are located within blockade epitopes (Figure 
4.1B). Four differences in blockade epitope residues also exist between P.D1 and 
P.D302 (A294G, S296T, G393S, N412D) (Figure 4.1B).  We synthesized GII.4-
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2006b, P.D1, and P.D302 genes, expressed VLPs representing these strains, and 
measured differences in antigenicity and HBGA binding among the chronic infection 
isolates and GII.4-2006b using biological assays.  In addition, several amino acid 
substitutions present in the chronic infection strains that are conserved in past 
epidemic strains may also influence the antigenic and HBGA binding characteristics 
of epitopes A (292, 295, 373), D (391), and E (414) (Figure 4.1B) based on their 
position relative to these epitopes in GII.4 homology models (Figure 4.1C).   
 
Comparison of HBGA binding in chronic infection isolates to GII.4-2006b.  
To evaluate differences in HBGA binding preferences among GII.4-2006b, 
P.D1, and P.D302, we measured VLP binding to synthetic biotinylated 
carbohydrates (A, B, Lea, Leb, Lex, Ley, H type 1, and H type 3).  As previously 
reported, GII.4-2006b bound A, B, Leb, Ley, and H type 3 [26].  In contrast, chronic 
infection strain VLPs exhibited differential HBGA binding profiles compared to GII.4-
2006b and to each other (Table 4.1).  P.D1 was able to bind A, B, and H type 3, 
while P.D302 bound only B and H type 3 synthetic biotinylated HBGAs.  This 
indicates that HBGA binding preferences may be altered over time during chronic 
infection. 
 
Reactivity with GII.4 Mouse and Human mAbs 
To measure antigenic differences among VLPs representing GII.4-2006b and 
chronic strains P.D1 and P.D302, we performed enzyme-linked immunoassays 
(EIAs) using mouse and human mAbs.  We tested five GII.4-2006b mouse mAbs 
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(G2, G3, G4, G6, G7) and two GII.4 human mAbs (NVB111, NVB43.9), all of which 
target epitope A residues (294, 296-298, 368, and 372), for EIA binding with GII.4-
2006b, P.D1, and P.D302 VLPs. GII.4-2006b and P.D1 differ in one epitope A 
position, where P.D1 contains S368A compared to GII.4-2006b.  P.D302 is different 
from GII.4-2006b at 3/6 epitope A residues: A294G, S296T, and S368A, while P.D1 
and P.D302 are different at 2/6 epitope A residues: A294G and S296T.  We also 
tested reactivity of these VLPs with one human mAb (NVB97), which targets epitope 
D residues (393-395).  While GII.4-2006b and P.D302 share identical epitope D 
residues, P.D1 has an S393G change compared to GII.4-2006b. We additionally 
tested one human mAb (NVB71.4) that targets an unmapped conserved GII.4 
epitope [10]. Consistent with previously-reported results, all mAbs reacted strongly 
with GII.4-2006b VLPs [10, 28] (Table 4.2). In contrast, EC50 values for P.D1 VLPs 
were significantly different (P<0.05) from GII.4-2006b VLPs for mouse mAbs G2, G4, 
G6, and human mAbs NVB43.9, and NVB111 (Table 4.2).  Moreover, EC50 values 
for P.D302 VLPs were significantly different from GII.4-2006b for all mAbs except 
NVB71.4, and different from P.D1 VLPs for all but NVB71.4 and NVB111 (Table 
4.2). This indicates that epitopes A and D are antigenically distinct among GII.4-
2006b, P.D1, and P.D302, demonstrating antigenic variation over the course of 
chronic infection in important blockade epitopes.  
 
Blockade Activity for GII.4 Mouse and Human mAbs 
Compared to EIA, neutralization is a more relevant measure of functional 
antigenic change.  To test potential neutralization activity of mAbs (GII.4-2006b-G2, 
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G3, G4, G6, and G7, and NVB43.9, NVB71.4, NVB97, NVB111) against GII.4-
2006b, P.D1, and P.D302 VLPs, we performed blockade assays, a correlate of 
protective immunity [20] and a neutralization surrogate. Consistent with previous 
findings, all mAbs were able to block ligand-VLP interactions for GII.4-2006b [10, 28] 
(Figure 4.2).  Likewise, P.D1 was blocked by all mAbs (Figure 4.2). However, EC50 
blockade titers for two out of five GII.4-2006b mouse mAbs, G2 (Figure 4.2A) and 
G7 (Figure 4.2E), and two of four GII.4 human mAbs, NVB111 (Figure 4.2G) and 
NVB71.4 (Figure 4.2I), were significantly different, requiring 7.1X, 2X, 2X, 3.2X more 
antibody, respectively, for blockade compared to GII.4-2006b VLPs.   P.D302 VLP-
ligand binding was blocked by GII.4-2006b mouse mAbs G2 (Figure 4.2A), G6 
(Figure 4.2D), G7 (Figure 4.2E), but not by G3 (Figure 4.2B) or G4 (Figure 4.2C), 
and blocked by GII.4 human mAb NVB71.4 (Figures 4.2I), but not by NVB43.9 
(Figure 4.2F), NVB111 (Figure 4.2G), or NVB97 (Figures 4.2H).  EC50 blockade titers 
were significantly different between GII.4-2006b and P.D302 for G2, G6, G7, and 
NVB71.4, requiring 12.6X, 15.9X, 12X, and 6.8X more mAb compared to GII.4-
2006b, respectively.  Overall, EC50 blockade titers were significantly higher for 
P.D302 compared to both GII.4-2006 and P.D1 for all tested mAbs, demonstrating 
major antigenic changes in epitopes A and D over the course of chronic norovirus 
infection. 
 
Blockade Response of Strain Specific Mouse Polyclonal Sera 
While monoclonal antibodies are informative of the changes in a single 
epitope, polyclonal sera are needed to evaluate global antigenic changes.  To 
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measure differences in the total antibody response, we immunized mice with virus 
replicon particles (VRPs) expressing the capsid gene from GII.4-2006b, P.D1, and 
P.D302 or GII.4-2009, the consecutive outbreak strain following GII.4-2006, and 
measured the induced serum blockade responses (Figure 4.3).  Mice immunized 
with GII.4-2006b VRPs mounted a robust blockade response against homotypic 
GII.4-2006b VLPs, while significantly more sera was needed to block GII.4-2009, 
P.D1, and P.D302 VLPs (16X, 9.4X, and 12.7X, respectively) (Figure 4.3A).  Sera 
from mice immunized with GII.4-2009 VRPs induced a strong blockade response 
against GII.4-2009 VLPs; however, significantly more sera was needed to block 
GII.4-2006b and P.D302 VLPs, with 39X more sera needed to block P.D302 VLPs 
compared to GII.4-2009 (Figure 4.3B).  Sera from mice immunized with P.D1 VRPs 
most efficiently blocked homotypic P.D1 VLPs. EC50 values indicated that more sera 
is required to block GII.4-2009 (3X) and P.D302 (25.8X) than P.D1, while GII.4-
2006b and P.D1 EC50 titers were not significantly different (Figure 4.3C). Sera from 
mice immunized with P.D302 VRPs efficiently blocked P.D302 VLP-ligand 
interactions and weakly blocked GII.4-2006b and P.D1, requiring 92X and 61X more 
sera, respectively.  P.D302 sera was unable to block GII.4-2009 VLPs (Figure 4.3D).  
This data shows that chronic isolate VLPs induce antibody responses that are 
different from the parental strain and each other, demonstrating major changes in 
total antibody response over the course of chronic infection. 
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Antigenic Cartography 
We next compared the antigenic distance between intra-host variants and 
naturally occurring epidemic strains over time.  We used AntigenMap 3D [139] to 
visualize and measure the antigenic relationships among outbreak strains GII.4-
1987, GII.4-1997, GII.4-2002, GII.4-2006b, GII.4-2009, and GII.4-2012 as well as 
chronic isolates P.D1 and P.D302. The antigenic distances between strains were 
measured using GII.4-1987, GII.4-2002, GII.4-2006b, GII.4-2009, P.D1, and P.D302 
mouse sera EC50 blocking titers against VLPs representative of the specified GII.4 
strains. Consonant with earlier findings [28], early (GII.4-1987, GII.4-1997, GII.4-
2002) and late strains (GII.4-2006b, GII.4-2009, GII.4-2012) formed distinct but inter-
related clusters that diverged over time (Figure 4.4).  Not surprisingly, the early 
within host variant, P.D1, grouped closely with late strains (Figure 4.4), reflecting its 
origins from the GII.4-2006b lineage.  In contrast, P.D302 did not group with any 
other strain and was antigenically distant from both the early and contemporary 
isolates. We compared Euclidean distances, D, between each pair of VLPs across 
all serum utilized for antigenic cartography.  We first examined the groupings of early 
and late GII.4 outbreak strains.  The average distance within a group was 3.79 
(range 2.11-6.39) while the average distance between early and contemporary 
clusters was 10.7 (range 8.49-13.32). As shown in Figure 4, P.D1 grouped closely 
with late outbreak strain VLPs, with an average D of 3.46 (range 2.26-5.09). In 
contrast, P.D302 was quite distinct from both early and late outbreak strain viruses, 
as well as from P.D1, with an average D of 9.92 (range 8.73-11.62). During an ~10 
month chronic infection in this individual, our data demonstrate that intra-host 
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evolution can generate novel variants with unique HBGA binding patterns and 
encode unique antigenic differences that are as dramatically distinct as time-
ordered, epidemic outbreak strains that emerge in human populations.   
 
Expansion of Epitope A 
We next determined whether novel sites of within host evolution can refine 
existing epitope maps and identify potential immunogenic changes in epidemic 
strains of the future. Amino acid position 373 exhibited a N373H change between 
P.D1 and P.D302, but was conserved in major GII.4 epidemic strains up until a 
N373R substitution in GII.4-2012 Sydney.  As changes at site 373 have never been 
shown to influence immunogenicity, it is not included as a diagnostic A epitope 
residue, potentially hampering new epidemic strain identification. To determine 
whether position 373 contributes to antigenic differences in epitope A, we used the 
blockade assay to test potential neutralization of VLPs representing parental strains 
GII.4-2009 New Orleans, GII.4-2012 Sydney, and chimeric sequences GII.4-
2012.09A, GII.4-2012.09A.R373N, and GII.4-2012.R373N (Figure 4.5) by epitope A 
targeting human mAb 43.9. GII.4-2009 was efficiently blocked by mAb 43.9, while 
GII.4-2012 required significantly more (55.3X) mAb for blockade.  Blockade 
response was partially restored in chimeras GII.4-2012.09A and GII.4-2012.R373N, 
but required 1.5X and 4.8X more mAb, respectively, for blockade compared to GII.4-
2009. EC50 blockade titers were not statically different between GII.4-
2012.09A.R373N and GII.4-2009 VLPs. Similar trends were seems using mouse 
mAbs targeting epitope A residues (data not shown).  As this data demonstrates that 
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residue 373 is a diagnostic and immunogic residue of the evolving epitope A, it 
seems likely that within host evolutionary trends can map and perhaps even predict 
novel amino acids changes that may regulate new strain emergence and escape 
from herd immunity in the future.  
 
Discussion 
Noroviruses are a major cause of worldwide disease burden, and result in 
over 2.5 billion dollars in economic losses and healthcare costs each year in the 
United States alone [141]. Furthermore, noroviruses are an important cause of 
gastroenteritis in immunocompromised individuals [82, 142], who are at increased 
risk for severe disease outcomes [3, 142]. Recent vaccine trials utilizing a VLP-
based vaccine approach support the idea that efficacious vaccines can be generated 
that elicit short term protection in some healthy individuals, but vaccines may not 
protect immunocompromised populations. The current lack of approved vaccines, 
antivirals, or other therapeutics that effectively treat or prevent norovirus make 
continued development of such therapeutics a top health priority. 
In immunocompetent people, norovirus infection results in acute disease 
outcomes [58]. In contrast, immunocompromised individuals can develop 
symptomatic disease and high titer viral shedding for months to years.  
Unfortunately, the literature on specific chronically-infected norovirus patient 
populations is sparse, and duration and severity of chronic norovirus infections is 
likely influenced by several factors including underlying condition, drug treatment 
regime, degree of immunosuppression and the rate of within host virus evolution, 
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making it difficult to define the characteristics of a typical chronic norovirus case.  
From these limited studies, it is difficult to discern whether there are characteristics 
of chronic norovirus infection that are broadly applicable to all populations, 
characteristics that are true to specific populations, or whether characteristics vary 
by each individual case.  However, previous work has shown that during the course 
of chronic infection, virus genetic diversity can expand quickly [127, 128, 130, 137]; 
however, it was previously unknown whether this genetic variation translated into 
antigenic variation or the emergence of antigenically unique isolates that differ 
significantly from contemporary epidemic strains. For the first time, our work clearly 
demonstrates the potential for significant antigenic variation over the course of 
chronic infection within an individual, which is important in terms of both therapeutic 
treatment considerations and for studying the potential role for chronic shedders as 
reservoirs for evolving new outbreak strains. 
Since there is no known animal reservoir for human noroviruses [143], the 
available data indicate that new GII.4 strains likely arise naturally within the human 
population by epochal evolution, immune driven selection and inter-host 
transmission over time [10, 11, 28, 38, 39].  The occurrence of frequent long-term 
chronic infections in immunosuppressed patients also represents a possible source 
of new GII.4 norovirus strains with epidemic potential [128, 130, 137].  While their 
immune responses are unable to clear the infection, these patients may provide an 
appropriate environment for sustained immune-directed molecular evolution, 
apparently targeting previously identified surface exposed blockade epitopes for 
mutation driven escape.  Evidence supporting this hypothesis includes sequence 
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data from chronically infected patients that demonstrate the emergence of genetic 
changes in GII.4 blockade epitopes that modulate inter-host antigenicity [127, 137]. 
This diverse pool may contain variants antigenically distinct from the predominant 
circulating strain, allowing emergence of a new strain under the right conditions 
[130]. However, host and environmental factors coupled with the type and degree of 
immunosuppression may affect the rate and complexity of intra-host evolution that 
occurs over time [128], and future work that evaluates the role of different 
immunosuppressive conditions on intra-host norovirus evolution are needed. 
Starting from these observations, we measured the impact of genetic change on 
antigenic divergence and distance between two intra-host isolates (P.D1 and 
P.D302), which originated from the GII.4-2006b lineage, and several strains that 
have circulated in human populations over the past 20 years. 
Reactivity and blockade with mouse and human mAbs demonstrated a 
temporal change in antigenicity in epitopes A and D during a chronic norovirus 
infection in an immunocompromised patient. Epitope A targeting mAbs generally 
exhibited weaker reactivity with P.D1 compared to GII.4-2006b, and though all mAbs 
maintained blockade activity against P.D1, three required significantly more sera for 
blockade. Six of seven epitope A targeting mAbs lost reactivity with P.D302, and 
GII.4-2006-G6 demonstrated significantly weaker binding compared to both GII.4-
2006b and P.D1.  All seven mAbs demonstrated a significantly weaker blockade 
against P.D302 as compared to P.D1 and GII.4-2006b, and four mAbs completely 
lost blockade capacity against P.D302.  Interestingly, P.D302 contained residue 
substitutions in amino acid positions 292, 295, and 373, which are conserved in 
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major GII.4 outbreak strains, except for 373, which was alteredi in the most recent 
predominant strain, GII.4-2012 Sydney. Changes in these residues likely impact 
epitope A antibody binding and blockade response either by altering the 
conformational landscape of the epitope or directly inhibiting the interaction of the 
antibody with the capsid. Using GII.4-2009/GII.4-2012 chimeric VLPs, we 
demonstrated that residues at position 373 impact the blockade response of human 
mAb NVB 43.9, an antibody that targets epitope A.  This demonstrates that 373 is 
part of epitope A, expanding this epitope to 7 positions including 294, 296-298, 368, 
372, and 373.  Furthermore, we suggest that monitoring intra-host evolved strains 
may provide a novel strategy to map key residues capable of mediating antigenic 
changes in future outbreaks.  While positions 292 and 295 have been conserved in 
previous predominantly-circulating GII.4 strains, their ability to change in this patient 
and their proximity to known epitope A residues suggest that these residues have 
diagnostic potential to identify future epidemic strains by impacting antigenic change 
in epitope A.  
Reactivity and blockade response data for antibody NVB97 demonstrates 
antigenic evolution in epitope D during chronic infection.  Epitope D minimally 
include residues 393-395, is in close proximity to the carbohydrate binding pocket 
[79], and previous work demonstrates that modulation of residues within this epitope 
modulate HBGA specificity [12].  Evolution in this epitope is likely driven both by 
antibody selective pressure and pressure to maintain binding to one or more 
HBGAs.  Despite conservation of residues 393-395 between GII.4-2006b and 
P.D302, antigenic phenotypes differ significantly, demonstrating that NVB97 
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recognition is modulated by amino acid positions outside of the previously-defined 
epitope D. Position 391, which is close to the carbohydrate binding pocket, is 
conserved in major outbreak strains and between GII.4-2006b and P.D1. Previous 
work demonstrated that an alanine substitution at this residue had little impact on 
HBGA binding, recognizing the limitations inherent in this approach [88]. Neither the 
antigenic consequences of residue changes nor the impact of other residue 
substitutions on HBGA binding at this position have been rigorously evaluated, 
meaning that the D391N change in P.D302 may contribute to both the HBGA 
reactivity and antibody blockade differences observed for P.D302.  To explore this 
possibility, we created homology models of these P2 domains and compared the 
predicted polar interactions present in residues 390-395 (Figure 4.6) among GII.4-
2006b, P.D1, and P.D302. Conformational comparisons between GII.4-2006b and 
P.D1 show general similarities in the shape created by residues 390-395, with 
exceptions being the loss of a side chain in 393 of P.D1, and slight shifts in position 
for side chains in residues 394 and 395 (Figure 4.6A and 4.6B). These 
conformational changes appear to impact the polar interactions within these 
residues, as the loss of the side chain in residue 393 ablates the hydrogen bond 
present in GII.4-2006b.  In addition, the positional shifts in residues 394 and 395 in 
P.D1 appear to prevent formation of another hydrogen bond present in GII.4-2006b. 
Conformational comparisons between GII.4-2006b and P.D302 demonstrate that the 
residue change at 391 has significant impact on the shape and hydrogen bonding 
networks for residues 390-395 (Figures 4.6A and 4.6C).  In P.D302, position 391 is 
bent downward, which differs from the position of this amino acid in GII.4-2006b and 
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P.D1.  The result of this change is the formation of a hydrogen bond between the 
side chain and main chain of 391. In addition, though residue 393 is conserved 
between GII.4-2006b and P.D302, the side chain is shifted downward in P.D302 
compared to GII.4-2006b, shifting the position of the hydrogen bond found at this 
residue.  The formation of two additional novel hydrogen bonds between 390 & 393 
and 390 & 395 suggests that the 391 residue change and resulting conformational 
changes allowed for these increased polar interactions. A slight conformational shift 
in residue 395 in P.D302 appears to ablate a polar interaction found in GII.4-2006b 
at this position. We also compared polar interactions of GII.4-2006, P.D1, and 
P.D302 to residues outside of 390-395 (Figure 4.6D-F).  GII.4-2006b and P.D1 
displayed five conserved polar interactions to surrounding amino acids (Figures 4.6D 
and 4.6E), while P.D302 lost the polar interaction at residue 391 and gained an 
additional bond at residue 394 (Figure 4.6F). In addition to epitope D being an 
antibody blockade epitope, these residues modulate HBGA binding, so evolution in 
this epitope is likely driven both by antibody selective pressure and pressure to 
maintain binding to one or more HBGAs.  Interestingly, all three structures 
maintained the two hydrogen bonds to positions 443 and 444. Residue 443 is in the 
HBGA binding site [79], and maintaining interaction with this residue may be 
selected for in this individual in order to retain HBGA binding. The altered HBGA 
binding profile and reduced NBV 97 binding and blockade for P.D302 may be 
explained by these polar differences, although this cannot be confirmed without a 
crystal structure of these P2 domains bound to NVB 97 and HBGAs. 
	   100	  
Our demonstration of intra-host changes in HBGA binding profiles in 
chronically infected immunocompromised patients could select for a quasispecies 
population that is enriched for variants that bind patient-specific HBGAs. While 
speculative, the potential emergence of intra-host variants that target patient specific 
HBGA expression profiles could select for the emergence of novel strains that 
recognize unique or broad combinations of HBGA patterns, allowing for altered 
pathogenicity and transmission efficiencies in an individual or across select human 
populations.  We could not evaluate this possibility in our study because the HBGA 
expression profile of this chronically infected patient is unknown. 
How much intra-host and inter-host antigenic variation is necessary to give 
rise to a new strain that could escape herd immunity in the general population?  To 
address this question, we used antigenic cartography, which provides an unbiased 
measure of the global antigenic relationships among strains and has previously been 
used to study antigenic differences in influenza strains [140].  Using blockade EC50 
data from mouse sera against GII.4-2006b, GII.4-2009 (representative of a 
successive outbreak strain), P.D1, and P.D302, we demonstrate that the antigenic 
variation between P.D1 and P.D302 is 1.5X greater than that seen between GII.4-
2006b and GII.4-2009.  Antigenic cartography measures provide further support, 
demonstrating that the antigenic space between P.D302 and both GII.4-2006b 
(D=9.91) and P.D1 (D=9.15) is greater than the average between the consecutive 
outbreak strains used in this study (D=4.98; range 2.11 to 12.11) and mirrors the 
global difference between early GII.4 isolates (1987, 1997, 2002) and contemporary 
strains (2006b, 2009). The use of mouse sera, rather than human sera, to compare 
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antigenic profiles among strains permits us to have an immunologically clean 
background, whereas the human immune response may be skewed by exposure to 
multiple norovirus strains over time.  Future work will require well defined, time-
ordered human sera during natural epidemic outbreaks, time-ordered sera during 
intra-host chronic infections, and synthetic reconstruction of capsids representing 
both outbreak and unique panels of inter-host variants over time; unfortunately, to 
date, we have been unable to obtain the samples necessary to pursue this line of 
investigation.  Nonetheless, our data and others demonstrate that individuals 
chronically infected with norovirus are capable of generating replication competent 
isolates that are as antigenically divergent as successive outbreak strains. 
Moreover, our data suggest that 1) multiple time-ordered sera can be used to 
determine antigenic relatedness for noroviruses using antigenic cartography, 2) 
antigenic cartography is an appropriate tool to identify potential pre-emergent strains 
that pose a future epidemic threat, and 3) intra-host evolution over a 10-month 
period can yield sufficient antigenic change to escape existing herd immunity.  
Clearly, additional work examining norovirus infectivity after prolonged shedding is 
needed in order to clarify whether chronically infected patients are a probable source 
of novel epidemic strains. 
The high global disease burden of noroviruses and their potential to cause 
severe outcomes in immunocompromised individuals makes development of 
vaccines, therapeutics, and effective control measures a top health priority. 
Therapeutics are needed to alleviate clinical disease during long-term norovirus 
infection and prevent the potential emergence of novel antigenic variants with 
	   102	  
epidemic potential in the general population. Recent work suggests that immune 
globulin (IgG) administered enterically can be used to treat chronic norovirus 
infection [134], but this intervention is likely only effective in cases where the 
administered IgG has neutralizing antibodies to the strain infecting the patient.  Our 
data demonstrating that P.D302, but not P.D1, escapes the blockade response 
directed against parental GII.4-2006b suggest that early during chronic infection, the 
virus present in the host may not be antigenically distinct enough to escape human 
herd immunity and could possibly be treated with IgG containing neutralizing 
antibodies against the infecting strain.  However, as time goes on, accumulated 
genetic changes may lead to antigenic changes that escape herd immunity to the 
infecting strain, leading IgG treatment to be ineffective because of the lack of 
neutralizing antibodies against the intra-host variant. This argues that identifying 
potentially chronic norovirus infections early during infection may provide the best 
option for treating with IgG therapy, and that screening the virus strain and the IgG 
for neutralizing antibodies that match the strain may be important for successful 
treatment.   
The successful use of IgG to treat chronic norovirus also suggests that 
similarly-administered broadly neutralizing antibodies may be viable treatment 
options for patients suffering from long-term norovirus infection.  Our work 
demonstrates that GII.4 broadly-neutralizing mAb NVB71.4 retains blockade 
response against P.D1 and P.D302, even though both these strains are antigenically 
distinct from GII.4-2006b, GII.4-2009, and presumably other major GII.4 strains.  
This suggests that NVB71.4 or other antibodies with broad cross-blockade activity 
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could be isolated and successfully used as norovirus therapeutics.  Importantly, 
different monoclonal antibodies will be needed that target other GI and GII strain 
chronic infections.  Furthermore, increased surveillance of norovirus isolates from 
chronically infected patients should be considered in order to better understand the 
transmission dynamics and genetic potential of norovirus isolates from these 
patients since these are likely different from what is seen in the general population.  
Overall, our work supports the idea that chronically infected individuals are potential 
reservoirs for antigenically novel norovirus strains, and further work to characterize 
their role in transmission and emergent norovirus outbreaks and development of 
therapeutics to combat chronic infections should be a top priority. 
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CHAPTER 5:  A VLP-BASED GII.4 NOROVIRUS VACCINE PLATFORM ELICITS 
ABROADLY BLOCKING IMMUNE RESPONSE AGAINST ANCESTRAL AND 
CONTEMPORARY GII.4 STRAINS 
 
Introduction 
As the primary cause of acute gastroenteritis, noroviruses annually infect 
more than 21 million people in the United States [102] and result in an estimated 
200,000 deaths in children under five worldwide [74].  Furthermore, norovirus-
associated economic losses due to health care costs and lost productivity total an 
estimated 5.5 billion dollars per year in the United States alone [141].  Because of 
these staggering health and economic burdens, a norovirus vaccine is highly 
desirable for those who work in high risk environments including health care 
settings, schools and daycares, nursing homes, military barracks, and restaurants.  
Unfortunately, progress toward an effective vaccine has been slow due in part to the 
lack of a tissue culture system, the highly heterogeneous nature of different 
genogroups and genotypes, and lack of understanding of the mechanisms that drive 
protective immunity and the duration of protective immunity in humans.   
Noroviruses are positive sense RNA viruses and members of the Caliciviridae 
family.  They are divided into five genogroups, and genogroups I and II infect 
humans and are further divided into 9 and 22 genotypes, respectively [6, 7].  The 
~7.5 KB norovirus genome is divided into three open reading frames.  ORF1 
encodes the non-structural proteins, ORF2 encodes VP1, the major capsid protein, 
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and ORF3 encodes VP2, the minor capsid protein [75]. VP1 is divided into the shell 
(S) and protruding (P) domains, and upon expression of the major capsid gene, VP1 
dimers self-assemble into virus-like particles (VLPs), which are antigenically and 
morphologically comparable to native virions.  The capsid P domain is further 
divided into the P1 and P2 subdomains. The capsid P2 subdomain is the most 
surfaced exposed area of the virion and interacts with antibodies and cellular binding 
ligands, the histoblood group antigens (HBGAs) [19, 78, 79, 84, 85, 116].  HBGAs 
are a diverse group of carbohydrates differentially expressed on mucosal surfaces 
and differentially targeted by the various norovirus genotypes [12, 19, 85, 117].  
Importantly, in the absence of a cell culture model for human norovirus, the blockade 
assay [10], a correlate of human protection [20, 22], evaluates potential antibody 
neutralization by measuring the ability of monoclonal antibodies or sera to block 
VLP-ligand interactions. 
Evolutionary patterns and contribution to disease outbreaks vary by 
genogroup and genotype.  GI.1 (Norwalk virus) and other GI noroviruses exhibit a 
limited capacity for antigenic change over time [25], while GII.4 noroviruses 
demonstrate a pattern of epochal evolution, whereby a circulating strain in replaced 
by an emergent strain, likely in response to herd immunity [10, 11, 13, 28, 38, 39]. 
GII.3 noroviruses exhibit a similar evolutionary rate to GII.4 noroviruses, but the 
evolutionary mechanism appears to be different [40].  GII.2 norovirues, on the other 
hand, exhibit limited antigenic evolution over time [41]. Of the remaining human 
norovirus genotypes, little is known about their evolutionary mechanisms.  In terms 
of disease burden, GII.4 noroviruses consistently account for over 70% of all 
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outbreaks [104].  Several additional G1 and GII genotypes contribute to norovirus 
disease outbreaks at lower levels, but relative contributions vary by year and 
geographic location.  Since an effective norovirus vaccine should protect against the 
strains most commonly responsible for outbreaks, GII.4 noroviruses are the most 
medically relevant group to vaccinate against; however, considering the 
heterogeneous nature of noroviruses, a vaccine strategy that would protect against a 
wide array of viruses would be beneficial.  In addition, due to antigenic variation in 
GII.4 noroviruses, the GII.4 component of a vaccine would likely need to be 
reformulated over time, reflecting the antigenic characteristics of newly evolved 
contemporary strains.  
There is some uncertainty in the field as to the duration of protective immunity 
following norovirus infection.  While early human challenge studies suggested that 
protection was between 6 months and 2 years [21, 144], the acquisition of norovirus 
illness is dose-dependent [4, 5], and the challenge dose used in these studies was 
likely much higher than that of a typical human exposure suggesting that early 
studies minimized the ability of the immune response to control a natural infection 
[42].  Other studies showing strain replacement and extinction of early GII.4 
epidemic strains suggested that many individuals may mount more long-term 
protective immunity [12, 15, 24]. More recent work using a community-based 
transmission model suggests that the duration of immune protection is much longer, 
from 4-8 years [42], meaning that an efficacious norovirus vaccine may provide 
some individuals protection for several years.   
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Results testing the GI.1 component of Takeda’s norovirus vaccine, the only 
human challenge norovirus vaccine efficacy study to date, indicate that 3 weeks 
after administration of an intranasal VLP-based GI.1 vaccine, gastroenteritis was 
reduced by 47% [22].  Interestingly, 31% of the placebo group did not become ill 
despite administration of 10X the ID50 [22], suggesting that some study participants 
may have had preexisting immunity to the virus.  Longer term monitoring of these 
participants is also being conducted to determine the duration of protection provided 
by this vaccine.  
Several additional vaccine strategies are under development. Different VLP-
based vaccine platforms are currently being investigated including GII.4 consensus 
VLP and multivalent VLP approaches.  Immunization studies in mice have 
demonstrated that multivalent VLP vaccines induce a blockade response against 
VLPs representing strains included in the vaccine formulation and also broaden the 
blockade response against VLPs representing strains not included in the vaccine 
[29].   
Our work involves the development of strategies to rapidly reformulate GII.4 
norovirus VLP-based vaccines, simultaneously investigating the capacity of rational 
structure-guided antigen design to expand and broaden the antigenic properties of a 
VLP based vaccine.  In this manuscript, we designed and constructed a chimeric 
GII.4 vaccine by admixing previously identified blockade epitopes [10, 11, 13] from 
multiple strains into a single vaccine background to induce a more broadly blocking 
immune response than a single GII.4 strain vaccine.  Here, we utilize an alphavirus 
replicon system (VRP) [77], which both acts as an adjuvant [145, 146] and allows 
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expression of the norovirus capsid gene, resulting in in vivo formation of VLPs when 
used to immunize mice [29, 51].  As proof of principle, we demonstrate that a 
chimeric GII.4 capsid vaccine can induce a more broadly blocking immune response 
than single GII.4 strain capsid, inducing robust blockade titers of GII.4 VLPs from 
GII.4-1987 through GII.4-2012, including those strains not included in the chimeric 
VLP.  Furthermore, this broadened response is similar to a multivalent vaccine 
formulation, which was previously shown to broaden blockade responses [29].  Our 
work provides a new conceptual template for the design of multivalent VLP vaccine 
formulations using structure-guided antigen design and represents a new and 
promising GII.4 norovirus vaccine strategy. 
 
Methods 
Structure-Guided Antigen Design 
Capsid sequences for major GII.4 outbreak strains were aligned and 
structural homology models based on RCSB PBD structure 2OBT were made for 
strains representing 1987, 1997, 2002, 2006, 2009, and 2012. Changing residues in 
the capsid P2 subdomain were noted and putative epitopes were defined and 
characterized as previously reported [10, 11, 13]. Chimeric capsid sequences were 
created between strains whereby GII.4-2006 A, D, and/or E epitopes were replaced 
with the epitope sequence(s) from one or more heterologous GII.4 strains.  These 
sequences were synthesized (BioBasic), cloned into expression vector pVR21, and 
verified by sequencing. 
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Production of VRPs and VLPs 
 VRPs expressing the norovirus capsid gene were produced as previously 
described [77].  Briefly, pVR21 3526 is an expression vector encoding the VEE 
genome yet lacks the VEE structural genes. The norovirus ORF2 gene was 
synthesized (BioBasic) and inserted into pVR21 3526 in place of the VEE structural 
genes behind the 26S promotor. RNA was made from the VEE-norovirus ORF2 
construct, as well as from two additional separate plasmids expressing either the 
VEE 3526 E1 and E2 glycoprotein genes or capsid gene.  RNA from all three 
constructs was electroporated into BHK cells and VRPs were harvested 48 hours 
later and purified by high speed centrifugation. VRPs were titered by counting 
fluorescent cells detected with FITC-labeled antibody.  For production of VLPs, BHK 
cells were inoculated with VRPs as previously described [10], and VLP production 
was confirmed by electron microscopy, enzyme immunoassay, and carbohydrate 
binding. 
 
VLP-Carbohydrate Ligand-Binding Antibody Blockade Assays  
Pig Gastric Mucin Type III (PGM) (Sigma Chemicals) contains HBGAs α-1,2-
fucose (H antigen) and α-1,4-fucose (Lewis antigen)[12, 13, 120] and has been 
validated as a substrate for norovirus VLP antibody-blockade assays. Blockade 
assays were performed as previously described [10]. VLPs bound to PGM were 
detected by rabbit anti-GII.4 norovirus polyclonal sera. The percent control binding 
was defined as the VLP-ligand binding level in the presence of test antibody or sera 
compared to the binding level in the absence of antibody multiplied by 100. All sera 
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were tested for blockade potential at two-fold serial dilutions ranging from 0.0098 to 
5%. Data shown are the average of sera from five individual mice and represent at 
least two replicates and are indicative of similar data from at least two independent 
trials.  Sigmoidal dose response analysis was performed as previously described 
[10]. EC50 values among VLPs were compared using One-way ANOVA with 
Dunnett’s post test. P<0.05 was considered significant. Blockade assays utilize VLP 
concentrations in the low nanomolar range; therefore, this assay does not 
discriminate between antibodies with sub-nanomolar affinities. 
 
Mouse Immunizations 
Groups of five each 5-7 week old Balb/c mice were immunized by footpad 
injection with 5 x 104 VRPs expressing the norovirus capsid gene and boosted on 
day 21.  Mice were euthanized and serum was harvested 7 days post boost. 
 
Results 
Design of Chimeric VLP Vaccine 
Previous work has demonstrated both genetic and antigenic changes over 
time in major GII.4 norovirus strains, including changes in at least three blockade 
epitopes that are linked to antigenic variation and the emergence of new epidemic 
strains in human populations [10, 11, 13].  We aligned the sequences from three 
GII.4 strains representing an ancestral strain, 1987, an early pandemic strain, 2002, 
and a more contemporary pandemic strain, 2006b in epitopes A, D, and E to 
illustrate the changes over time in these epitopes (Figure 5.1A) and mapped their 
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location on the surface of the capsid P2 dimer (Figure 5.1B).  Previous work 
indicates that blockade epitopes are portable among GII.4 strains, conferring 
blockade antibody reactivity gains and losses to the background strain [10, 11, 13].  
We then used structure-guided design to create synthetic genes in which broad 
combinations of time-ordered blockade epitopes were assembled into a single 
chimeric construct, which was used to produce a novel nanoparticle-based VLP 
vaccine with broadened immunogenicity.  We created a single epitope chimera, 
GII.4-2006.87A, which is comprised of the GII.4-2006 background with epitope A 
(residues 294, 296-298, 368, and 372) from GII.4-1987, and a double epitope 
chimera, GII.4-2006.87A.02E, which is comprised of the GII.4-2006 background with 
epitope A from GII.4-1987 and epitope E (residues 407, 412-413) from GII.4-2002 
(Figure 5.1C).  
 
Individual GII.4 Strain VLPs Do Not Induce Broad Blockade Responses. 
To determine the breadth of blockade induced by single parental GII.4 strain 
VLPs, we first immunized groups of five BALB/c mice with VRPs expressing the 
major capsid gene of GII.4 strains from 1987, 2002, 2006, or 2009 and then used 
sera from these mice to assess the ability of each VLP to induce a blockade 
response against a panel of GII.4 strain VLPs representing over 25 years of variation 
including 1987, 1997, 2002, 2006, 2009, and 2012.  Sera from mice immunized with 
GII.4-1987 VRPs were able to block carbohydrate-VLP interaction for early strains 
GII.4-1987, GII.4-1997, and GII.4-2002 but not for late strains GII.4-2006, GII.4-
2009, or GII.4-2012 (Figure 5.2A).  Likewise, sera from mice immunized with GII.4-
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2002 were only able to block the early strains (GII.4-1987, GII.4-1997, and GII.4-
2002) but not the late strains (GII.4-2006, GII.4-2009, and GII.4-2012) (Figure 5.2B).  
Conversely, sera from mice immunized with GII.4-2006 did not block early strains 
GII.4-1987, GII.4-1997, or GII.4-2002 but efficiently blocked homotypic GII.4-2006, 
and heterotypic late strains GII.4-2009 and GII.4-2012 (Figure 5.2C).  Sera from 
mice immunized with GII.4-2009 did not block early strains GII.4-1987, GII.4-1997, 
or GII.4-2002 but blocked GII.4-2006, GII.4-2009, and GII.4-2012 (Figure 5.2D).  
Overall, our data show that none of the parental strain VLPs we tested induces a 
broad blockade response against ancestral and contemporary GII.4 strains, 
consistent with previous work demonstrating GII.4 antigenic variation over time [28, 
38, 39]. 
 
Chimeric VLPs retain blockade epitopes of the component VLPs. 
To determine if chimeric VLPs retain the antigenic properties of multiple GII.4 
strains, we tested the blockade ability of sera from mice immunized with parental 
strain VRPs (GII.4-1987, GII.4-2002, GII.4-2006, or GII.4-2009) to block VLP-ligand 
interactions for two chimeric VLPs.  Sera from mice immunized against parental 
strains GII.4-1987, GII.4-2002, GII.4-2006, or GII.4-2009 were all able to block both 
GII.4-2006.87A and GII.4-2006.87A.02E VLP-carbohydrate interactions but to 
differing degrees (Figure 5.3). Sera from mice immunized against GII.4-1987 (Figure 
5.3A) blocked GII.4-2006.87A and GII.4-2006.87A.02E VLPs to a similar degree, 
while sera from mice immunized against GII.4-2002 (Figure 5.3B) blocked GII.4-
2006.87A.02E VLPs significantly better than GII.4-2006.87A VLPs, likely because 
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this chimeric VLP contained a GII.4-2002 blockade epitope. Sera from mice 
immunized against GII.4-2006 (Figure 5.3C) and GII.4-2009 (Figure 5.3D) blocked 
GII.4-2006.87A VLPs significantly more efficiently than GII.4-2006.87A.02E VLPs. 
These results demonstrate that chimeric VLPs can maintain antigenic blockade 
properties of multiple GII.4 strains.  
 
Chimeric VLPs Induce a Broadly Blocking Immune Response Against 
Homotypic and Heterotypic Strain VLPs 
Since antigenic variation in GII.4 noroviruses is a major hurtle to development 
of an efficacious vaccine, creating a vaccine that induces neutralization against a 
broad panel of strains is ideal.  Since chimeric VLPs retain the antigenic properties 
of multiple GII.4 strains, we tested their potential as a vaccine.  In order to determine 
whether a chimeric VLP can induce a more broadly blocking immune response than 
parental VLP strains, we developed VRPs that express the capsid genes for 
chimeric sequences GII.4-2006.87A and GII.4-2006.87A.02E.  We immunized 
groups of five BALB/c mice with VRPs expressing either the GII.4-2006.87A or GII.4-
2006.87A.02E capsid gene and compared the ability of the sera from these mice to 
block VLP-ligand interactions against our VLP panel with previously-mentioned 
representative strains from 1987-2012.  Unlike the parental VLPs, which only 
blocked a subset of the VLPs tested, sera from mice immunized with GII.4-2006.87A 
or GII.4-2006.87A.02E VRPs were able to block all of the VLP strains tested from 
GII.4-1987 through GII.4-2012 (Figure 5.4).  GII.4-2006.87A sera exhibited 
significantly more robust blockade responses compared to GII.4-2006.87A.02 sera 
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for VLPs representing strains GII.4-1987 (Figure 5.5A), GII.4-1997 (Figure 5.5B), 
GII.4-2006 (Figure 5.5D), GII.4-2009 (Figure 5.5E), and GII.4-2012 (Figure 5.5F) 
where between 1.5X-3.9X more GII.4-2006.87A.02E sera was needed for EC50 
blockade.   GII.4-2006.87A and GII.4-2006.87A.02E immunized mouse sera 
blockade of GII.4-2002 VLPs was not different, indicating that introducing epitope E 
from GII.4-2002 into the GII.4-2006 did not have a measurable effect on the ability to 
block GII.4-2002 VLP-ligand interaction (Figure 5.5C).   
 
Comparison of Immune Response Elicited by Chimeric VLPs versus a 
Multivalent Formulation of VLPs  
Previous work in our lab showed that immunizing with a multivalent VLP 
vaccine formulation induced a broadly blocking response against both VLPs 
representing strains included and not included in the formulation [29].  We wanted to 
compare the blockade response induced by immunizing with chimeric VRPs versus 
a multivalent VRP cocktail.  Since GII.4-2006.87A VRPs generally induced a 
stronger broadened blockade response than GII.4-2006.87A.02E VRPs, we used 
GII.4-2006.87A to represent the chimeric immunization scheme.  Importantly, this 
demonstrates that the incorporation of epitope A alone is sufficient to attain a 
broadened blockade response against multiple GII strains.  We immunized groups of 
five BALB/c mice with VRPs expressing either a chimeric (GII.4-2006.87A) capsid 
gene or a multivalent cocktail of parental VRPs expressing GII.4-1987, GII.4-2002, 
and GII.4-2006 capsid genes.  Sera from mice immunized with the multivalent 
cocktail displayed broad blockade activity, agreeing with previous studies [29], 
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although the blockade potential against different strains varied between the 
multivalent sera and the chimeric sera (Figure 5.6).  Sera from mice immunized with 
the multivalent cocktail were able to block GII.4-1987 VLP-ligand interaction to 
similar levels compared to chimeric sera (Figure 5.6A).  Multivalent sera EC50 
blockade titers were 2.2X lower for GII.4-1997 VLPs and 6.8X lower for GII.4-2002 
VLPs compared to chimeric sera (Figure 5.6B-C).  Chimeric sera blocked late strains 
GII.4-2006, GII.4-2009, and GII.4-2012 more efficiently than sera from the 
multivalent VLP-vaccinated mice (Figure 5.6D-F), with 4X, 2.9X, and 2.1X more 
multivalent sera required, respectively, for EC50 blockade.  When the blockade 
responses induced by single strain, multivalent strain, and chimeric strain 
immunizations are compared, sera against a single parental strain blocks the 
homotypic VLP-ligand interaction significantly better than either multivalent sera or 
chimeric sera for GII.4-1987 (Figure 5.7A), GII.4-2002 (Figure 5.7B), GII.4-2006 
(Figure 5.7C), and GII.4-2009 VLPs (Figure 5.7D).  However, for all VLPs, sera from 
chimeric GII.4-2006.87A or multivalent formulations blocked as well or better as sera 
from the closest heterotypic strain.  Chimeric GII.4-2006.87A and multivalent sera 
blocked GII.4-1987 VLPs more efficiently than GII.4-2002 sera (Figure 5.7A), and 
multivalent sera blocked GII.4-2002 VLPs more efficiently than GII.4-1987 sera 
(Figure 5.7B). GII.4-2006.87A sera blocked GII.4-2006 VLPs more efficiently than 
GII.4-2009 sera (Figure 5.7C), while blockade of GII.4-2009 VLPs was equivalent for 
GII.4-2006 and GII.4-2006.87A sera (Figure 5.7D).  Overall, our data show that 
chimeric and multivalent vaccine formulations can broaden the blockade response 
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against homotypic and heterotypic strain VLPs compared to a single strain vaccine 
formulation. 
 
Discussion 
Vaccine design for human noroviruses has been hindered by several factors 
including lack of tissue culture systems for human norovirus cultivation, the 
heterologous properties of different genogroups and genotypes, incomplete 
understanding of duration of immunity to noroviruses, the effects of pre-exposure 
history on the kinetics and duration of adaptive immunity, and antigenic variation in 
GII.4 noroviruses.  Since GII.4 noroviruses account for over 70% of all norovirus 
outbreaks, they are the most medically important group to target with a vaccine; 
however, they pose a unique challenge as new GII.4 strains emerge every 2-4 years 
by escaping human herd immunity.  This antigenic change over time suggests that 
frequent vaccine reformulation may be necessary in order to continuously protect 
against the GII.4 genotype.  An approach that uses an approved backbone gene 
with targeted replacements of key antigenic epitopes for eliciting protective immunity 
offers a strategy for improving vaccine performance while streamlining FDA approval 
processes for human use.  In this manuscript, we demonstrate that detailed 
molecular characterization of key varying blockade epitopes, coupled with structure 
guided antigen design and synthetic biology yields a VLP vaccine formulation that 
induces a more broadly blocking immune response than a single outbreak strain 
capsid. This, and recent work using a similar epitope transfer strategy in dengue 
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virus [147], demonstrates that structure-guided antigen design provides a novel 
method of mapping immunogenic targets in medically-important RNA viruses.   
Multivalent VLP-based vaccines have demonstrated induction of broadly-
blocking immune responses in mice, blocking both VLPs included in the formulation 
and heterologous strain VLPs [29].  Of the other VLP-based norovirus vaccine 
strategies being investigated, the Takeda vaccine is furthest along in human clinical 
trials. The GII.4 component of the vaccine is based on a GII.4 consensus sequence 
from three major epidemic strains. Though clinical results have not yet been 
published, the consensus VLP approach may similarly broaden the protective 
response against multiple GII.4 strains.  Another vaccine strategy currently being 
explored is based on norovirus P particles, which consist of varying numbers of P 
domains in a single particle.  This approach utilizes the most surface-exposed, 
antigenically-important portion of the norovirus capsid protein to generate an 
immune response in mice.  While multiple studies have found that P particles 
generate good immune responses (Fang, 2013, Plos One; Xia, 2011, Vaccine; Tan, 
2011, JVI), a study comparing P particles to VLPs demonstrated that VLP immune 
induction is generally stronger and able to induce cross reactive B and T cells, while 
P particles did not (Tamminen, 2011).  Another norovirus vaccine approach involves 
using polyvalent complexes made up of dimeric glutathione S-transferase (GST) 
fused with norovirus P domains (Wang, 2013, Biomaterials).  This approach induces 
a stronger blockade response and overall norovirus-specific immune response 
compared to P particles (Wang, 2013), but the quality of immune response induction 
comparisons between polyvalent complexes and VLPs are not yet known.  
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Our work demonstrates that chimeric and multivalent GII.4 strains induce 
broadly blocking immune responses in mice, although single strain VLPs induce a 
stronger blockade response against the parental strain than either chimeric or 
multivalent VLPs.  Whether this is due to differences in the number of epitopes from 
each strain presented, immune interference, or both is unknown.  However, both 
immune interference and antigen dose are known to affect the strength of immune 
response.  Immune interference has been noted in other multivalent norovirus 
vaccines [14], and multivalent VLP-based HPV vaccines [148], live virus vaccines 
[149, 150], and killed/recombinant vaccines [151] when compared to monovalent 
vaccines.  Importantly, unlike multivalent vaccines, chimeric VLP-based vaccines 
may not induce immune interference since only one type of particle is present in the 
vaccine.  This, coupled with our data showing that multivalent and chimeric sera 
more efficiently blocked strains that were most represented in their respective 
vaccine, makes it likely that antigen dose and epitope dominance are more likely to 
account for differences in immune induction in our study. Despite having stronger 
blockade against a homotypic strain, the immune response to a single GII.4 VLP 
does not broadly block heterologous strains, suggesting that the ability of a single 
strain to induce a neutralizing response against closely related circulating GII.4 
strains is limited. This is problematic for a GII.4 vaccine since emerging strains may 
quickly escape the herd immunity elicited by a single strain. Previous work suggests 
that an increase in dosage of a single strain VLP would probably not increase 
blockade breadth, whereas increasing the dosage of a chimeric or multivalent 
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vaccine could potentially compensate for the comparative weakness in blockade 
strength [29].   
Our results also suggest that incorporating immunodominant epitope A from 
one strain into another is sufficient to induce a blockade response against that strain. 
Of our two chimeric VLPs, GII.4-2006.87A VLPs induce a generally stronger 
blockade response against all VLPs tested from GII.4-1987 through GII.4-2012, with 
the exception of GII.4-2002, which was not different between the two chimeric VLPs.  
This demonstrates that epitope A alone was sufficient to induce a blockade 
response against early strains GII.4-1987, GII.4-1997, and GII.4-2002 and supports 
earlier work demonstrating that epitope A is the immunodominant GII.4 epitope [11].  
The addition of GII.4-2002 epitope E in GII.4-2006.87A.02E did not significantly 
increase blockade response against GII.4-2002, suggesting that this is a minor 
epitope or that additional residues are required in this epitope to fully recapitulate the 
antigenic properties of the epitope.   
Public health preparedness requires a platform strategy to survey disease 
prevalence in human populations, categorize sequence variation, identify antigenic 
variants that may seed future outbreaks, and inform vaccine design.  A similar 
strategy to that in place for reformulation of the annual influenza vaccine could be 
used to address reformulation of future norovirus vaccines. The current influenza 
paradigm involves a synchronized effort by public health agencies and centers 
around the world to conduct ongoing epidemiological antigenic testing and genetic 
characterization of influenza isolates and make predictions about which may cause 
the greatest threat to human health worldwide [152].  Norovirus surveillance systems 
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like CDC Calicinet [113] and the European NoroNet, while relatively new, are key to 
developing a similar, widespread, coordinated effort to track norovirus epidemiology 
and emergent strains [115]. The apparent plasticity and immunodominance of 
epitope A has applications for both GII.4 norovirus surveillance and vaccine design; 
epitope A accounts for 25-55% of the total blockade response between major 
epidemic strains in humans [10, 11, 38, 39], demonstrating that changes in this 
epitope have a major impact on new strain emergence.  Epidemiological work on 
GII.4-2012 Sydney has shown that this strain was present at low levels in the 
population for at least a year before its emergence as a major circulating strain 
[153], showing that new strains are likely present early enough before emergence for 
detection, antigenic testing, and targeted surveillance.  As is done for Influenza, 
panels of defined antibodies could be used to probe the antigenic properties of 
epitope A in pre-emergent strains. When coupled with epidemiologic surveillance 
data, this system could provide a mechanism for predicting future emergent strains 
and vaccine reformulation prior to epidemic seasons (Figure 5.8), providing a key 
public health preparedness platform and vaccine reformulation strategy for 
noroviruses. 
These studies, coupled with studies reported by other groups, highlight the 
power of antibody-based identification of key neutralizing epitopes in viral 
pathogens. This information provides an opportunity to map the conformational 
epitopes and identify key residues, which influence immunogenicity and protective 
immunity.  When coupled with structure guided antigen and synthetic gene design, 
chimeric VLPs or even recombinant live viruses can be constructed with novel 
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properties that broaden neutralization antibody responses and protective immunity--
even against strains not included in the original design.  This fledgling strategy 
promises to revolutionize the design of new generation vaccines, with the ultimate 
goal of improving the global health of populations. 
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CHAPTER 6:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary 
 The studies described in this dissertation investigate the underlying 
mechanisms that influence GII.4 norovirus evolution with the goal of identifying 
targets that can be used to for rational design of effective norovirus vaccines and 
therapeutics that reduce norovirus-induced morbidity and mortality.  Our work 
employs novel methods and reagents for approaching questions about norovirus 
evolution and antigenic variation in the face of limited animal models and in the 
absence of a cell culture system for human norovirus.  As an overall approach, we 
used chimeric VLPs and VLPs representing common outbreak strains along with a 
large panel of strain- and genotype-specific mouse and human monoclonal 
antibodies in biological binding and blockade assays to measure antigenic 
differences among strains and to map important potential neutralizaton epitopes for 
GII.4 noroviruses.  Our work characterized both population-wide and intra-host 
antigenic variation for GII.4 noroviruses and identified the immunodominant 
blockade epitope for GII.4 noroviruses, allowing the design of more targeted 
norovirus vaccines and therapeutics. 
 Central to the success of the work presented in this dissertation was previous 
work done in our lab using structure-guided approaches to aid in the identification of 
potential neutralization epitopes.  The capsid sequences of major GII.4 outbreak 
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strains from 1974-2006 were aligned, and the changes over time were mapped onto 
crystal structure homology models representing these strains.  We then identified 
amino acid positions in the capsid P2 subdomain that are surface exposed, change 
over time, and map together on the crystal structure.  Using this structure-guided 
approach, we predicted the location of five putative neutralization epitopes, A-E.   
Chapter 2 describes experiments that characterize epitope A and confirm that 
it is the immunodominant blockade epitope for GII.4 noroviruses.  In addition, this 
work demonstrates that antigenic epitopes can be exchanged between strains while 
retaining the epitope’s strain-specific antigenic properties.  Furthermore, this chapter 
demonstrates that Epitope D impacts HBGA A and B binding, supporting earlier 
work from our lab showing that residue 393 is important for HBGA B binding, but not 
A binding [12], and we provide evidence that residues 394 and 395 are important for 
interaction with HBGA A.  Chapter 3 describes experiments that characterize the 
antigenic variation between two consecutive predominant GII.4 norovirus strains, 
GII.4-2009 New Orleans and GII.4-2012 Sydney, allowing us to explore population-
wide evolutionary mechanisms.  Using both mouse and human polyclonal sera, we 
note significant global antigenic change between these two strains and demonstrate 
major epitope A and D-specific antigenic differences using mouse and human 
monoclonal antibodies.  Chapter 4 describes experiments that explore intra-host 
antigenic variation in an individual chronically infected with norovirus, and we 
compare the within-host variation to the degree of variation typically observed with 
major consecutive GII.4 outbreak strains using antigenic cartography.  Furthermore, 
we consider a broadly-blocking GII.4 monoclonal antibody as a potential norovirus 
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therapeutic in chronically infected patients.  Chapter 5 describes proof-of-concept 
experiments for using chimeric VLPs as a vaccine platform that is both broadly 
blocking against multiple GII.4 strains and easy to reformulate as virus escape from 
human herd immunity gives rise to antigenically novel strains.  We show that 
incorporating epitope A from one strain into the background of another strain is 
sufficient to induce a blockade response against both strains included in the chimeric 
VLP and heterologous GII.4 strains.  This suggests that a chimeric VLP-based 
vaccine that is reformulated as epitope A changes is a promising GII.4 norovirus 
vaccine strategy.  
 
Norovirus Epitope Mapping 
 Efforts to map norovirus blockade epitopes have yielded the identification of 
three GII.4 potential neutralization epitopes, A, D, and E [10, 11, 13]; however, our 
understanding of norovirus neutralization sites is in its infancy.  From ongoing work 
in our lab, it is clear that the defined amino acid positions that comprise epitopes A 
(residues 294, 296-298, 368, 372), D (393-395), and E (407, 412, 413) are the 
minimal residues that make up these antigenically important domains, and additional 
amino acid positions may impact antibody binding.  For example, these epitopes are 
based on residue changes occurring between 1987 and 2006, but the most recent 
pandemic strain, Sydney 2012, contains a residue change N373R, a previously 
conserved residue that is one amino acid position from epitope A position 372.  
Based on structural modeling, this residue change likely impacts epitope A antibody 
binding.  Likewise, in the chronic infection isolates, VLPs representing GII.4-2006 
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and late isolate P.D302 had very different antibody binding to a mAb that recognizes 
epitope D despite having the same residues at 393-395.  However, a residue 
change at 391 (a historically conserved residue) in P.D302 compared to GII.4-2006 
may explain the antigenic differences noted in this epitope as well as HBGA binding 
differences between these isolates. Future work on GII.4 epitope mapping must 
consider how novel genetic changes over time may impact antibody interaction in 
these epitopes, and epitopes should be updated based on the newest available 
data. Figure 6.1 shows an updated prediction of epitopes A, D, and E based on 
nearby amino acid positions that changed in intra-host evolved strains and major 
outbreak strains since GII.4-2006, presenting a more accurate roadmap for tracking 
emergent strains.   
In addition to expanding these epitopes as new strains emerge, fine 
resolution mapping of strain-specific mAb binding sites is needed.  Based on 
differential blockade and binding data from mAbs that recognize epitope A, it is clear 
that epitope A is actually made up of overlapping epitopes, some of which may be 
smaller than the defined epitope A.  Fine resolution mapping of strain-specific mAbs 
may allow us to tease apart individual amino acid position motifs within defined 
epitopes A, D, and E that contribute to the epitope for each unique antibody.  This 
could also be relevant to improving vaccine specificity since there may be dominant 
epitope targets within these overlapping antigenic sites.   
Our epitope mapping work thus far captures the evolving residues within an 
epitope, but nearby conserved residues may be part of these epitopes as well. 
These nearby conserved residues may represent important antibody binding sites, 
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with evolving residues mediating access to them; however, additional work will be 
needed to test this hypothesis.  Alternatively, these conserved residues may be 
necessary to maintain the structural integrity of the virion.  This possibility is less 
likely given that in the chronic infection isolate, P.D302, there were several amino 
acid positions in close proximity to our defined blockade epitopes that are normally 
static in GII.4 outbreak strains but were altered in this isolate.  These included amino 
acid positions 292 and 295 (epitope A), 391 (epitope D), and 414 (epitope E).  Since 
we were able to build intact, functional VLPs from this patient isolate sequence, it 
argues that these conserved residues are not maintained by structural dependence.   
Despite mapping most of our mAbs, our panel of mAbs contains three 
blockade antibodies that do not recognize the known blockade epitopes.  This 
suggests that there are additional unmapped or partially overlapping blockade 
epitopes for GII.4 noroviruses.  One of these is a broadly-blocking GII.4 human mAb 
that has therapeutic potential, and the other two are strain specific mouse mAbs.  
The fact that each of these three mAbs have differential binding and blockade 
patterns suggests that they recognize unique blockade epitopes. 
Beyond GII.4 noroviruses, there are at least 30 other norovirus genotypes.  
No blockade epitopes that have been identified for any of these genotypes; future 
work mapping epitopes in other epidemiologically important genotypes should be 
pursued in order to better understand the similarities and differences among groups 
and aid in identification of vaccine and therapeutic targets.  In particular, given that 
there is some cross-blockade activity among GI genotypes, vaccine design 
strategies could be improved by identifying these common epitopes.  Because the 
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GI viruses do not undergo much genetic change over time, it is hard to pick out 
areas of antigenic importance over areas that are not important.  We can use 
structure-guided approaches similar to our GII.4 epitope mapping by looking for 
surface-exposed areas that stick out from the P2 dimer surface; however, while this 
strategy works for GII.4 noroviruses, it is presently unclear if cross-neutralizing GI 
epitopes would also exist in a similar location or if they would be more hidden from 
antibody recognition.   
Additional chimeric VLP studies can be done to address some of these 
questions.  For instance, teasing apart epitope A overlapping epitopes could be 
done by incorporating smaller sets of amino acids within epitope A from one strain 
into another.  This would allow for more specific mapping of each antibody.  
Chimeric VLPs could also be used to identify blockade epitopes for the mAbs that 
are not yet mapped.  Because each has a specific binding and blockade profile, 
specific amino acid changes that occur between strains that are blocked and strains 
that escape blockade could be used to predict where these epitopes are located, 
and chimeric VLPs could be built to test these predictions.  Furthermore, chimeric 
VLPs could be built to test the impact of novel amino acids that replace previously 
conserved residues on the blockade response of identified epitopes.  We are 
currently building two chimeric VLPs (2012.09A+R373N and 2012.R373N) to test the 
impact of the novel 373 change on the antigenic variation in epitope A between 
GII.4-2009 and GII.4-2012. 
Crystal structures of antibody-bound P dimers or VLPs are needed to address 
many of the unanswered questions referenced above.  Future studies with crystal 
	   128	  
structures of antibody-bound GII.4 P dimers or VLPs will be needed to determine 
which residues in or around these epitopes are antibody binding sites and how 
alterations in amino acid size and charge may impact virus-antibody interactions.  In 
addition, crystallization studies with unmapped blockade antibodies could help 
identify additional GII.4 blockade epitopes.  Development of GI cross-blockade 
mAbs and their crystallization with different GI genogroup P2 dimers or VLPs could 
help identify shared GI blockade epitopes, and similar studies could be conducted to 
find potential shared blockade epitopes within GII genotypes.  We have ongoing 
collaborations to address some of these questions using crystal structure studies, 
unfortunately, attempts to crystallize antibodies with P dimers and VLPs have failed 
thus far.  
 
Norovirus Vaccine Design 
 Vaccine development for noroviruses is hampered by several factors 
including (1) the limited number of challenge and vaccine efficacy studies done in 
humans, (2) the absence of a cell culture system and limited animal models for 
testing vaccines, (3) the limited and conflicting data on how long protective immunity 
lasts after infection or vaccination in humans, (4) differing evolutionary patterns and 
antigenic profiles between genogroups and among genotypes within genogroups, (5) 
antigenic variation within GII.4 noroviruses and possibly within other genotypes, and 
(6) the unknown effects of exposures to multiple norovirus genotypes and strains 
during a lifetime on the immune response to newly-encountered strains.  Despite 
these challenges, many strategies are being explored to develop efficacious, broadly 
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protective norovirus vaccines.  The majority of groups working on norovirus vaccines 
utilize VLP-based approaches, as VLPs have shown to be highly immunogenic in 
mice and humans, stimulating balanced Th1/Th2 responses and induction of IgA 
and blockade antibodies [22, 46, 154].  These VLP approaches include different 
delivery methods including intramuscular, intranasal, and edible vaccines, and 
different monovalent and multivalent vaccine formulations, each utilizing differing 
approaches to choosing genotypes to target and methods of inducing broadened 
blockade against multiple genotypes and strains. 
 Work in this dissertation focuses specifically on addressing the issue of 
changing antigenicity over time in GII.4 noroviruses and how to best develop 
vaccines that are able to induce broadened GII.4 protection and be reformulated 
over time as new strains emerge.  The identification of major GII.4 norovirus 
blockade epitopes has allowed us to specifically target evolving areas of antigenic 
importance.  We propose a chimeric VLP-based vaccine approach where we 
simultaneously broaden GII.4 blockade response and provide a strategy for targeted 
reformulation.  Our approach, as presented here, utilizes alphavirus VRPs that 
encode a chimeric norovirus capsid protein to deliver norovirus VLPs in vivo and that 
simultaneously act as an adjuvant to boost immune response.  Alternatively, 
chimeric VLPs could be produced and directly administered with or without an 
adjuvant, although future work should compare these approaches to evaluate 
differences in immune induction.  Both of these approaches allow for a vaccine 
platform that is both specifically targeted to circulating strains and easy to 
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and disadvantages.  While a VRP system allows for inherent adjuvant activity, it will 
be harder to get approved for human use given that there are potential safety 
concerns in using a pathogenic virus as an expression system. In addition, with a 
multivalent vaccine, there may be differences in VLP expression efficiency of the 
vaccine components with a VRP system, which will need to be further studied and 
monitored if this vaccine approach is developed.  A VLP-based vaccine presents 
fewer safety risks, but this approach may require adjuvants in order to induce robust, 
long-lasting immune responses.  
 Our work demonstrates that chimeric VLPs containing epitope A from one 
strain in the background of another strain can broaden GII.4 blockade responses 
against both strains contained in the chimeric particles and expand blockade to 
strains not included in the chimeric particle. Multiple studies from our lab have 
determined that epitope A is the immunodominant GII.4 blockade epitope in the 
strains we have tested and accounts for ~50% of the human polyclonal blockade 
response [10, 11].  Other blockade epitopes including epitopes D and E, and other 
currently unidentified epitopes, make up the remaining 50% of the blockade 
response.  This suggests that a chimeric VLP-based vaccine can target ~50% of the 
blockade response from two separate strains with a single VLP.  This is important 
considering that when an emergent GII.4 strain replaces the previously-circulating 
major GII.4 strain to become the new predominant GII.4 strain, the old strain still 
circulates at low levels in the population for 1-2 years [153]. A chimeric vaccine 
composed of two successive circulating strains could provide balanced protection 
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against both the new emergent strain and the previous circulating strain, reducing 
overall GII.4 disease burden. 
 In order for the chimeric VLP vaccine approach described in this dissertation 
to work efficiently, epidemiological sampling must include measures that specifically 
and consistently track genetic and antigenic changes in epitope A to prepare for 
potential changes in the predominant GII.4 strain.  Just as predictions are made and 
vaccines are reformulated annually for the seasonal influenza vaccine, the GII.4 
component of a norovirus vaccine could be monitored in the same way.  Noroviruses 
and influenza have similar seasonal high points occurring during the winter months, 
so it is theoretically plausible that careful tracking and prediction of potential 
emergent GII.4 strains during one winter season could inform vaccine reformulation 
for the following season.  This, of course, assumes that the next emergent strain is 
identifiable during the previous season.  Epidemiological data from the emergence of 
GII.4-2012 Sydney suggest that this is possible.  The GII.4-2012 Sydney sequence 
was published in March 2012 and identified as an important new strain before its 
replacement of GII.4-2009 New Orleans as the predominant GII.4 strain in 
November 2012.  In addition, sequence data collected by the CDC indicates that this 
strain was actually circulating at low levels for several months prior to the sequence 
being published (unpublished data, personal communication). This demonstrates 
that potential epidemic strains are likely present at least one season before their 
emergence as a predominant strain.  However, how well these potential new 
epidemic strains can be selected from other background variants has yet to be 
assessed.  Since there is no cell culture model for human norovirus, antigenic 
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properties of these viruses have been investigated in isolation from other potential 
factors that may influence strain emergence like replication efficiency and 
recombination.  Whether GII.4 antigenic variation alone can be measured to predict 
future strain emergence is unknown, but should be evaluated.  This could be 
accomplished by sequencing of epidemiological samples, tracking genetic changes 
in epitope A variants, constructing VLPs that represent this genetic diversity, 
evaluating antigenic profiles of these VLPs, and choosing specific isolates that are 
antigenically distinct.  Since there are no studies evaluating antigenic variation in 
minor circulating variants, it is unclear whether antigenic divergence is a rare 
occurrence or whether many antigenically distinct variants evolve and other factors 
influence their epidemic potential.  Future collaborations with agencies involved with 
norovirus surveillance will help address this question.  Another challenge facing 
vaccine design is that selection of one GII.4 variant over another for incorporation in 
the vaccine may drive evolution of GII.4 strains in another direction as the population 
is protected from that particular variant, resulting in the emergence of a strain that 
was not accounted for.  Despite these complications, additional work should be done 
to explore the feasibility of developing a chimeric GII.4 norovirus vaccine and 
improving design of other norovirus vaccine platforms. 
 Beyond the issue of antigenic variation in GII.4 noroviruses, several other 
factors will impact the efficacy of future norovirus vaccines.  Among these are 
genetic and environmental factors that influence induction of protective immunity.  
Based on preliminary data from human serum samples collected from the Takeda 
bivalent GI.1/GII.4c human vaccine trials, blockade responses vary considerably by 
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individual (Lindesmith, unpublished), with some individuals responding to both 
vaccine components and others only responding to either the GI or GII.4c 
component.  Furthermore, broadened responses also varied; some individuals 
mounted vaccine component-specific responses, while others demonstrated 
broadened responses against other GII.4 strains, and/or other GI or GII genotypes 
(Lindesmith, unpublished).  Given that some of the non-responders had high pre-
existing blockade titers against some strain VLPs, it is likely that individual immune 
responses can be explained in part by differing exposures to norovirus strains in the 
past; however, host genetic factors may also play a role in the immune response to 
vaccines.   
Identification of host genetic factors that impact vaccine efficacy is difficult to 
address in humans, but the collaborative cross offers a genetically diverse mouse 
model to evaluate potential genetic determinants of immune response to VLP-based 
norovirus vaccines and adjuvants.  Preliminary data on 10 collaborative cross mouse 
lines indicate that there are genetic differences in the response to VLP-based 
vaccines and adjuvants.  Continued work with collaborative cross lines will 
characterize these differences and identify specific potential host genetic factors that 
influence norovirus vaccine and adjuvant efficacy, allowing for better refinement of 
norovirus strain and adjuvant selection for vaccines.  
 
Norovirus Therapeutics 
 Immunocompromised, the elderly, and very young children are at risk for 
severe norovirus disease and death.  While most populations would probably not 
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benefit from norovirus therapeutics due to the short duration of disease, 
development of therapeutics should be a top priority because they could treat 
serious infections in these at-risk populations.  We pioneered work on intra-host 
antigenic variation, investigating GII.4 norovirus antigenic changes over time in an 
immunocompromised patient.  Importantly, we found that intra-host evolution in 
chronically infected patients can give rise to antigenically distinct strains over time.   
That intra-host evolution can give rise to antigenic variation is critical 
knowledge for therapeutic development, as it means strain-specific therapeutics may 
become ineffective over time during chronic infection in some patients.  For this 
reason, more broadly-acting therapies are needed.  Our work identified a human 
monoclonal antibody that has broad blockade activity against all major GII.4 strains 
as well as against intra-host evolved variants.  This suggests that this or other 
broadly-blocking mAbs could be used to treat severe norovirus infections.  However, 
since our data are representative of a single person, further work with additional 
chronic infection isolate VLPs from other patients will determine whether our work 
has broader applications to specific immunocompromised populations, and whether 
our mAb has potential as a therapeutic antibody.  Future work will also attempt to 
map the antibody epitope for this monoclonal antibody to identify this conserved 
GII.4 blockade epitope. 
  
Conclusions 
Noroviruses are a significant source of global disease burden and continued 
development of vaccines and therapeutics is warranted.  The work described in this 
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dissertation significantly advances our understanding of the mechanisms governing 
GII.4 evolution and the antigenic determinants of GII.4 noroviruses, and we 
demonstrate how this information can be applied to norovirus vaccine and 
therapeutic development.  Future work will aim to identify blockade epitopes in other 
norovirus genotypes as well as additional GII.4 epitopes, identify specific epitope 
binding sites, improve norovirus vaccines, develop broadly-acting norovirus 
therapeutic antibodies, and identify potential host genetic factors that influence 
vaccine performance.  Through this work, we hope to contribute to the development 
of vaccines and therapeutics that reduce global norovirus disease burden. 
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APPENDIX 1: CHAPTER 1 FIGURES AND TABLES 
 
Figure 1.1 
 
 
Figure 1.1:  Norovirus Structure, Phylogeny, and HBGA Phenotype Pathways 
A: NoV genome schematic. The norovirus genome encodes three open reading 
frames. ORF 1 encodes the non-structural proteins (blue); ORF 2 encodes VP1, the 
major capsid protein(purple); and ORF 3 encodes VP2, the minor capsid protein 
(green). VP1 is further divided into the shell, which forms the base of the virion (teal); 
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the P1 subdomain, which forms a stalk-like projection from the surface (orange); and 
the P2 subdomain, which is the most variable and surface-exposed area of the 
virion, contains ligand binding sites, and interacts with potentially-neutralizing 
antibodies (red). B: Norovirus phylogenetic tree. Noroviruses are divided into 5 
genogroups. Genogroups 1 (pink) and 2 (orange) cause the majority of human 
disease. Genogroups are further divided into genotypes.  Genotype GII.4 NoVs (red 
bracket) account for ~80% of outbreaks. Genotype GI.1 are the prototypic Norwalk 
viruses. C: NoV capsid protein (VP1) cryo EM image and P2 dimer. Colors in cryo 
EM correspond approximately to the shell (teal), the P1 subdomain (yellow/orange) 
and the P2 subdomain (red). Close up of a P2 dimer (pink) shows locations of 
epitopes A (blue), D (green), and E (purple). Black denotes HBGA binding pocket. D. 
Secretor/Non-secretor Phenotype Pathways. Enzymes (Secretor or Lewis) add 
specific modifications to a precursor molecule. Individuals without a functional FUT2 
gene cannot express HBGAs from the left branch of the pathway (left of the dotted 
line) on mucosal surfaces. For those without a functional FUT2 gene (non-
secretors), the precursor molecule can still be modified by the Lewis enzyme to 
make Lewis a antigen (branch on the right side of the dotted line).  
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Figure 1.2 
 
 
Figure 1.2:  GII.4 Variation in Blockade Epitopes 
A: GII.4 P2 subdomain variation over time. Colored residues indicate change over 
time since 1974; changes present in 1987=yellow, 1997=red, 2002=teal, 
2004=green, 2005=orange, 2006=purple, 2009=blue, HBGA interaction sites=black. 
Carbohydrate shown in white sticks. B: GII.4 blockade epitopes. Three blockade 
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epitopes have been identified in GII.4 NoVs.  Epitope A-residues 294, 296-298, 368, 
and 372(green), Epitope D-residues 393-395(orange), and Epitope E-residues 407, 
412-413(yellow) all map to the P2 subdomain on the surface of the virion.  The 
HBGA interaction sites are shown in black. C: GII.4 NoV variation over time in 
blockade epitope regions. GII.4 NoV blockade epitopes undergo change over time, 
likely in response to human herd immunity. Colors indicate in which outbreak strain a 
particular residue change originated. D: Mapping of GII.4 variation over time in 
blockade epitope regions. Each VLP shows areas within blockade epitopes that 
change over time.  Yellow indicates differences from 1974 present in 1987, 
red=1997, teal=2002, green=2004, orange=2005, purple=2006, and blue=2009. 
These blockade epitopes continue to evolve in new outbreak strains since 2009. 
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Figure 1.3 
 
 
Figure 1.3:  Factors Complicating Norovirus Vaccine Design 
Vaccine development for noroviruses is hampered by several factors including the 
limited number of challenge and vaccine efficacy studies done in humans, the 
absence of a cell culture system and limited animal models for testing vaccines, the 
limited and conflicting data on how long protective immunity lasts after infection or 
vaccination in humans, differing evolutionary patterns and antigenic profiles between 
genogroups and among genotypes within genogroups, antigenic variation within 
GII.4 noroviruses and possibly within other genotypes, and the unknown effects of 
exposures to multiple norovirus genotypes and strains during a lifetime   on the 
immune response to newly-encountered strains. 
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Figure 1.4 
 
 
 
 
Figure 1.4:  Design of a Multivalent Norovirus VLP Vaccine 
(A)  Large circles represent the two major norovirus genogroups that infect humans, 
GI and GII.  Smaller circles within the larger circles represent the nine (G1) and 22 
(GII) individual genotypes within each genogroup.  (B) Heterogeneity of GI and GII 
viruses necessitates a multivalent vaccine to maximize protective coverage of 
multiple genotypes.  Multivalent vaccines containing VLPs representing GI.1 and 
GII.4 components (red circles) cover norovirus genotypes responsible for ~80% of 
outbreaks, but a multivalent approach likely broadens the immune response to 
potentially protect against some heterologous norovirus gentypes (green circles) as 
well. Heterologous genotypes (green) are shown as examples and are not 
representative of published data. (C) Continued work on norovirus VLP vaccines 
should consider that there will likely be epidemiological changes over time where 
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relative changes in disease burden by different genotypes occur, and strain 
replacement occurs every 2-4 years for GII.4 noroviruses, thus norovirus vaccines 
will need to be reformulated over time 1) in response to changes in epidemiologically 
important viruses, and 2) in response to changing antigenicity of GII.4 noroviruses. 
Changes in epidemiologically important norovirus genotypes in C.1 are shown as 
examples and are not representative of published data.  
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APPENDIX 2:  CHAPTER 2 FIGURES AND TABLES 
 
Figure 2.1 
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Figure 2.1:  Putative Epitopes A and D.  
A) Amino acid differences between GII.4-1987 Camberwell and GII.4-2006 Minerva 
in the P2 region of VP1. Green shading indicates amino acids within putative 
Epitope A, and orange indicates amino acids within putative Epitope D. Shared 
residue 296S was included because it falls within putative Epitope A.  B) Epitope A 
is shown in green, consisting of 6 amino acids 294, 296, 297, 298, 368, and 372. 
Epitope D is shown in orange, consisting of 3 amino acids 393-395. Black shading 
indicates HBGA binding pocket.  C) Epitope A chimeric VLPs. The parental GII.4-
2006 and GII.4-1987 amino acid residues are shown in purple and yellow, 
respectively. GII.4-2006 Minerva residues (purple) were replaced in each chimera by 
GII.4-1987 Camberwell residues at the positions shown in yellow.  A total of four 
Epitope A chimeric VLPs were created.  D) Representative EM images of parental 
and chimeric VLPs. a. GII.4-1987, b. GII.4-2006, c. GII.4-1987(+06D), d. GII.4-
2006(+87D), e. GII.4-2006(+87A.1), f. GII.4-2006(+87A.2), g. GII.4-2006(+87A.3), h. 
GII.4-2006(+87A.4). 
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Figure 2.2 
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Figure 2.2: Epitope D chimeric VLP reactivity with synthetic HBGAs and anti-GII 
mAbs.  
A) HBGA reactivity. Synthetic CHO was diluted to 10 µg/ml and assayed by CHO 
binding assay for interaction with GII.4-1987, GII.4-2006, GII.4-1987(+06D), and 
GII.4-2006(+87D).  Amino acid residues from GII.4-1987 were exchanged with GII.4-
2006 residues at positions 393-395. The dashed line represents 3X the background 
level of binding and indicates a positive signal. B) anti-GII.4 mAb reactivity. Anti-
GII.4-1987 and -2006 mAbs were diluted to 2 µg/ml and assayed by EIA for 
reactivity with GII.4-1987, GII.4-2006, GII.4-1987(+06D), and GII.4-2006(+87D) 
VLPs. Amino acid residues from GII.4-1987 were exchanged with GII.4-2006 at 
positions 393-395. Bars represent the mean optical density values with standard 
error of the means.  The dashed line represents 3X the background level of binding 
and indicates a positive signal. 
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Figure 2.3 
 
Figure 2.3: GII.4-2006(+87A.1) reactivity with anti-GII.4 mAbs.  
Anti-GII.4-1987 and -2006 IgG were diluted to 2 µg/ml and assayed by EIA for 
reactivity with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.1) VLPs. Amino acid 
residues from GII.4-1987 were inserted into the GII.4-2006 backbone at positions 
294, 297, 298, 368, and 372 to create GII.4-2006(+87A.1). Bars represent the mean 
optical density values with standard error of the means. The dashed line represents 
3X the background level of binding and indicates a positive signal. 
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Figure 2.4 
 
 
 
Figure 2.4: Epitope A chimeric VLP reactivity with synthetic HBGAs.  
Synthetic CHOs were diluted to 10 µg/ml and assayed by CHO binding assay for 
interaction with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.1).  Amino acid 
residues from GII.4-1987 were inserted into the GII.4-2006 backbone at positions 
294, 297-298, 368, and 372. The dashed line represents 3X the background level of 
binding and indicates a positive signal. 
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Figure 2.5 
 
 
 
Figure 2.5: GII.4-2006(+87A.2) reactivity with anti-GII.4 mAbs.  
Anti-GII.4-1987 and -2006 IgG were diluted to 2 µg/ml and assayed by EIA for 
reactivity with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.2) VLPs. Amino acid 
residues from GII.4-1987 were inserted into the GII.4-2006 backbone at positions 
297 and 298 to create GII.4-2006(+87A.2). Bars represent the mean optical density 
values with standard error of the means.  The dashed line represents 3X the 
background level of binding and indicates a positive signal. 
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Figure 2.6 
 
 
 
 
Figure 2.6: GII.4-2006(+87A.3) reactivity with anti-GII.4 mAbs.  
Anti-GII.4-1987 and -2006 IgG were diluted to 2 µg /ml and assayed by EIA for 
reactivity with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.3) VLPs. Amino acid 
residues from GII.4-1987 were inserted into the GII.4-2006 backbone at positions 
368 and 372 to create GII.4-2006(+87A.3). Bars represent the mean optical density 
values with standard error of the means.  The dashed line represents 3X the 
background level of binding and indicates a positive signal. 
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Figure 2.7 
 
 
 
 
Figure 2.7: GII.4-2006(+87A.4) reactivity with anti-GII.4 mAbs.  
Anti-GII.4-1987 and -2006 IgG were diluted to 2 µg /ml and assayed by EIA for 
reactivity with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.4) VLPs. An amino acid 
residue from GII.4-1987 was inserted into the GII.4-2006 backbone at position 294 
to create GII.4-2006(+87A.4). Bars represent the mean optical density values with 
standard error of the means.  The dashed line represents 3X the background level of 
binding and indicates a positive signal. 
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Table 2.1  
 
 
 
Table 2.1: Relative reactivity of chimeric versus parental homotypic VLPs.   
For anti-GII.4-1987 mAbs, binding of chimeric and parental GII.4-2006 VLPs was 
compared to that of GII.4-1987.  For anti-GII.4-2006 mAbs, binding of chimeric and 
parental GII.4-1987 VLPs was compared to that of GII.4-2006.  Scoring is as follows: 
VLPs that exhibited 0-5% of the binding level of the homotypic parental VLP (GII.4-
1987 or GII.4-2006) received a score of “0”, 6-25% scored “1”, 26-50% scored “2”, 
51-75% scored “3”, and 76%+ scored “4”.   
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Figure 2.8 
 
Figure 2.8:  Anti-GII.4 mAb blockade of VLP/synthetic HBGA interactions.  
(A) The ability of anti-GII.4-1987-G1 and (B) anti-GII.4-2006-G7 to block VLP 
interaction with synthetic HBGA was measured by surrogate neutralization assay 
and expressed as a percent of the control (100%) binding.  An antibody is 
considered a “blocking antibody” if it is able to block at least 50% of the control 
(dashed line).  Anything below the dashed line represents potential neutralization.  
Error bars represent standard error of the means from experiments run in triplicate.      
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Figure 2.9 
 
 
Figure 2.9:  GII.4-1987 mouse polyclonal sera blockade.  
A) GII.4-1987 polyclonal mouse sera was diluted 1:1000 and assayed by EIA for 
reactivity with GII.4-1987, GII.4-2006, and GII.4-2006(+87A.1) VLPs. Bars represent 
the mean optical density values with standard error of the means.  The dashed line 
represents 3X the background level of binding and indicates a positive signal. B) 
GII.4-1987 polyclonal mouse sera blockade of GII.4 VLP/synthetic HBGA 
interactions. Ability of GII.4-1987 polyclonal mouse sera to block VLP/synthetic CHO 
was measured by surrogate neutralization assay and expressed as a percent of the 
control (100%) binding.  An antibody is considered a “blocking antibody” if it is able 
to block at least 50% of the control (dashed line).  Anything below the dashed line 
represents potential neutralization.  Error bars represent standard error of the means 
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from experiments run in triplicate.  C) GII.4-1987 polyclonal mouse sera BT50 values 
for GII.4-1987, GII.4-2006, and GII.4-2006(+87A.1). Blocking titers of GII.4-1987 
mouse polyclonal sera were determined as the serum concentration at which 50% of 
the VLP/synthetic HBGA was blocked. Box and whiskers plots represent the mean 
serum concentration at which BT50 was achieved for each VLP.  
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Figure 2.10 
 
Figure 2.10: 1988 human outbreak sera blockade. A) 1988 human outbreak sera 
was diluted 1:500 and assayed by EIA for reactivity with GII.4-1987, GII.4-2006, and 
GII.4-2006(+87A.1) VLPs. Bars represent the mean optical density values with 
standard error of the means.  The dashed line represents 3X the background level of 
binding and indicates a positive signal. B) 1988 human outbreak sera blockade of 
GII.4 VLP/synthetic HBGA interactions. Ability of human sera to block VLP/synthetic 
CHO was measured by surrogate neutralization assay and expressed as a percent 
of the control (100%) binding.  An antibody is considered a “blocking antibody” if it is 
able to block at least 50% of the control (dashed line).  Anything below the dashed 
line represents potential neutralization.  Error bars represent standard error of the 
means from experiments run in triplicate.  C) 1988 human outbreak sera BT50 
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values for GII.4-1987, GII.4-2006, and GII.4-2006(+87A.1). Blocking titers of human 
sera were determined as the serum concentration at which 50% of the VLP/synthetic 
HBGA was blocked. Box and whiskers plots represent the mean serum 
concentration at which BT50 was achieved for each VLP.  
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Figure 2.11 
 
 
Figure 2.11:  Homology models comparing GII.4-1987, GII.4-2006, and GII.4-
1987(+06D).  
A) Overlay of binding pocket of GII.4-1987 (yellow), GII.4-2006 (purple), and GII.4-
1987(+06D) (grey). Side chains are shown for residues in sites 1 and 2  (342-347, 
374, 390-395, and 440-444). Residues 393-395 are shown in teal (GII.4-
1987(+06D)), orange (GII.4-1987), and red (GII.4-2006). B) Residue 390 (yellow) 
forms a hydrogen bond with residue 395 (yellow) in GII.4-1987(+06D) that is not 
found in GII.4-2006. GII.4-2006 residues 393 and 395 form hydrogen bonds not 
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found in GII.4-1987(+06D). C) Residue 343 (yellow) forms a hydrogen bond (red 
arrow) with the FUC of HBGA B (orange) in GII.4-1987(+06D) but not with GII.4-
2006. D) Three hydrogen bonds are formed between residue 345 (yellow) and the 
FUC of HBGA B in GII.4-2006 but only one is formed with GII.4-1987(+06D).  E) 
Residues 343 and 444 (both yellow) share a hydrogen bond in GII.4-1987(+06D) but 
not in GII.4-2006.  F) Residue 442 (yellow) participates in hydrogen bonding with the 
FUC of HBGA B in GII.4-1987(+06D) but not with GII.4-2006.  In GII.4-1987(+06D), 
residue 442 (yellow) also forms a hydrogen bond with residue 443, which is not 
found in GII.4-2006.  
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APPENDIX 3:  CHAPTER 3 FIGURES AND TABLES 
Figure 3.1 
 
 
Figure 3.1: GII.4 norovirus Structure and Genetic Variability in Blockade Epitopes 
(A) Schematic representation of the norovirus genome. ORF1 encodes the non-
structural proteins, ORF2 encodes the major capsid protein, and ORF3 encodes the 
minor capsid protein. The major capsid protein is divided into the shell and the P1 
and P2 subdomains. (B) Blockade epitopes for GII.4 noroviruses. A structural model 
of a GII.4 norovirus P2 dimer indicates the location of previously identified blockade 
epitopes A, D, and E.  (C) GII.4-2012 Changes in Evolving Blockade Epitopes. 
Amino acid sequences from GII.4-2006, GII.4-2009, and GII.4-2012 were aligned 
and changes occurring in epitopes A, D, and E are noted in the tables. (D) 
Previously-reported epitope binding specificity of GII.4-2006 and GII.4-2009 mouse 
mAbs and GII.4 human mAbs.
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Figure 3.2 
 
Figure 3.2:  GII.4-2012 HBGA Binding 
VLPs representing GII.4-2006, GII.4-2009, and GII.4-2012 strains were assayed for 
their ability to bind synthetic biotinylated HBGAs or PGM.  The mean OD450 nm was 
calculated and graphed.  Error bars represent SEM.  VLP reactivity is defined as a 
positive signal over 3X the background binding, indicated by the dashed line. 
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Figure 3.3
 
 
Figure 3.3:  GII.4-2006 Mouse mAb EIA Reactivity and Blockade Response Against 
GII.4-2012  
(A) Mouse monoclonal antibodies (1 µg/ml) against GII.4-2006 (G2, G3, G4, G6, and 
G7) were assayed for ability to react with GII.4-2006, GII.4-2009, and GII.4-2012 
VLPs by EIA. The mean OD450 nm was calculated and graphed. Error bars 
represent SEM.  * Reactivity is significantly different from that of the homotypic GII.4-
2006 VLP. Reactivity is defined as a positive signal above 0.2 by EIA, represented 
by the dashed line. VLP reactivity below the dashed line is considered non-reactive. 
(B-G) Mouse monoclonal antibodies against GII.4-2006 (G2, G6, G7) were assayed 
for ability to block GII.4-2006, GII.4-2009, and GII.4-2012 VLP interaction with 
carbohydrate ligand PGM (B-D) or biotinylated B (E-G). The mean percent control 
binding (percent of the VLP bound to carbohydrate ligand in the presence of an 
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antibody compared to the amount of VLP bound with no antibody present) of each 
VLP was fit with a sigmoidal curve, and the mean EC50 (µg/ml) blockade titers for 
GII.4-2006, GII.4-2009, and GII.4-2012 were calculated. Error bars represent 95% 
confidence intervals. * Mean EC50 blockade titer for the test VLP is significantly 
different from the mean EC50 for GII.4-2006 (p<0.05). Monoclonal antibodies that 
did not block a particular VLP were assigned an EC50 of 4 µg/ml for statistical 
analysis and are shown on the graph by data points above the upper limit of 
detection (dashed line). Statistics for both EIA and blockade assays were calculated 
by One-way ANOVA with Dunnett’s post test. 
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Figure 3.4 
 
 
Figure 3.4: GII.4-2009 Mouse mAb EIA Reactivity and Blockade Response Against 
GII.4-2012  
(A) Mouse monoclonal antibodies (1 µg/ml) against GII.4-2009 (NO37, 52, 66, and 
224) were assayed for ability to react with GII.4-2006, GII.4-2009, and GII.4-2012 
VLPs by EIA. The mean OD450 nm was calculated and graphed. Error bars 
represent SEM.  * Reactivity is significantly different from that of the homotypic GII.4-
2009 VLP. Reactivity is defined as a positive signal above 0.2 by EIA, represented 
by the dashed line. VLP reactivity below the dashed line is considered non-reactive. 
(B-E) Mouse monoclonal antibodies against GII.4-2009 (NO 52, 224) were assayed 
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for ability to block GII.4-2006, GII.4-2009, and GII.4-2012 VLP interaction with 
carbohydrate ligand PGM (B-C) or biotinylated B (D-E). The mean percent control 
binding (percent of the VLP bound to carbohydrate ligand in the presence of an 
antibody compared to the amount of VLP bound with no antibody present) of each 
VLP was fit with a sigmoidal curve, and the mean EC50 (µg/ml) blockade titers for 
GII.4-2006, GII.4-2009, and GII.4-2012 were calculated. Error bars represent 95% 
confidence intervals. * Mean EC50 blockade titer for the test VLP is significantly 
different from the mean EC50 for GII.4-2009 (p<0.05). Monoclonal antibodies that 
did not block a particular VLP were assigned an EC50 of 4 µg/ml for statistical 
analysis and are shown on the graph by data points above the upper limit of 
detection (dashed line). Statistics for both EIA and blockade assays were calculated 
by One-way ANOVA with Dunnett’s post test. 
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Figure 3.5 
 
Figure 3.5:  GII.4 Human mAb EIA Reactivity and Blockade Response Against GII.4-
2012  
(A) Human monoclonal antibodies against GII.4 norovirus (1 µg/ml) were assayed 
for ability to react with GII.4-2006, GII.4-2009, and GII.4-2012 VLPs by EIA. The 
mean OD450 nm was calculated and graphed. Error bars represent SEM.  * 
Reactivity is significantly different from that of the GII.4-2009 VLP. Reactivity is 
defined as a positive signal above 0.2 by EIA, represented by the dashed line. VLP 
reactivity below the dashed line is considered non-reactive. (B-E) Human 
monoclonal antibodies against GII.4 noroviruses were assayed for ability to block 
GII.4-2006, GII.4-2009, and GII.4-2012 VLP interaction with carbohydrate ligand 
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PGM (B-C) or biotinylated B (D-E).  The mean percent control binding (percent of 
the VLP bound to carbohydrate ligand in the presence of an antibody compared to 
the amount of VLP bound with no antibody present) of each VLP was fit with a 
sigmoidal curve, and the mean EC50 (µg/ml) blockade titers for GII.4-2006, GII.4-
2009, and GII.4-2012 were calculated. Error bars represent 95% confidence 
intervals. *Mean EC50 blockade titer for the tested VLP is significantly different from 
the mean EC50 for GII.4-2009 (p<0.05). Monoclonal antibodies that did not block a 
particular VLP at the highest mAb concentration tested were assigned an EC50 of 
2X the upper limit tested in µg/ml for statistical analysis and are shown on the graph 
by data points above the upper limit of detection (dashed line). Statistics for both EIA 
and blockade assays were calculated by One-way ANOVA with Dunnett’s post test. 
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Figure 3.6 
 
 
Figure 3.6:  Monoclonal Antibody Blockade of Chimeric GII.4-2012 VLPs 
Mouse and human epitope A targeting monoclonal antibodies against GII.4 
noroviruses (2006-G2, G3, G4, G6, G7, NO37, NO52, and NVB 43.9) were assayed 
for ability to block GII.4-2012.T294P, GII.4-2012.E368A, and GII.4-2012.09A 
interaction with carbohydrate ligand, and graphs representative of two distinct 
patterns are shown.  The mean percent control binding (percent of the VLP bound to 
carbohydrate ligand in the presence of an antibody compared to the amount of VLP 
bound with no antibody present) of each VLP was fit with a sigmoidal curve, and the 
mean EC50 (µg/ml) blockade titers for GII.4-2009, GII.4-2012 VLP, GII.4-
2012.T294P, GII.4-2012.E368A, and GII.4-2012.09A were calculated. Error bars 
represent 95% confidence intervals. *Mean EC50 blockade titer for the tested VLP is 
significantly different from the mean EC50 for GII.4-2009 (p<0.05). Monoclonal 
antibodies that did not block a particular VLP at the highest mAb concentration 
tested were assigned an EC50 of 2X the upper limit tested in µg/ml for statistical 
analysis and are shown on the graph by data points above the upper limit of 
detection (dashed line). Statistics for both EIA and blockade assays were calculated 
by One-way ANOVA with Dunnett’s post test. 
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Figure 3.7 
 
Figure 3.7:  GII.4-2012 and GII.4-2012.09A Blockade by GII.4-2009 Outbreak 
Human Sera 
Human convalescent polyclonal sera from 8 individuals infected in 2010 with GII.4-
2009 New Orleans were assayed for ability to block GII.4-2009, GII.4-2012, and 
GII.4-2012.09A VLP interaction with carbohydrate ligand.  The mean percent control 
binding (percent of the VLP bound to carbohydrate ligand in the presence of sera 
compared to the amount of VLP bound with no sera present) of each VLP was fit 
with a sigmoidal curve, and the mean EC50 (% sera) blockade titers for GII.4-2009, 
GII.4-2012, and GII.4-2012.09A were calculated. Error bars represent 95% 
confidence intervals. * Mean EC50 blockade titer is significantly different from the 
mean EC50 for GII.4-2009 (p<0.05). Statistics were calculated by One-way ANOVA 
with Dunnett’s post test. 
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Figure 3.8 
 
Figure 3.8:  GII.4-2009 Outbreak Human Sera Blockade by Individual 
Individual human convalescent polyclonal sera from 8 individuals infected in 2010 
with GII.4-2009 New Orleans were assayed for ability to block GII.4-2009, GII.4-
2012, and GII.4-2012.09A VLP interaction with carbohydrate ligand.  The mean 
percent control binding (percent of the VLP bound to carbohydrate ligand in the 
presence of sera compared to the amount of VLP bound with no sera present) of 
each VLP was fit with a sigmoidal curve, and the mean EC50 (% sera) blockade 
titers for GII.4-2009, GII.4-2012, and GII.4-2012.09A were calculated. Error bars 
represent 95% confidence intervals. * Mean EC50 blockade titer is significantly 
different from the mean EC50 for GII.4-2009 (p<0.05). Statistics were calculated by 
One-way ANOVA with Dunnett’s post test. 
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APPENDIX 4:  CHAPTER 4 GRAPHS AND TABLES 
Figure 4.1 
 
 
 
Figure 4.1:  Sequence Changes in Chronically Infected Patient Strains Compared to 
GII.4-2006b. 
(A) Available capsid amino acid sequences for GII.4-2006b, P.D1 and P.D302 were 
aligned using Clustal Omega, and sequence differences among GII.4-2006, P.D1, 
and P.D302 are shown. GII.4-2006b residues are shown in purple. P.D1 and P.D302 
differences from GII.4-2006b are indicated in light blue, while orange indicates a 
reversion to the GII.4-2006b residues. (B) Alignment of GII.4-2006b, P.D1, and 
P.D302 amino acid sequences in and around Epitopes A, D, and E. Green indicates 
a position within a defined epitope, while white indicates nearby residues that may 
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impact antigenicity in these epitopes.  (C) Structural homology models of GII.4-
2006b, P.D1, and P.D302 capsid P2 dimers shown from top view.  Purple shows 
location of Epitopes A, D, and E on the capsid P2 dimer, while green shows 
changing amino acid residues in P.D1 and P.D302 compared to GII.4-2006b.  
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Table 4.1 
 
Table 4.1: Chronic Infection Strain HBGA Binding Preferences 
VLPs representing GII.4-2006b, P.D1, and P.D302 were assayed for their ability to 
bind synthetic biotinylated HBGAs A, B, Lea, Leb, Lex, Ley, H type 1, and H type 3 by 
carbohydrate binding assay.  Positive reactivity was defined as a value greater or 
equal to 3X the background binding value. 
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Table 4.2
 
Table 4.2:  GII.4 Mouse and Human mAb EIA Reactivity with Chronic Infection 
Strains  
Mouse and human GII.4 monoclonal antibodies against were assayed for reactivity 
with GII.4-2006b, P.D1, and P.D302 VLPs by multiple dilution EIA. The mean 
percent binding (percent of the VLP bound to antibody in the dilution course 
compared to the amount of VLP bound with antibody at 1 ug/mL) of each VLP was fit 
with a sigmoidal curve, and the mean EC50 (µg/ml) EIA reactivity titers for GII.4-
2006b, P.D1, and P.D302 were calculated. * Mean EC50 EIA reactivity titer for the 
test VLP is significantly different from the mean EC50 for GII.4-2006b (light grey), or 
** was significantly different from both GII.4-2006b and P.D1 (p<0.05) (dark grey). 
Monoclonal antibodies that did not demonstrate EIA reactivity at or above OD450 
nm 0.2 at 1 ug/mL with a particular VLP are denoted by an EC50 of >1 ug/mL. 
Statistics were calculated by One-way ANOVA with Bonferroni post test. 
	   175	  
Figure 4.2 
 
 
 
Figure 4.2: GII.4 Mouse and Human mAb Blockade Response Against Chronic 
Infection Strains 
(A-I) Mouse and human GII.4 monoclonal antibodies were assayed for ability to 
block GII.4-2006b, P.D1, and P.D302 VLP interaction with carbohydrate ligand.  The 
mean percent control binding (percent of the VLP bound to carbohydrate ligand in 
the presence of an antibody compared to the amount of VLP bound with no antibody 
present) of each VLP was fit with a sigmoidal curve, and the mean EC50 (µg/ml) 
blockade titers for GII.4-2006b, P.D1, and P.D302 were calculated. Error bars 
represent 95% confidence intervals. * Mean EC50 blockade titer for the test VLP is 
significantly different from the mean EC50 for GII.4-2006b (p<0.05), or ** was 
significantly different from both GII.4-2006b and P.D1 (p<0.05). Monoclonal 
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antibodies that did not block a particular VLP were assigned an EC50 of 2X the upper 
limit of detection for statistical analysis and are shown on the graph by data points 
above the upper limit of detection (dashed line). Statistics were calculated by One-
way ANOVA with Bonferroni post test. 
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Figure 4.3 
 
Figure 3:  Blockade Activity of Mouse Polyclonal Sera Against Homotypic and 
Heterotypic VLPs 
Mice were immunized with VRP expressing the capsid gene of GII.4-2006b, GII.4-
2009, P.D1, and P.D302, and sera collected from these mice were tested for 
blockade activity against GII.4-2006b, GII.4-2009, P.D1, and P.D302 VLPs.  (A) 
Blockade activity of sera from mice immunized against GII.4-2006b (A), GII.4-2009 
(B), P.D1 (C), and P.D302 (D) with homotypic and heterotypic VLPs. The mean 
percent control binding (percent of the VLP bound to carbohydrate ligand in the 
presence of sera compared to the amount of VLP bound with no sera present) of 
each VLP was fit with a sigmoidal curve, and the mean EC50 (% sera) blockade titers 
for GII.4-2006b, GII.4-2009, P.D1, and P.D302 were calculated. Error bars represent 
95% confidence intervals. * Mean EC50 blockade titer for the test VLP is significantly 
different from the mean EC50 for the homotypic strain (p<0.05). Sera that did not 
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block a particular VLP were assigned an EC50 of 10% sera for statistical analysis 
and are shown on the graph by data points above the upper limit of detection 
(dashed line). Statistics were calculated by One-way ANOVA with Bonferroni post 
test. 
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Figure 4.4 
 
Figure 4.4:  Antigenic Cartography for GII.4 Noroviruses 
Sera from mice immunized with GII.4 VRPs expressing the norovirus major capsid 
gene for strains GII.4-1987, GII.4-2002, GII.4-2006b and GII.4-2009, and chronic 
isolates P.D1 and P.D302 were tested for the ability to block VLP-PGM interactions 
for strains GII.4-1987 (yellow), GII.4-1997 (red), GII.4-2002 (light blue), GII.4-2006b 
(light purple), GII.4-2009 (dark blue), GII.4-2012 (dark purple), P.D1 (light green), 
and P.D302 (dark green).  EC50 blockade titers were calculated and this data was 
used to generate a 3D antigenic cartography map in AntigenMap 3D that illustrates 
the antigenic differences among GII.4 norovirus strains.  A) Early strains GII.4-1987, 
GII.4-1997, and GII.4-2002 grouped together (lower right hand quadrant), and late 
strains GII.4-2006b, GII.4-2009, and GII.4-2012 grouped together (lower left hand 
quadrant).  P.D1 grouped with late strains, closest to GII.4-2006b, while P.D302 was 
separate from either late or early strains (upper right quadrant).  B) Side view of the 
same 3D graph showing the antigenic differences between strains. 
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Figure 4.5 
 
Figure 4.5:  Expansion of Epitope A 
Epitope A targeting human GII.4 mAb 43.9 was assayed for its ability to block GII.4-
2009 New Orleans, GII.4-2012 Sydney, GII.4-2012.09A, GII.4-2012.R373N, and 
GII.4-2012.09A.R373N VLP interaction with carbohydrate ligand. The mean percent 
control binding (percent of the VLP bound to carbohydrate ligand in the presence of 
an antibody compared to the amount of VLP bound with no antibody present) of 
each VLP was fit with a sigmoidal curve, and the mean EC50 (µg/ml) blockade titers 
for all VLPs were calculated. Error bars represent 95% confidence intervals.  
Statistics were calculated by One-way ANOVA with Dunnett’s post test. * Mean EC50 
blockade titer was significantly different from GII.4-2009.  
	   181	  
Figure 4.6 
 
Figure 4.6:  Comparison of Epitope D Polar Interactions Among GII.4-2006 and 
Chronic Infection Strains 
Pymol was used to model the polar interactions within residues 390-395 (A-C) and 
interactions between these residues and surrounding residues (D-F). GII.4-2006b is 
shown in purple (A and D), P.D1 is shown in teal (B and E), and P.D302 is shown in 
pink (C and F). Residues 390-395 are shown in orange for GII.4-2006b, yellow for 
P.D1, and aqua for P.D302.  Dotted lines represent structure-based predicted polar 
interactions. Dark purple residues represent positions that interact with HBGAs (D-
F). 
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APPENDIX 5:  CHAPTER 5 GRAPHS AND TABLES 
Figure 5.1 
 
Figure 5.1:  Design of Chimeric Vaccine VLPs 
(A) Sequences from GII.4-1987, GII.4-2002, and GII.4-2006 were aligned and 
residues in blockade epitopes A, D, and E are shown.  (B)  Capsid P2 dimer (grey) 
showing the location of blockade epitopes A (pink), D (green), and E (orange).  (C) 
Chimeric VLP P2 dimers. Differential epitope A residues from parental strain GII.4-
1987 (A294V, R297H, N298D, S368T, E372N) are inserted into the parental GII.4-
2006 strain background to create chimeric VLP GII.4-2006.87A. Chimeric VLP GII.4-
2006.87A.02E contains the same GII.4-1987 residue substitutions as well as epitope 
E substitutions (N412T, V413G). 
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Figure 5.2 
 
Figure 5.2:  Single Strain VRPs Do Not Induce a Broad Blockade Response 
Balb/c mice were immunized with with VRPs expressing the norovirus capsid gene 
from parental strains GII.4-1987, GII.4-2002, GII.4-2006, or GII.4-2009 via footpad 
injection.  The ability of sera from mice immunized with (A) GII.4-1987, (B) GII.4-
2002, (C) GII.4-2006, and (D) GII.4-2009 VRPs was evaluated for ability to block 
VLP interaction with carbohydrate ligand pig gastic mucin type III (PGM) for VLPs 
representing strains GII.4-1987, GII.4-1997, GII.4-2002, GII.4-2006, GII.4-2009, and 
GII.4-2012.  For each VLP, the mean percentage of control binding (percent of the 
VLP bound to PGM in the presence of sera compared to the amount of VLP bound 
with no sera present) was fit to a sigmoidal curve, and the mean EC50 % sera was 
calculated (percentage of sera required to block 50% of the VLP-PGM interaction).  
Sera that did not block a particular VLP were assigned a value of 10% (2X the upper 
limit of detection) for statistical analysis and placed as a data point above the dotted 
line (upper limit of detection). 
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Figure 5.3 
 
Figure 5.3: Single Strain VRP Sera Blockade Response Against Chimeric VLPs 
Balb/c mice were immunized with with VRPs expressing the norovirus capsid gene 
from parental strains GII.4-1987, GII.4-2002, GII.4-2006, or GII.4-2009 via footpad 
injection.  The ability of sera from mice immunized with (A) GII.4-1987, (B) GII.4-
2002, (C) GII.4-2006, and (D) GII.4-2009 VRPs was evaluated for ability to block 
VLP interaction with carbohydrate ligand pig gastic mucin type III (PGM) for chimeric 
VLPs GII.4-2006.87A and GII.4-2006.87A.02E.  For each VLP, the mean percentage 
of control binding (percent of the VLP bound to PGM in the presence of sera 
compared to the amount of VLP bound with no sera present) was fit to a sigmoidal 
curve, and the mean EC50 % sera was calculated (percentage of sera required to 
block 50% of the VLP-PGM interaction).  Sera that did not block a particular VLP 
were assigned a value of 10% (2X the upper limit of detection) for statistical analysis 
and placed as a data point above the dotted line (upper limit of detection).  
*Statistical significance was determined by 1-way analysis of variance (ANOVA) with 
Bonferroni post-test. 
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Figure 5.4 
 
Figure 5.4:  Chimeric VRPs Induce Broad Blockade Responses 
Balb/c mice were immunized with with VRPs expressing the norovirus capsid gene 
from chimeric sequences GII.4-2006.87A and GII.4-2006.87A.02E via footpad 
injection.  The ability of sera from mice immunized with (A) GII.4-2006.87A and (B) 
GII.4-2006.87A.02E VRPs was evaluated for ability to block VLP interaction with 
carbohydrate ligand pig gastic mucin type III (PGM) for VLPs representing strains 
GII.4-1987, GII.4-1997, GII.4-2002, GII.4-2006, GII.4-2009, and GII.4-2012.  For 
each VLP, the mean percentage of control binding (percent of the VLP bound to 
PGM in the presence of sera compared to the amount of VLP bound with no sera 
present) was fit to a sigmoidal curve, and the mean EC50 % sera was calculated 
(percentage of sera required to block 50% of the VLP-PGM interaction).  Sera that 
did not block a particular VLP were assigned a value of 10% (2X the upper limit of 
detection) for statistical analysis and placed as a data point above the dotted line 
(upper limit of detection).  
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Figure 5.5 
 
 
Figure 5.5:  Comparison of Chimeric VRP Sera Blockade Response Against 
Parental GII.4 VLPs 
Balb/c mice were immunized with with VRPs expressing the norovirus capsid gene 
from chimeric sequences GII.4-2006.87A and GII.4-2006.87A.02E via footpad 
injection.  The ability of sera from mice immunized with GII.4-2006.87A and GII.4-
2006.87A.02E VRPs was evaluated for ability to block VLP interaction with 
carbohydrate ligand pig gastic mucin type III (PGM) for VLPs representing strains 
(A) GII.4-1987, (B) GII.4-1997, (C) GII.4-2002, (D) GII.4-2006, (E) GII.4-2009, and 
(F) GII.4-2012.  For each VLP, the mean percentage of control binding (percent of 
the VLP bound to PGM in the presence of sera compared to the amount of VLP 
bound with no sera present) was fit to a sigmoidal curve, and the mean EC50 % 
sera was calculated (percentage of sera required to block 50% of the VLP-PGM 
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interaction).  Sera that did not block a particular VLP were assigned a value of 10% 
(2X the upper limit of detection) for statistical analysis and placed as a data point 
above the dotted line (upper limit of detection). *Statistical significance was 
determined by 1-way analysis of variance (ANOVA) with Bonferroni post-test.  
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Figure 5.6 
 
Figure 5.6: Comparison of Chimeric versus Multivalent VRP Sera Blockade 
Response Against Parental GII.4 VLPs 
Balb/c mice were immunized with with VRPs expressing either the norovirus capsid 
gene from chimeric sequence GII.4-2006.87A or a multivalent mix of VRPs 
expressing the capsid gene from GII.4-1987, GII.4-2002, and GII.4-2006 via footpad 
injection.  The ability of sera from mice immunized with GII.4-2006.87A and 
multivalent VRPs was evaluated for ability to block VLP interaction with 
carbohydrate ligand pig gastic mucin type III (PGM) for VLPs representing strains 
(A) GII.4-1987, (B) GII.4-1997, (C) GII.4-2002, (D) GII.4-2006, (E) GII.4-2009, and 
(F) GII.4-2012.  For each VLP, the mean percentage of control binding (percent of 
the VLP bound to PGM in the presence of sera compared to the amount of VLP 
bound with no sera present) was fit to a sigmoidal curve, and the mean EC50 % 
sera was calculated (percentage of sera required to block 50% of the VLP-PGM 
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interaction).  Sera that did not block a particular VLP were assigned a value of 10% 
(2X the upper limit of detection) for statistical analysis and placed as a data point 
above the dotted line (upper limit of detection). *Statistical significance was 
determined by 1-way analysis of variance (ANOVA) with Bonferroni post-test. 
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Figure 5.7 
 
 
Figure 5.7: Parental Strain Blockade Comparisons Among Homotypic, Heterotypic, 
Chimeric, and Multivalent Sera 
Balb/c mice were immunized with with VRPs expressing either the norovirus capsid 
gene fromGII.4-1987, GII.4-2002, GII.4-2006, GII.4-2009, chimeric sequences GII.4-
2006.87A or GII.4-2006.87A.02E or a multivalent mix of VRPs expressing the capsid 
gene from GII.4-1987, GII.4-2002, and GII.4-2006 via footpad injection.  Sera from 
these mice were evaluated for ability to block VLP interaction with carbohydrate 
ligand pig gastic mucin type III (PGM) for VLPs representing strains (A) GII.4-1987, 
(B) GII.4-2002, (C) GII.4-2006, and (D) GII.4-2009.  For each VLP, the mean 
percentage of control binding (percent of the VLP bound to PGM in the presence of 
sera compared to the amount of VLP bound with no sera present) was fit to a 
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sigmoidal curve, and the mean EC50 % sera was calculated (percentage of sera 
required to block 50% of the VLP-PGM interaction).  Sera that did not block a 
particular VLP were assigned a value of 10% (2X the upper limit of detection) for 
statistical analysis and placed as a data point above the dotted line (upper limit of 
detection). *Statistical significance was determined by 1-way analysis of variance 
(ANOVA) with Bonferroni post-test, and statistical differences compared to the 
homotypic VLP are shown. 
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Figure 5.8 
 
Figure 5.8: Model of Chimeric GII.4 VLP-based Vaccine Reformulation Strategy 
Starting with the current predominant circulating GII.4 strain, (1) epidemiological 
studies identify sequence changes in epitope A in minor variants that arise in the 
population. (2) Using the sequences of these epitope A variants, a panel of VLPs 
representing this genetic diversity is built and monoclonal antibodies and polyclonal 
sera can be used to evaluate changes in antigenicity for each variant.  (3)  From this 
data, specific variants that are antigenically distinct from the predominant strain are 
identified and can be more closely monitored in the population.  (4) If one of these 
variants seems likely to emerge as a new predominant strain, the chimeric VLP is 
already made and can quickly be introduced into a new vaccine formulation.  (5)  
When a new predominant strain emerges, this process can be repeated in order to 
consistently address GII.4 antigenic variation.  
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APPENDIX 6:  CHAPTER 6 GRAPHS AND TABLES 
Figure 6.1 
 
 
Figure 6.1:  Putative Updated Blockade Epitopes 
Sequences from contemporary GII.4 outbreak strains (GII.4-2006b, GII.4-2009, and 
GII.4-2012) and intra-host evolved isolates were aligned and evolving residues in 
and around previously-identified epitopes A (green), D (orange), and E (yellow) are 
noted (blue shades).  *Indicates amino acid positions that have changed in outbreak 
strains prior to GII.4-2006. 
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